




3 1761 12063201 3

Year-Over-Year Changes In the  
Patent Medicine Index 1988-  
1995

-CA1  
RG20  
-A56  
c. 1  
GOVT



Digitized by the Internet Archive  
in 2024 with funding from  
University of Toronto

<https://archive.org/details/31761120632013>










Patented Medicine  
Prices Review Board




Conseil d'examen du prix  
des médicaments brevetés

# Year-over-Year Changes in the Patented Medicine Price Index 1988-1995



## Eighth Annual Report

For the  
Year Ended  
December 31,  
1995



The Patented Medicine Prices Review Board  
Box L 40  
Standard Life Centre  
333 Laurier Avenue West  
Suite 1400  
Ottawa, Ontario  
K1P 1C1

Telephone: (613) 952-7360  
Facsimile: (613) 952-7626  
TTY: (613) 957-4373



Printed on recycled paper



Patented Medicine  
Prices Review Board



Conseil d'examen du prix  
des médicaments brevetés

May 31, 1996

The Honourable David Dingwall, P.C., M.P.  
Minister of Health  
House of Commons  
Ottawa, Ontario  
K1A 0A6

Dear Minister:

I have the honour to present to you, in accordance with the provisions of sections 89 and 100 of the Patent Act, the Annual Report of the Patented Medicine Prices Review Board for the year ended December 31, 1995.


Yours very truly,

Robert G. Elgie  
Chairperson

# Mission and Values of the PMPRB

---

Photo courtesy of Health Canada



The mission of the Patented Medicine Prices Review Board (PMPRB) is to contribute to Canadian health care by ensuring that prices of patented medicines are not excessive.

The PMPRB achieves this by:

- promoting voluntary compliance with Guidelines established by the Board
- reviewing prices and taking remedial action when necessary
- analyzing and reporting to Canadians on price trends of all medicines and on research and development conducted by patentees
- consulting with interested parties on Guidelines and other matters of policy
- fostering awareness of the Board's mandate, activities and achievements through communication, dissemination of information and public education.

In fulfilling its mission the PMPRB is committed to innovative leadership based on the following values:

- effectiveness and efficiency
- fairness
- integrity
- mutual respect
- transparency of process
- a supportive and challenging work environment.



# Table of Contents

<b>Letter to the Minister</b>	<b>1</b>
<b>Mission and Values of the PMPRB</b>	<b>2</b>
<b>List of Tables and Figures</b>	<b>4</b>
<b>Chairperson's Message</b>	<b>5</b>
<b>The Patented Medicine Prices Review Board</b>	<b>7</b>
Mandate	7
Jurisdiction	7
Membership	8
<b>Sales of Drugs in Canada in 1995</b>	<b>9</b>
The Pharmaceutical Industry in Canada	9
Sales of Pharmaceutical Drug Products in Canada	9
<b>Trends in Drug Prices and Expenditures</b>	<b>11</b>
Prices of Patented Drugs in 1995	11
Price Trends of All Drugs — Patented and Non-Patented	11
Price Trends in Canada and the United States	12
Summary of Study on Top 200 Selling Patented Drug Products	13
Increased Expenditures on Drugs	13
Factors Influencing Increases in Drug Expenditures	14
Trends in Quantities of Sales of Patented Drug Products	15
Sales by ATC Classification	16
<b>Compliance with the Excessive Price Guidelines</b>	<b>17</b>
New Drug Products in 1995	17
New Chemical Entities in 1995	17
Price Review of New Patented Drugs in 1995	18
Existing Drug Products in 1995	19
Update of Seventh Annual Report — Year Ending December 31, 1994	19
<b>Enforcement Activities</b>	<b>20</b>
Voluntary Compliance Undertakings	20
Public Hearings	21
Investigation of Novopharm Limited	21
Savings from Compliance and Enforcement Activities	22
<b>Analysis of Research-and-Development (R&amp;D) Expenditures</b>	<b>23</b>
Data Sources	23
R&D Expenditures	23
Revenues from Sales	23
R&D-to-Sales Ratios	23
<b>Glossary</b>	<b>30</b>

## List of Tables and Figures

### Tables

Table 1	Manufacturers' Sales of All Drugs and Patented Drugs, 1990 - 1995	10
Table 2	Total Health Expenditures by Category of Expenditure, Canada, 1975 - 1994	14
Table 3	Patented Drug Products by ATC Classification, 1995	16
Table 4	Categorization of New Patented Drug Products	17
Table 5	Patented Medicines Introduced in Canada in 1995 - New Chemical Entities	18
Table 6	Total R&D Expenditures and R&D-to-Sales Ratios, 1988 - 1995	24
Table 7	Current R&D Expenditures by Type of Research, 1994 and 1995	24
Table 8	Current R&D Expenditures by R&D Performer, 1994 and 1995	26
Table 9	Total R&D Expenditures by Source of Funds, 1994 and 1995	26
Table 10	Current R&D Expenditures by Location, 1994 and 1995	26
Table 11	Ratios of R&D Expenditures to Sales Revenues by Reporting Patentee, 1994 and 1995	27
Table 12	Current R&D Expenditures by Province and by R&D Performer, 1995	29
Table 13	Patented Drug Products Introduced in Canada in 1995	33
Table 14	Patented Drug Products and Canadian Patentees, January 1, 1995 - December 31, 1995	35

### Figures

Figure 1	Manufacturers' Sales of Patented and Non-Patented Drugs, 1990 - 1995	10
Figure 2	Year-over-Year Changes in the PMPI, 1988-1995	11
Figure 3	Year-over-Year Changes in PMPI, IPPI (pharmaceuticals) and CPI, 1988 - 1995	11
Figure 4	Summary of Price Trends, Average Annual Percentage Changes, 1983 - 1987; 1988 - 1995	12
Figure 5	Year-over-Year Changes in Pharmaceutical Price Indices, Canada and the U.S.	12
Figure 6	Canadian Prices Relative to Foreign Prices — Top-Selling Patented Drug Products, 1994	13
Figure 7	Drug Expenditures as a Percentage of Total Health Expenditures, 1975 - 1994	14
Figure 8	Year-over-Year Changes in Drug Expenditures, 1976 - 1994	15
Figure 9	Year-over-Year Changes in PMPI and in Quantity Index, 1988 - 1995	15
Figure 10	Annual Savings from Compliance and Enforcement Activities	22
Figure 11	Current R&D Expenditures by Type of Research, 1988 - 1995	25
Figure 12	Share of Current R&D Expenditures by Type of Research, 1988 - 1995	25



## Chairperson's Message

It is my distinct pleasure to introduce the 1995 Annual Report of the Patented Medicine Prices Review Board (PMPRB). Although the Board's mandate is limited to the manufacturers' prices of patented medications, I believe that the progress reported here demonstrates that the PMPRB has had a significant impact and continues to play an important role in moderating prices and price increases of drugs in the Canadian health care system.

The publication of this report, which marks the completion of my first year as Chairperson of the PMPRB, provides me with the opportunity to reflect on the effectiveness of the Board's mandate as established by Parliament in 1987.

Through Bill C-22 in 1987 and Bill C-91 in 1993, Parliament, on behalf of the people of Canada, made a number of decisions with respect to patented pharmaceutical drug products. From the outset, Parliament sought to extend the period of patent exclusivity in order to protect the intellectual property rights of the patent holders and bring those rights in line with Canada's trade agreements. At the same time, it intended this extension of exclusive rights to encourage expansion of this industry in Canada and to increase its investment in significant research and development (R&D).

The pharmaceutical industry acknowledged that, in return for this extended patent protection, it was prepared to significantly increase investments placed in R&D in Canada in order to assure Canadians that an increasing cadre of qualified scientists and investigators would remain and grow in this country to lead and take part in significant research programs. Along with these changes, Parliament clearly wanted to assure the public, as consumers, that this extended period of exclusivity would not result in excessive prices.

The Patented Medicine Prices Review Board was accordingly created as an independent quasi-judicial agency to regulate prices of patented medicines, to report on price trends and to report on the patentees' R&D expenditures.

Expenditures on all drugs, in contrast to expenditures on physicians and hospitals, represent a growing proportion of total Canadian health expenditures - a reality that will continue to subject the pharmaceutical industry in general to close scrutiny. It is, however, interesting to note that the overall cost of drugs has increased much faster than the prices of patented medications, and that the PMPRB has ensured that manufacturers' prices for patented drugs have not gone up more than the CPI. In fact, since 1987, the PMPRB has kept price increases for patented drugs, on average, well below the rate of inflation. In addition, the downward trend reported by the PMPRB in 1994 has continued in 1995. Overall, in 1995, prices for patented drugs declined 1.75% as compared to an increase in the CPI of 2.14%.

Canadian prices have also gone down relative to international prices. The PMPRB's study, published in February 1996, on the prices of the top 200 selling patented drug products in Canada in 1994 shows that, for the second year in a row, Canadian prices continued to decline relative to prices in other countries and were lower than those in the United States, Germany and Switzerland. In 1994, for the first time, Canadian prices on average were below the median international prices.

*Overall, in 1995,  
prices for patented  
drugs declined 1.75%  
as compared to an  
increase in the CPI  
of 2.14%.*

*The PMPRB has had a significant impact and continues to play an important role in moderating prices and price increases of drugs in the Canadian health care system.*


This annual report also illustrates how the PMPRB carries out its regulatory role. In 1995, the PMPRB initiated a review of its policy on patent dedication, and in the fall of 1995 announced that patentees could no longer escape the jurisdiction of the Board by dedicating their patents. In addition, it began examining its price review operations to increase its efficiency and effectiveness, to better focus its resources,

and to assist patentees by lifting some of the administrative burden.

Other initiatives relate to the PMPRB's role as a centre for information on pharmaceutical prices and R&D expenditures. It is the PMPRB's goal to provide an objective source of information and to share knowledge and expertise with interested parties through its extensive database. It strives to improve and enhance the information it provides through publications such as this report and various studies. These sources will also enable the Board to offer current and sound information to the parliamentary committee that will be reviewing the pharmaceutical patent laws in 1997.

The work of the PMPRB would not have been possible without the dedication and commitment of its very capable staff, to whom I would like to extend my personal thanks. It is with pleasure that I take this opportunity to welcome our new Board members, Réal Sureau, also Vice-Chairperson of the Board, Judith Glennie, and Ysolde Gendreau. In addition, I would like to express my sincere gratitude to Harry Eastman for agreeing to stay on as a Board member after his seven-year tenure as Chairperson of the PMPRB. His encyclopedic understanding of the pharmaceutical industry is invaluable and I know I speak for all new Board members when I express my appreciation for his continuing presence.

As Canada's health care sector undergoes a period of evaluation, the Board looks forward to making its contribution to meeting the accompanying challenges that will arise in the coming years.



Robert G. Elgie  
Chairperson



# The Patented Medicine Prices Review Board

## Mandate

The PMPRB is an independent quasi-judicial body created by Parliament in 1987 under the Patent Act. The PMPRB contributes to Canadian health care by regulating the prices charged by manufacturers of patented medicines to ensure that they are not excessive.

The PMPRB reports to Parliament through the Minister of Health. The Annual Report, which covers each calendar year, includes a review of the PMPRB's major activities, analyses of the prices of patented medicines and of the price trends of all drugs, and reports on the R&D expenditures by patent-holding drug manufacturers.

## Jurisdiction

The PMPRB is responsible for regulating the maximum prices that patentees may charge for prescription and non-prescription patented drugs sold in Canada for human and veterinary use. In most cases, that price is the "factory-gate" price at which the manufacturer sells the product to wholesalers, hospitals or pharmacies. The PMPRB's jurisdiction includes patented medicines marketed or distributed under voluntary licences. The Board does not regulate the prices of non-patented drugs, including generic drugs sold under compulsory licences, and has no jurisdiction over prices charged by wholesalers or retailers and pharmacists' fees.

In Canada, Health Canada assesses new medicines to ensure that they conform with the Food and Drugs Act and Regulations. Formal authorization to market or distribute a medicine is granted through a Notice of Compliance (NOC). A medicine may be temporarily distributed with specified restrictions before receiving a NOC, as an Investigational New Drug or under the Emergency Drug Release (EDR) Program.


The PMPRB regulates the price of each patented drug product, including each strength of each dosage form of a patented medicine. This is normally the level at which Health Canada assigns a Drug Identification Number (DIN) or General Public (GP) number.

In 1995, following public consultation, the Board changed its policy relating to patent dedication. Patent dedication is a practice whereby a patentee advises the Commissioner of Patents that it is abandoning its patent and dedicating it to the public domain. Previously, the Board had considered its jurisdiction to end upon the dedication of a patent. An analysis conducted by the PMPRB revealed that patentees might have used patent dedication to avoid its jurisdiction. With the adoption of the new policy, the Board will assert its jurisdiction after a patent has been dedicated until the term of the patent expires pursuant to express provisions of the Patent Act. The Board's change in practice applies to patents dedicated after January 30, 1995.<sup>1</sup>

<sup>1</sup> See the Bulletin series, issues 15 to 18 inclusively.

## Membership


The Board consists of no more than five part-time members appointed by the Governor in Council for a term of five years. Four new members, including the Chairperson and Vice-Chairperson, were appointed in 1995.



Chairperson:  
**Robert G. Elgie,**  
LL.B., M.D., F.R.C.S. (C)

Dr. Elgie, a lawyer and neurosurgeon, Fellow of the Royal College of Surgeons (Neurosurgery), has been the Director of Dalhousie University's Health Law Institute since 1991. He is also part-time Chair of the Workers' Compensation Board of Nova Scotia. Dr. Elgie has taught at the Medical Schools of Queen's

University and the University of Toronto and has held several positions with the Scarborough General Hospital, including Chief of Medical Staff. In 1977, he was elected to the Ontario Legislative Assembly and subsequently served in several Cabinet positions. He resigned from the Ontario Legislature in September 1985 to become Chair of the Workers' Compensation Board of Ontario where he served until 1991. Dr. Elgie was appointed Member and Chairperson of the PMPRB in March 1995.



Vice-Chairperson:  
**Réal Sureau, FCA**


Mr. Sureau, a chartered accountant, is President of Sureau Management Limited. He recently completed his tenure as President of the Order of Chartered Accountants of Québec. He was also a member of several committees of the Order, including the Disciplinary Committee, the Professional Practice Committee, the

Professional Development Committee and the Committee on Government Finances. He was Vice-President, Finance, at Forex and Canam-Manac. Currently, Mr. Sureau sits on the boards of directors of several organizations. Mr. Sureau was appointed Member and Vice-Chairperson of the PMPRB in October 1995.

### Members:

**Harry C. Eastman,**  
B.A., Ph.D., F.R.S.C.

An economist and Professor Emeritus at the University of Toronto, Professor Eastman chaired the Federal Commission of Inquiry on the Pharmaceutical Industry from 1984 to 1985. He was a member of the Ontario Council on University Affairs from 1983 to 1989 and of the Ontario Council of Health Task Force on Medical Manpower from 1982 to 1983. First appointed to the PMPRB in 1987, Professor Eastman served as its first chairperson until March 1995.



**Judith Glennie,**  
Pharm., D.

Dr. Glennie is a clinical pharmacist specializing in pharmacoeconomics at the Health Sciences Centre in Winnipeg. She is an assistant professor in the Faculty of Pharmacy and the Department of Pharmacology, Faculty of Medicine, University of Manitoba. She was appointed to the PMPRB in March 1995.



**Ysolde Gendreau,**  
B.C.L., LL.B., LL.M., Ph.D.

Dr. Gendreau is a professor in the Faculty of Law of the Université de Montréal, where she teaches intellectual property law and competition law. She is also sessional lecturer at McGill University, where she teaches intellectual property law. She was appointed to the PMPRB in October 1995.





# Sales of Drugs in Canada in 1995

## The Pharmaceutical Industry in Canada

The global pharmaceutical industry is dominated by a number of large multinational enterprises based in several countries. Many of these companies have Canadian subsidiaries which, along with domestic pharmaceutical firms, account for the development, sale and distribution of drugs in Canada.

It has been estimated that worldwide sales of drugs were over \$340 billion in 1995 of which sales in Canada represented less than 2%.<sup>2</sup> The top ten companies in the world accounted for approximately 40% of the global market.

Most of the major manufacturers of pharmaceuticals conduct research and development and protect the intellectual property of their inventions by obtaining patents in other countries and in Canada. Some firms specialize in making copies of existing drugs that are no longer subject to patent protection, i.e., generic drugs. These companies also engage in R&D but not ordinarily for the purposes of developing new products; therefore they do not usually hold patents.

In Canada, the PMPRB protects consumer interests by regulating the prices charged by pharmaceutical patentees during the time they benefit from patent protection. Ordinarily, a patentee is the exclusive supplier of a patented product, but there may also be alternative medicines available. Similarly, although a drug that is no longer protected by a patent may become the subject of competition, there are also instances where the manufacturer of a non-patented drug may remain the sole supplier.

In Canada, it has been reported that the top ten pharmaceutical companies accounted for approximately 46% of total sales by manufacturers in 1995.<sup>3</sup> Of the top ten firms, two are generic companies.<sup>4</sup>

In 1995, 69 companies reported sales of patented medicines in Canada to the PMPRB. The decline from 73 in 1994 is largely attributable to mergers within the industry in 1995.<sup>5</sup>

In 1995, the pharmaceutical industry accounted for less than 2% of all sales and employment in the manufacturing sector of the Canadian economy. Because of its R&D activities, however, the industry accounted for more than 10% of total R&D in that sector.<sup>6</sup> (For a report on patentees' R&D expenditures in 1995, please refer to page 23).

## Sales of Pharmaceutical Drug Products in Canada

In 1995, patentees reported total factory-gate sales of patented drugs of \$2.6 billion, an increase of 10.0% from 1994. As shown in Table 1, manufacturers' sales of patented drugs increased by more than 10% in every year since 1990, except in 1994 when they experienced a slight decline.




Photo courtesy of Health Canada

2 SCRIIP 1996 Yearbook Vol. 1., page 104.

3 See IMS, Canadian Pharmaceutical Market: Drug Stores and Hospital Purchases, December 1995.

4 See page 21 regarding an investigation into Novopharm's status as a patentee.

5 A list of all reporting patentees and patented drug products appears in Table 14. The R&D-to-sales ratio for each patentee appears in Table 11.

6 Statistics Canada Catalogues, 31-203 and 88-202.

**Table 1 Manufacturers' Sales of All Drugs and Patented Drugs, 1990 - 1995**

Year	Total Sales (\$Billions)	Change (%)	Patented Sales (\$Billions)	Change (%)	Patented as Percentage of Total
1995	6.0	2.0	2.6	10.0	44.1
1994	5.9 <sup>7</sup>	8.7	2.4	-0.4	40.7
1993	5.4	12.5	2.4	14.3	44.4
1992	4.8	9.1	2.1	10.5	43.8
1991	4.4	18.9	1.9	18.7	43.2
1990	3.7	-	1.6	-	43.2


Sources: Statistics Canada and PMPRB

According to data from Statistics Canada, total sales by manufacturers of pharmaceuticals in 1995 were estimated at \$6.0 billion, an increase of 2% from 1994.

As shown in Table 1, patented drugs represented about 44% of total sales by manufacturers in 1995, consistent with their relative share in recent years except 1994.

Figure 1 shows the growth in annual sales of patented and non-patented drugs from 1990 to 1995. Sales of non-patented medicines can be estimated as the difference between the total sales as calculated by Statistics Canada and the

**Figure 1 Manufacturers' Sales of Patented and Non-Patented Drugs 1990-1995**



Sources: Statistics Canada and PMPRB

<sup>7</sup> Revised.

<sup>8</sup> See IMS, Canadian Pharmaceutical Market: Drug Stores and Hospital Purchases, December 1995.

sales of patented drugs as reported to the PMPRB. Statistics Canada's estimates of total sales, and consequently the estimates of sales of non-patented drugs, are subject to revision.

Non-patented medicines include

products that were previously subject to patent protection, those that are not yet or never have been protected by a patent, and generic copies of patented drugs. Information filed by patentees with the PMPRB indicates that most non-patented drugs are sold by companies that also sell patented drugs. Sales of patented drug products only represent about 50% of the total drug sales of patentees. Trade publications have estimated that generic products accounted for approximately 12% of total sales by manufacturers in Canada in 1995.<sup>8</sup>

The PMPRB regulates the prices of individual drug products, including each strength and dosage form of patented medicines. A total of 900 patented drug products were sold in Canada during all or part of 1995. This number represents a slight increase from the 871 products sold in 1994. The number of patented drugs reported to the PMPRB is smaller than the 1,281 patented drug products with a Notice of Compliance (NOC) because not all products with a NOC were actually sold in Canada during the year. In addition, drugs that do not have a NOC but are sold as Investigational New Drugs or under the Emergency Drug Release (EDR) program administered by Health Canada are subject to review by the PMPRB. In 1995 there were 21,190 drug products approved for sale in Canada. Although the number of patented drug products with a NOC in 1995 represented only 6% of the total number of drug products approved for sale, sales of patented drugs accounted for over 44% of total sales as shown in Table 1.



# Trends in Drug Prices and Expenditures

## Prices of Patented Drugs in 1995


The PMPRB maintains the Patented Medicine Price Index (PMPI), an index of the manufacturers' prices for patented drugs as reported annually to the PMPRB. Because the PMPI is derived from the actual prices charged by manufacturers for all patented medicines, it provides a precise measure of price changes for drugs reported to the PMPRB.

In 1995, the prices of patented medicines, as measured by the PMPI, declined by 1.75% from their level in 1994. As shown in Figure 2, this was the second consecutive year of decline; the PMPI went down 0.42% in 1994.

## Price Trends of All Drugs — Patented and Non-Patented

The Patent Act provides that the Board shall consider changes in the Consumer Price Index (CPI) in determining if the price of a patented medicine is excessive. As a result, the Board's Guidelines provide that the prices of individual patented drug products may not increase by more than the CPI.

**Figure 2** Year-over-Year Changes in the PMPI 1988-1995




Source: PMPRB

In 1995, consumer prices, as measured by the CPI, increased by 2.14% in contrast with the continued decline in the PMPI.

The pharmaceutical component of the Industrial Products Price Index (IPPI), published by Statistics Canada, provides an index

comparable to the PMPI that measures manufacturers' prices for all pharmaceuticals, including both patented and non-patented drugs. In 1995, the IPPI (pharmaceuticals) increased only slightly, by 0.09%, a smaller increase than seen in previous years. As shown in Figure 3, the IPPI (pharmaceuticals) has increased in every year since the creation of the PMPRB, by an amount greater than the PMPI, and closer to the changes in the CPI.

**Figure 3** Year-over-Year Changes in PMPI, IPPI (pharmaceuticals) and CPI 1988-1995




Sources: Statistics Canada and PMPRB

As shown in Figure 4, from 1988 to 1995, the IPPI (pharmaceuticals) and the CPI have increased on average by almost the same amount, just over 3.1% per year. By contrast, prices for patented drugs have increased at a significantly lower rate over that time period, by 1.6% per year, on average.


**Figure 4 Summary of Price Trends  
Average Annual Percentage Changes**

1983-1987; 1988-1995



Sources: Statistics Canada and PMPRB

**Figure 5 Year-over-Year Changes in Pharmaceutical Price Indices, Canada and the U.S.**



Sources: PMPRB, Statistics Canada and the U.S. Bureau of Labor Statistics

Figure 4 also shows information on pharmaceutical price trends prior to the creation of the PMPRB in 1987. From 1983 to 1987, when there was no direct regulation of drug prices, price increases for all drugs, as measured by the IPPI (pharmaceuticals), averaged 7.8% per year as compared to increases in consumer prices of 4.2% per year. The decline in the rate of increase in the prices of all drugs relative to the CPI coincided with the introduction of price regulation for patented medicines which represent

about 44% of the sales of all drugs.

These trends indicate that limiting price increases for patented drugs has served to keep the rate

of increase in prices for all drugs lower than would otherwise have been the case.

*... limiting price increases  
for patented drugs has  
served to lower the rate  
of increase in prices  
for all drugs.*

## Price Trends in Canada and the United States

A comparison of price trends between Canada and the United States also suggests that drug price increases in Canada have declined since the creation of the PMPRB.

As shown in Figure 5, from 1984 to 1987, Canadian manufacturers' prices for all drugs increased at a rate equal to or even greater than the rate of increase in manufacturers' prices in the U.S. Since then, the average annual rate of increase in the IPPI (pharmaceuticals) in Canada has declined relative to the rate of increase in the comparable pharmaceutical component of the Producer Price Index (PPI) in the United States.

Figure 5 also shows that the overall rate of increase in the prices of patented medicines regulated by the PMPRB has consistently been lower than the rate of increase in manufacturers' prices for drugs in the United States.




## Summary of Study on Top 200 Selling Patented Drug Products

In February 1996, the PMPRB published a study on the price trends of the top selling patented drug products in Canada.<sup>9</sup> The analysis included a report on price trends of the top 200 selling patented drug products sold in Canada from 1990 to 1994.

The analysis of the top 200 selling patented drugs in 1994 found:

- Manufacturers' prices of 86% of the top selling patented drug products in Canada either stayed the same or went down in 1994. This figure was up from 70% in 1993 and contrasts sharply with 1992, when only 30% of the top 200 patented drug products did not increase in price.
- The prices of Canada's most popular patented drug products declined by 0.28%, on average in 1994. This was consistent with the overall decline in patented drug prices in that year of 0.42%.
- For the first time, prices in Canada were on average below the median international prices of the same drug products in 1994 (Figure 6). The results of the study show that the PMPRB has achieved the objective of changes to its Guidelines in 1993, namely that Canadian prices not exceed the median of foreign prices.
- In 1994, patented drugs in Canada experienced the lowest incidence of price increases of all eight countries used for international comparisons. Only 14% of the top selling patented drug products in Canada went up in price, compared with increases for 19% of those products in Switzerland, 21% in France, 22% in the U.K., 25% in Germany, 25% in Italy, 62% in Sweden, and 79% in the U.S.
- The prices of drugs categorized as substantial improvement and breakthrough drug products in 1994, were, on average, 11% lower than their median international prices.

**Figure 6 Canadian Prices Relative to Foreign Prices  
Top-Selling Patented Drug Products 1994**



Source: PMPRB

## Increased Expenditures on Drugs

Total spending by Canadians on pharmaceutical products includes more than the sales by manufacturers of patented drugs. It also includes sales of non-patented drugs, the markups charged by wholesalers and retailers, and the dispensing fees charged by pharmacists. These additional elements of total expenditures are regulated or controlled in some cases by provincial governments.

An analysis of the National Health Expenditures, compiled by Health Canada, reveals that expenditures on drugs by Canadians have continued to increase over the past 20 years. As shown in Table 2, total drug expenditures were \$1.1 billion, or 8.7% of total health expenditures, in 1975 and increased to \$9.2 billion, or 12.7%, in 1994.<sup>10</sup> In the latter year, drug expenditures were about one-third the expenditures on hospitals and slightly less than expenditures on physicians' services and all other expenditures, but they had increased faster than the other two major components.

<sup>9</sup> See PMPRB's "The Top 200 Selling Patented Drug Products in Canada (1994)", February 1996.

<sup>10</sup> Drug expenditures as reported by Health Canada do not include drugs purchased by hospitals.

**Table 2 Total Health Expenditures by Category of Expenditure, Canada, 1975 - 1994**

Year	Hospitals (\$ Billions)	Physicians (\$ Billions)	Drugs (\$ Billions)	Other Expenditures (\$ Billions)	Total (\$ Billions)
1994	27.0	10.3	9.2	10.6	72.5
1993	27.1	10.4	8.8	10.1	71.8
1992	26.8	10.5	8.5	9.3	70.0
1991	25.7	10.2	7.7	8.6	66.3
1990	23.9	9.3	6.9	7.9	61.0
1989	22.4	8.5	6.2	7.1	56.2
1988	20.5	7.9	5.5	6.1	51.1
1985	16.4	6.1	3.8	4.6	40.0
1980	9.4	3.3	1.9	2.3	22.4
1975	5.5	1.8	1.1	1.3	12.3

Source: Health Canada

Figure 7 shows that drug expenditures have represented an increasing proportion of total health costs. In 1975, drugs accounted for 8.7% of total health expenditures, but this share has gradually increased to 12.7% in 1994. The rate of increase in expenditures on drugs appears to have declined in recent years. As shown in Figure 8, the annual increase in drug expenditures was usually 10% or more in

each year from 1976 to 1992. In 1993 and 1994, the increase in drug expenditures was 4.6% and 3.8%, respectively.


## Factors Influencing Increases in Drug Expenditures

Figure 8 shows that drug expenditures in Canada went up 3.8% in 1994 even though it was previously reported by the PMPRB that patented drug prices declined 0.42% in that year. Several factors contribute to explaining this phenomenon.

Firstly, the PMPRB only regulates manufacturers' prices of patented drugs which represent about 44% of the sales of all drugs. Secondly, expenditures on drugs include wholesale costs and dispensing fees, which are not included in the PMPI.

Thirdly, changes in total expenditures resulted from changes in prescribing habits and utilization of drugs as well as in prices. For example, consumption of larger quantities of drugs could result in increased expenditures even if prices go down. Similarly, shifts in prescribing from cheaper drugs to more expensive ones would result in increased costs even if the actual price levels of the products involved did not change.


**Figure 7 Drug Expenditures as a Percentage of Total Health Expenditures 1975-1994**



Source: Health Canada



**Figure 8** Year-over-Year Changes in Drug Expenditures 1976-1994



Source: Health Canada

### Trends in Quantities of Sales of Patented Drug Products

The data available to the PMPRB allow it to measure changes in the quantities as well as the prices of patented drugs sold from year to year. This analysis reveals that the quantities of patented drugs sold in each year have consistently increased at a much faster rate than prices.

Figure 9 shows the changes in the price and quantity indices for 1988 to 1995. In 1995, prices for patented medicines declined 1.75%, on average, but the quantities sold increased 14.8%, the largest increase since 1988.

From 1988 to 1995, the average annual increase in quantities of patented drugs sold was 9.1% as compared with an average annual increase of 1.6% in their prices.


The information available to the PMPRB does not permit a full explanation of the reasons for the increase in the quantities of patented drugs sold; further study is required.

The index for the quantities of patented drugs sold may not be representative of total sales of all pharmaceuticals. Among other things, this analysis does not take into account shifts in utilization between patented drugs and non-patented drugs; nor does it account for changes in patent status. For example, drugs continue

to be consumed even though their patents expire and their prices are no longer subject to the PMPRB's jurisdiction.

*In 1995, prices for patented medicines declined 1.75%, on average, but the quantities sold increased 14.8%, the largest increase since 1988.*

**Figure 9** Year-over-Year Changes in PMPI and in Quantity Index 1988-1995



Source: PMPRB

**Table 3 Patented Drug Products by ATC Classification, 1995**

Major ATC Classification	Patented Drug Products		Revenue from Sales	
	#	%	\$M	%
A. Alimentary tract and metabolism	103	11.4	412	15.6
B. Blood and blood forming organs	35	3.9	261	9.9
C. Cardiovascular system	99	11.0	419	15.9
D. Dermatologicals	35	3.9	76	2.9
G. Genito-urinary system and sex hormones	32	3.6	112	4.2
H. Systemic hormonal preparations, excluding sex hormones	22	2.4	23	0.8
J. General antiinfectives for systemic use	172	19.1	395	15.0
L. Antineoplastics and immunomodulating agents	58	6.4	134	5.1
M. Musculo-skeletal system	44	4.9	101	3.8
N. Nervous system	65	7.2	396	15.0
P. Antiparasitic products	3	0.3	0	0.0
Q. Veterinary products	115	12.8	86	3.4
R. Respiratory system	59	6.6	170	6.4
S. Sensory organs	23	2.6	16	0.6
V. Various	35	3.9	36	1.4
<b>Totals</b>	<b>900</b>	<b>100</b>	<b>2,637</b>	<b>100</b>

Source: PMPRB

General antiinfective drugs (ATC classification J) accounted for the largest number of patented drug products, 19.1%, and 15% of total sales. Other groups, also accounting for 15% or more of the revenues from sales, were cardiovascular drugs (ATC classification C), alimentary tract and metabolic drugs (ATC classification A), and drugs affecting the nervous system (ATC classification N).

The number of patented drugs for veterinary use (ATC classification Q) declined from 119 to 115, or 12.8% of the total. The revenue from sales of patented veterinary drugs also declined slightly from \$87 million to \$86 million in 1995, so that they only represented 3.4% of the total sales of patented drugs.

## Sales by ATC Classification

The PMPRB classifies all drugs sold in Canada according to the Anatomical Therapeutic Chemical (ATC) classification system.<sup>11</sup>

Table 3 breaks out the 900 patented drug products sold during 1995 according to the major ATC classifications, showing the number of drug products and respective revenues from sales for each group. (The breakdown for all drugs may differ from that for patented medicines.)



Photo courtesy of Health Canada

<sup>11</sup> See PMPRB's ATC Classification System Manual, 1995 Canadian Edition.



# Compliance with the Excessive Price Guidelines

## New Drug Products in 1995

For purposes of the review of prices charged in 1995, new drug products include those introduced between December 1, 1994 and November 30, 1995. Because of the timing of the filing requirements under the Patented Medicines Regulations (Regulations) and the manner of calculating benchmark prices, drug products introduced in December are considered to have been introduced in the following year.

Eighty-nine patented drug products (DINs) were first sold in Canada in 1995. As can be seen from Table 4, this total represents an increase from 1993 and 1994 but is lower than the number of new patented drug products introduced in 1991 and 1992.

Of these new products, 81, or more than 90%, were drugs for human use. This proportion is consistent with previous years except 1994, when a relatively large number of patented drug products for veterinary use were introduced.

The Guidelines establish three categories of new patented drug products for purposes of conducting introductory price reviews.<sup>12</sup>

- Category 1 - new DINs of an existing or comparable dosage form of an existing medicine, usually a new strength of an existing drug.
- Category 2 - the first drug product to treat effectively a particular illness or which provides a substantial improvement over existing drug products, often referred to as “breakthrough” or “substantial improvement”.
- Category 3 - new drugs or new dosage forms of existing medicines that provide moderate or no therapeutic improvement over existing medicines.

The PMPRB has categorized all 89 drugs. Table 4 provides a breakdown by category of the new drug products introduced in 1995 as compared with previous years.

**Table 4      Categorization of New Patented Drug Products**

DRUG TYPE	1995	1994	1993	1992	1991
<b>Human</b>					
Category 1	34	29	35	23	51
Category 2	2	3	8	15	5
Category 3	45	32	34	50	38
<b>Total</b>	<b>81</b>	<b>64</b>	<b>77</b>	<b>88</b>	<b>94</b>
<b>Veterinary</b>					
Category 1	6	7	4	0	1
Category 2	1	0	0	0	0
Category 3	1	10	3	3	3
<b>Total</b>	<b>8</b>	<b>17</b>	<b>7</b>	<b>3</b>	<b>4</b>
<b>Total</b>	<b>89</b>	<b>81</b>	<b>84</b>	<b>91</b>	<b>98</b>

Source: PMPRB

## New Chemical Entities in 1995

Among the new patented drug products for human use introduced in Canada in 1995, there were 20 new chemical entities (NCEs). This represents a small increase from 1994, when there were 18 NCEs for human use. A listing of the new chemical entities and their category appears in Table 5. A NCE may represent more than one drug product if it is sold in more than one strength or dosage form.

*Eighty-nine patented drug products (DINs) were first sold in Canada in 1995.*

<sup>12</sup> For complete definitions of the categories, please refer to the Compendium of Guidelines, Policies and Procedures, Chapter 3, section 3.

**Table 5 Patented Medicines Introduced in Canada in 1995  
New Chemical Entities\***

Chemical Name	Brand Name	Company	Category	ATC
<b>Human</b>				
Aldesleukin	Proleukin	Ligand Pharmaceuticals Inc.	3	L03AA04
Cefipime hydrochloride**	Maxipime	Bristol-Myers Squibb Pharmaceutical Group	3	J01DA18
Cefprozil	Cefzil	Bristol-Myers Squibb Pharmaceutical Group	3	J01DA19
Dalteparin sodium	Fragmin	Pharmacia Inc.	3	B01AB06
Danaparoid sodium	Orgaran	Organon Canada Ltd. (Akzo)	3	B01AB07
Dexrazoxane	Zinecard	Pharmacia Inc.	2	V03AF03
Docetaxel	Taxotere	Rhône-Poulenc Rorer Canada Inc.	3	L01CD02
Famciclovir	Famvir	SmithKline Beecham Pharma Inc.	3	J05AB09
Iodixanol	Visipaque	Sanofi Winthrop	3	V08AB07
Lamotrigine	Lamictal	Glaxo Wellcome Inc.	3	N03AX03
Lansoprazole	Prevacid	Abbott Laboratories Limited	3	A02BC02
Losartan potassium	Cozaar	Merck Frosst Canada Inc.	3	C02EX01
Milrinone lactate	Primacor	Sanofi Winthrop	3	C01CE02
Mycophenolate mofetil**	CellCept	Hoffmann-La Roche Limited	3	L04AA05
Porfimer sodium	Photofrin	Ligand Pharmaceuticals Inc.	3	L01XX11
Rocuronium bromide	Zemuron	Organon Canada Ltd. (Akzo)	3	M03AC07
Sevoflurane	Sevorane	Abbott Laboratories Limited	3	N01AB04
Technetium TC-99M bicsate	Neurolite	Du Pont Merck Pharma Inc.	3	V04DA14
Tinzaparin sodium	Innohep	Leo Laboratories Canada Ltd.	3	B01AB05
Torsemide	Demadex	Jouveinal Inc.	3	C03CA03

\* New medicines not previously marketed in Canada.  
\*\* Introduced in December 1995. Considered a 1996 introduction for price review purposes.

Source: PMPRB

## Price Review of New Patented Drugs in 1995

The introductory prices of new drug products are reviewed for compliance with the Guidelines according to their category. The prices of most new drugs may not exceed the maximum price of other drugs that treat the same disease; the introductory prices of drugs in category 2 may not exceed the median of the foreign prices of the drugs.<sup>13</sup>

For a complete description of the Guidelines, please refer to the Compendium of Guidelines, Policies and Procedures.

The PMPRB has completed a preliminary review of 87 of the 89 new drug products introduced in 1995. The remaining two drug products, two strengths of one medicine, were introduced later in the year and the preliminary review is continuing.

The introductory prices of 71 of the new products, over 80% of those reviewed, were found to comply with the Guidelines. Investigations have been opened, and are ongoing for the remaining 16 products, involving 11 medicines. These cases all involve drug products for human use.

<sup>13</sup> Countries listed in the Patented Medicines Regulations: France, Germany, Italy, Switzerland, Sweden, United Kingdom and United States.



## Existing Drug Products in 1995

The PMPRB's Guidelines limit the price changes for existing patented drugs to changes in the Consumer Price Index (CPI). Also, prices cannot exceed the highest price of the same drug product in the countries listed in the Regulations. For the purposes of this report, existing medicines include all patented drug products that were on the market before 1995. Most pharmaceutical companies adjust prices annually, on January 1. Some companies adjust prices for some products every six months, on January 1 and July 1.

### Pricing Periods Ending June 1995

Among the 13 drug products with pricing periods ending June 30, 1995, there were no new instances of prices found to be outside the Guidelines.

### Pricing Periods Ending December 1995

There were 823 existing drug products with pricing periods ending December 31, 1995. The review of those prices identified six drug products, all for human use, with prices that appeared to have exceeded the Guidelines and investigations were commenced in all cases. Investigations with respect to two of those products have subsequently been closed following receipt of additional evidence revealing that the prices were within the Guidelines. The remaining four investigations are ongoing.

In addition, investigations were commenced in relation to three drug products, all for human use, following complaints received by the PMPRB. Two investigations were closed as it was determined that no patents pertained to the medicines and they are not under the PMPRB's jurisdiction. The third investigation is ongoing.



Photo courtesy of Health Canada

## Update of Seventh Annual Report — Year Ending December 31, 1994

In last year's annual report, the PMPRB reported that investigations had been opened into the prices of 13 of the 81 patented drug products introduced in 1994. The investigations involving ten of those products have now been resolved, three by Voluntary Compliance Undertakings and seven as a result of additional information which established that the prices were within the Guidelines. Investigations into the prices of the remaining three drug products are continuing.

It was also reported that investigations had been opened as a result of the prices in 1994 of 12 existing drug products. All but one of those investigations have now been concluded and the prices of those products were within the Guidelines in 1995. The investigation into the price of the remaining drug product is continuing. In addition, last year's report referred to one investigation opened as a result of complaints and that matter, Virazole and ICN Canada Ltd., is reported at page 21 of this report. Finally, reference was made to an ongoing investigation into the price of a veterinary drug product begun in 1993. That investigation has now been concluded following further evidence, which has established that the price is within the Guidelines.

At the time of printing of the 1995 Annual Report, the PMPRB was conducting investigations into the prices of 25 new and existing drug products, involving 20 medicines.

# Enforcement Activities

## Voluntary Compliance Undertakings

*A VCU is an alternative to the commencement of formal proceedings.*

Under the Board's Compliance and Enforcement Policy, patentees are given an opportunity to make a Voluntary Compliance Undertaking (VCU) when Board staff conclude, following an investigation, that a price appears to have exceeded

the Board's Guidelines. The Board's policies require that a VCU ensure that a price will be adjusted to conform with the Guidelines and, where appropriate, include measures to offset excess revenues that may have been received by the patentee. Approval of a VCU by the Chairperson or Board is an alternative to the commencement of formal proceedings through the issuance of a Notice of Hearing.

Since the 1994 Annual Report, the Chairperson has approved two VCUs, which are described in more detail below.

In 1995, the PMPRB approved a total of three VCUs; VCUs by Kenral Inc. and Amersham Canada Limited were reported at page 11 of the 1994 Annual Report and a VCU by Berlex Canada Inc. is reported below. These VCUs involved price reductions to comply with the PMPRB's Guidelines and measures to offset excess revenues of \$115,755, including a payment to the Government of Canada of \$72,054.

### **Betaseron - Berlex Canada Inc.** (Interferon beta-1b)

On October 10, 1995, the Chairperson approved a VCU by Berlex Canada Inc. to reduce the price of Betaseron by 5.2% to \$89.14 per vial to comply with the Guidelines and offset all excess revenues during the period of July 1994 to June 1995.

Betaseron is a patented medicine approved for use in ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations. It was first sold in Canada in 1994 under the Emergency Drug Release program and was reported in the 1994 Annual Report as a new drug in category 2, breakthrough or substantial improvement. It has since been approved for sale by Health Canada which issued a Notice of Compliance on July 19, 1995.

Under the Guidelines, the introductory price of Betaseron in Canada should not have exceeded the median of the prices for Betaseron in the other countries listed in the Patented Medicines Regulations. The prices in those countries are set out in the VCU.

Subsequently, it was reported that Schering AG, the parent company of Berlex Canada, claimed that the foreign prices quoted by the PMPRB were too low and the Canadian price was lower than the other countries.<sup>14</sup>

### **Prostep - Boehringer Ingleheim (Canada) Ltd.** (Nicotine)

On March 5, 1996, the Chairperson approved a VCU from Boehringer Ingleheim to reduce the price of Prostep 30 mg patch and 15 mg patch effective January 1, 1995, by 11.1% and 13.2% respectively, bringing the prices down to \$3.30 and \$3.22 to comply with the Guidelines. The VCU also involved the payment of \$14,959 to the Government of Canada to offset excess revenues received from the sale of Prostep during the period from November 15, 1994 to December 31, 1995. The VCU requires that the price of Prostep not exceed \$3.28 for the 15 mg patch and \$3.36 for the 30 mg patch, during 1996.

Prostep is a patented medicine approved as an aid to smoking cessation for the relief of nicotine withdrawal symptoms.

<sup>14</sup> See SCRIP World Pharmaceutical News, Issue No 2072, October 27, 1995.



## Public Hearings

---

### ICN Canada Ltd. and ICN Pharmaceuticals Inc. (ICN)

The Chairperson issued a Notice of Hearing on August 15, 1995, regarding alleged price increases by ICN for Virazole. According to the Notice of Hearing, Board staff alleged that ICN had increased the price of Virazole by 277% in 1994 and 1995 contrary to the Guidelines.

Virazole (ribavirin) is indicated for lower respiratory tract infection due to respiratory syncytial virus in hospitalized infants and children.

An amended Notice of Hearing was issued on September 28, 1995, on application by Board staff following the discovery of three additional patents alleged to pertain to Virazole.

On November 2 and 3, the Board received and heard evidence and argument on a motion by ICN that the Board does not have jurisdiction in this matter because Virazole was not a patented medicine during the relevant time period. On November 30, the Board issued its Decision and Reasons and concluded that it has jurisdiction. On December 1, ICN filed a motion with the Federal Court of Canada for judicial review of the Board's decision. On December 6, the Federal Court denied ICN's application to stay the Board's proceedings and heard the application for judicial review on January 29, 1996.

In a decision handed down on February 15, 1996, the Federal Court rejected ICN's application for judicial review and upheld the Board's decision.<sup>15</sup> In addition, the Court rejected ICN's submission regarding its subsequent disclaimer of parts of one of the patents at issue and concluded that the invention disclosed by that patent continues to pertain to the medicine. ICN appealed to the Federal Court of Appeal and the appeal was heard on May 21, 1996. Decision was reserved.

The Board's hearing regarding the price of Virazole commenced on April 9 and 10, 1996 and was scheduled to resume on June 25.

## Investigation of Novopharm Limited

---

In its 1993 and 1994 Annual Reports, the PMPRB reported that it was investigating the failure of Novopharm Limited to report information showing its expenditures on pharmaceutical R&D. This matter has now been concluded.

The issue involved whether Novopharm is a patentee for purposes of subsection 79(1) of the Patent Act as a result of the sale and supply of Novo-famotidine. Famotidine, which is manufactured by Merck Frosst, is also sold in Canada by Merck Frosst as a patented medicine under the brand name Pepcid and its price is subject to review by the PMPRB. Novopharm obtained a compulsory licence with respect to famotidine under the former provisions of the Patent Act. The effect of subsection 79(1) is to include, for purposes of the Act, any person who is entitled to exercise rights in relation to the relevant patent, except the rights under a compulsory licence. Compulsory licencees are exempt from the PMPRB's jurisdiction.

In 1993, while it was still precluded from exercising its rights under the compulsory licence, Novopharm entered into a distribution agreement with Merck Frosst whereby it acquired and sold famotidine under its own brand name, Novo-famotidine. It is the policy of the PMPRB that sellers of patented medicines in these circumstances are patentees for purposes of subsection 79(1) and are subject to its jurisdiction. Other sellers of patented medicines in these circumstances have complied with the filing requirements under the Patented Medicines Regulations and with the Guidelines.

Although it originally reported the sale of Novo-famotidine, Novopharm objected to filing information disclosing its R&D activities in 1994 and subsequently has failed to meet any of its reporting obligations under the Act and Regulations. The PMPRB's investigation

---

<sup>15</sup> ICN Pharmaceuticals Inc. and ICN Canada Ltd. v. Staff of the PMPRB et al, FC (TD) unreported decision #T-2541-95, rendered on February 15, 1996.

concerned whether Novopharm is required to file information on its R&D expenditures and the prices and sales of famotidine.

Information available to the PMPRB from public sources indicates that the price of Novo-famotidine has continued to be within the Guidelines. Information on Novopharm's R&D spending has been reported in other publications, although the PMPRB cannot verify that the information is accurate or consistent with the reporting requirements under the Patent Act. As of October 1996, Novopharm will be able to exercise its rights under its compulsory licence and therefore will no longer be subject to the PMPRB's jurisdiction. After careful consideration of the facts, and in light of all the circumstances, the Chairperson of the PMPRB has concluded that Novopharm is currently a patentee for purposes of subsection 79(1) and has failed to file information required under the Regulations, but that it would not be in the public interest to pursue the matter at this time.

With respect to the price of Novo-famotidine, the PMPRB reserves its ability to enforce the Act were it to receive evidence that the price of this drug product exceeds or has exceeded the Guidelines during the period of time it is subject to its jurisdiction.

## Savings from Compliance and Enforcement Activities

The savings to consumers from the price adjustments resulting from the PMPRB's compliance and enforcement activities continue in subsequent years.

From 1990 to 1995, the PMPRB has obtained more than 100 formal undertakings by patentees. It is estimated that consumers saved \$32.7 million in 1995 as a result of direct action by the PMPRB.

*Consumers saved  
\$32.7 million in 1995  
as a result of direct  
action by the  
PMPRB.*


Figure 10 shows the annual estimated savings from 1990 to 1995. The total savings to consumers over the six years was \$107 million.

When the PMPRB secures an undertaking, prices are reduced and savings are accrued for as long as the patented drug product remains under the PMPRB's jurisdiction. To offset revenues received in the past, VCUs may include additional price reductions or cash payments. Payments to the Government of Canada are included as part of the estimated savings.

Estimated savings are calculated as the difference between the patentee's price and the price allowed under the PMPRB's Guidelines from the effective date of the undertaking until the drug product is no longer within the Board's jurisdiction.

It is important to note that these estimated savings are only one measure of the effectiveness of the PMPRB. Savings to consumers are actually greater, as the analysis does not include savings from the effect of the Guidelines (i.e., when patentees sell their products at lower prices than they would in the absence of the PMPRB).

**Figure 10 Annual Savings from Compliance and Enforcement Activities**



Source: PMPRB



# Analysis of Research-and-Development (R&D) Expenditures

With the adoption of the 1987 amendments to the Patent Act, the Pharmaceutical Manufacturers Association of Canada (PMAC) made a public commitment that its members would increase their annual R&D expenditures as a percentage of sales to 8% by 1991, and to 10% by 1996.

The Patent Act requires that the PMPRB monitor and report on how much each patentee spends annually on pharmaceutical R&D in relation to revenues. The Board also monitors and reports on how much the patented industry as a whole spends on R&D. For individual patentees, this calculation includes all revenues from Canadian sales of medicines, including revenues from licensing agreements.

## Data Sources

Companies that reported sales of patented medicines in 1995 were also required to file R&D data for that calendar year. Only companies with active Canadian patents pertaining to a medicine sold in Canada are required by the Patent Act to report on R&D expenditures. As new patents are granted and others expire, the group of companies required to file R&D data may change from year to year.

For 1995, 69 companies, including 41 PMAC members, filed reports on R&D. The number of patentees has decreased this year largely as a result of mergers. The data from these firms are the basis of this report. Of these 69 companies, eight reported no eligible R&D expenditures for 1995. Sales revenues for these companies totalled \$81.8 million in 1995.

Two companies have failed to file R&D expenditures in 1995, ICN Canada Limited and Novopharm Ltd. Proceedings involving these two companies are reported at page 21.

## R&D Expenditures

Patentees must report those R&D expenditures that would have been eligible for an Investment Tax Credit for scientific research and experimental development under the provisions of the Income Tax Act in effect on December 1, 1987. Total R&D expenditures include current expenditures, capital equipment costs and allowable depreciation expenses.

## Revenues from Sales

The 69 patentees that filed R&D data reported total revenues of \$5.3 billion from Canadian sales (patented and non-patented drugs) in 1995, up 7.1% over 1994. Of total sales revenues, less than 1% was generated by licensing agreements.

## R&D-to-Sales Ratios

As a result, the ratio of R&D expenditures to sales revenues for the patented pharmaceutical industry was 11.8% in 1995, up from 11.3% in 1994. The ratio for the 41 companies that were members of the PMAC was 12.5% in 1995. Each patentee was given the opportunity to confirm the calculated R&D-to-sales ratio before publication of this report. Table 11 (page 27) lists all reporting patentees and their R&D-to-sales ratios.

As shown in Table 6, patentees reported total R&D expenditures of \$623.9 million in 1995, an increase of 11.2% over 1994. Current expenditures accounted for \$596.2 million or 95.6%, of total R&D expenditures. Capital equipment costs and allowable depreciation expenses amounted to 3.4% and 1.1% respectively.

*The ratio of R&D expenditures to sales revenues for the patented pharmaceutical industry was 11.8% in 1995, up from 11.3% in 1994.*

**Table 6 Total R&D Expenditures\* and R&D-to-Sales Ratios, 1988 - 1995**

Year	Companies Reporting	Total R&D Expenditures* (\$M)	Change from Previous Year (%)	Total Sales Revenues (\$M)	Change from Previous Year (%)	R&D-to-Sales Ratio	
						All Patentees (%)	PMAC Patentees (%)
1995	69	623.9	11.2	5,307.6	7.1	11.8	12.5
1994	73	561.1	11.4	4,957.4	4.4	11.3	11.6
1993	70	503.5	22.1	4,747.6	14.0	10.6	10.7
1992	71	412.4	9.6	4,164.4	6.9	9.9	9.8
1991	65	376.4	23.2	3,894.8	18.1	9.7	9.6
1990	65	305.5	24.8	3,298.8	11.0	9.3	9.2
1989	66	244.8	47.4	2,973.0	9.4	8.2	8.1
1988	66	165.7	-	2,718.0	-	6.1	6.5

\* Total expenditures include federal and provincial government grants, capital equipment expenditures and allowable depreciation expenses.

Source: PMPRB

Photo courtesy of Health Canada




Table 7 shows how current expenditures on R&D in 1995 were allocated among basic, applied, and other qualifying R&D. Total current expenditures on R&D rose by 11.1% in 1995.

Spending on basic research was \$132.2 million or 22.2% of the total. The lion's share of R&D spending continued to be on applied research, \$369.3 million or 61.9% of the total. Applied research is directed towards some practical application and has consistently absorbed the largest

share of expenditures, about 60%. In 1995, the greatest increase occurred in the category "other qualifying research", 14.5%. In the Canadian pharmaceutical industry, most applied research consists of clinical and pre-clinical trials.

Other qualifying research expenditures are for drug regulation submissions, bioavailability studies and Phase IV clinical trials.

Figure 11 shows current expenditures on R&D by type of research from 1988 to 1995.

While spending on basic research went up significantly in 1995, by 12.6%, it continued to represent a smaller share of total R&D spending. Figure 12 shows that basic research accounted for more than 25% of total expenditures for 1990 to 1993 but declined to 21.9% and 22.2% in 1994 and 1995.

Pharmaceutical patentees may report their expenditures on research they conduct themselves, (intra-mural) and research performed by others, including universities and hospitals and other manufacturers (extra-mural).

**Table 7 Current R&D Expenditures\* by Type of Research, 1994 and 1995**


Type of Research	1995		1994		Change 1995 / 1994 %
	\$M	%	\$M	%	
Basic	132.2	22.2	117.4	21.9	12.6
Applied	369.3	61.9	336.5	62.7	9.7
Other Qualifying	94.7	15.9	82.7	15.4	14.5
<b>Total</b>	<b>596.2</b>	<b>100.0</b>	<b>536.6</b>	<b>100.0</b>	<b>11.1</b>

\* Current expenditures exclude capital equipment and depreciation expenditures.

Source: PMPRB




**Figure 11 Current R&D Expenditures by Type of Research**  
1988-1995



Source: PMPRB

**Figure 12 Share of Current R&D Expenditures by Type of Research**  
1988-1995



Source: PMPRB

**Table 8 Current R&D Expenditures\* by R&D Performer, 1994 and 1995**

R&D Performer	1995		1994		Change 1995 / 1994 %
	\$M	%	\$M	%	
<b>Intra-mural</b>					
	339.8	57.0	317.8	59.2	6.9
<b>Extra-mural</b>					
Universities and Hospitals	131.5	22.1	128.4	23.9	2.4
Other Companies	61.4	10.3	42.4	7.9	44.8
Others	63.5	10.6	48.0	9.0	32.3
<b>Total</b>	<b>596.2</b>	<b>100.0</b>	<b>536.6</b>	<b>100.0</b>	<b>11.1</b>

\* Current expenditures exclude capital equipment and depreciation expenditures.

Source: PMPRB

**Table 9 Total R&D Expenditures\* by Source of Funds, 1994 and 1995**

Source of Funds	1995		1994		Change 1995 / 1994 %
	\$M	%	\$M	%	
Company Funds	607.1	97.3	545.7 <sup>r</sup>	97.3	11.3
Federal/Provincial Governments	7.6	1.2	8.1	1.4	-6.2
Others	9.2	1.5	7.3 <sup>r</sup>	1.3	26.0
<b>Total</b>	<b>623.9</b>	<b>100.0</b>	<b>561.1</b>	<b>100.0</b>	<b>11.2</b>

\* Total expenditures include capital equipment and allowable depreciation.  
<sup>r</sup> Revised

Source: PMPRB

**Table 10 Current R&D Expenditures\* by Location, 1994 and 1995**

Location of R&D	1995		1994		Change 1995 / 1994 %
	\$M	%	\$M	%	
Atlantic Provinces	8.4	1.4	8.8	1.6	-4.5
Québec	264.5	44.4	239.8	44.7	10.3
Ontario	268.1	45.0	236.2	44.0	13.5
Western Provinces	55.2	9.2	51.8	9.7	6.6
<b>Total</b>	<b>596.2</b>	<b>100.0</b>	<b>536.6</b>	<b>100.0</b>	<b>11.1</b>

\* Current expenditures exclude capital equipment and depreciation expenditures.

Source: PMPRB

Table 8 presents the current R&D expenditures by R&D performer and identifies the intra-mural and extra-mural expenditures. Most R&D was carried out by patentees. In 1995, 57.0% of R&D expenditures was directed to R&D performed by the patentee, compared with 59.2% in 1994. Expenditures on R&D performed by other companies on behalf of patentees incurred the largest increase, from \$42.4 million in 1994 to \$61.4 million in 1995, a 44.8% increase. Expenditures on R&D performed by universities and hospitals increased by 2.4% to \$131.5 million from 1994. The second-largest increase was 32.3% within the category "others." This category includes individuals, organizations such as private clinics and federal and provincial governments.

In 1995, as in previous years, most of the R&D expenditures of pharmaceutical patentees were funded by them. Table 9 shows that in 1995, more than 97% of all patentees' R&D was funded by internal funds and funds provided by associated companies. The share of funding by governments declined slightly to 1.2% of the total.

In 1995, R&D spending increased in all regions except the Atlantic provinces. There was no significant change in the regional distribution of R&D spending in 1995. As shown in Table 10, almost 90% of total expenditures continued to be made in Ontario and Québec.



**Table 11 Ratios of R&D Expenditures to Sales Revenues  
by Reporting Patentee<sup>1</sup>, 1994 and 1995**

Company	R&D-to-Sales Ratio (%)	
	1995	1994
3M Pharmaceuticals, 3M Canada Inc.	0.9	2.9
Abbott Laboratories, Limited	1.8	2.8
Alcon Canada Inc.	0.02	0.02
Allergan Inc.	3.9	4.8
Alpha Therapeutic Corporation	0.0	0.0
Alza Corporation	0.0	0.0
Amersham Canada Limited	2.2	1.8
Amgen Canada Inc.	103.2 <sup>2</sup>	115.0 <sup>2</sup>
Astra Pharma Inc.	10.1	9.5
Ayerst Veterinary Laboratories (Formerly Langford Inc.)	1.9	1.1
Baxter Corporation	0.2	0.2
Bayer Inc.	9.3	6.8
Bayer Inc., Agriculture Division	5.3	4.5
Berlex Canada Inc.	6.3	6.8
Block Drug Company (Canada) Ltd.	0.0	0.0
Boehringer Ingelheim (Canada) Ltd.	37.7	33.4
Boehringer Mannheim Canada Ltd.	15.2	25.9
Bristol-Myers Squibb Pharmaceutical Group	13.4	12.5
Canderm Pharmacal Ltd.	0.0	0.0
Cangene Corporation (Formerly RH Pharmaceuticals Inc.)	159.0 <sup>2</sup>	176.0 <sup>2</sup>
CIBA-Geigy Canada Ltd.	7.9	9.0
Connaught Laboratories Limited	75.1	35.8
Draxis Health Inc.	15.0	12.9
Du Pont Merck Pharma Inc.	11.5	6.4
Eli Lilly Canada Inc. (includes Provel)	11.0	8.5
Fabrigen Inc.	0.0	0.0
Ferring Inc.	5.4	10.3
Fisons Corporation Limited	1.4	7.5
Frank W. Horner Inc.	4.9	6.0
Fujisawa Canada Inc.	0.3	0.03
Galderma Canada Inc.	0.0	0.0
GenDerm Canada Inc.	1.4	1.2
Genentech Canada Inc.	7.6	16.2
Glaxo Wellcome Inc.	13.6	3
Hoechst Marion Roussel Canada Inc.	15.3	4
Hoffmann-La Roche Limited	16.3 <sup>5</sup>	26.9
Immuno (Canada) Ltd.	3.9	5.1
Johnson & Johnson Pharmaceutical Companies in Canada <sup>6</sup>	11.0	10.5
Jouveinal Inc.	2.8	1.5
Kenral Inc.	0.0	0.0
Leo Laboratories Canada Ltd.	6.0	7.3

Table 11 continued

Company	R&D-to-Sales Ratio (%)	
	1995	1994
Ligand Pharmaceuticals (Not a patentee in 1994)	22.0	
Mallinckrodt Medical Inc.	1.7	1.6
Mallinckrodt Veterinary Inc.	3.8	1.7
McNeil Consumer Products Company	2.1	7
Merck Frosst Canada Inc.	15.6	13.4
Novo Nordisk Canada Inc.	2.3	3.5
Ohmeda, Division of Canadian Oxygen Limited	1.4	1.0
Organon Canada Ltd.	1.4	1.1
Pfizer Canada Inc.	7.7 <sup>8</sup>	7.8
Pharmacia Inc.	13.9	15.7
Pharmascience Inc.	12.0	13.7
Procter & Gamble Pharmaceuticals Canada, Inc.	22.2	11.3
Purdue Frederick	5.9	6.2
Rhône-Poulenc Rorer Canada Inc.	8.7	4.6
Sandoz Canada Inc.	12.1	12.7
Sanofi Winthrop	14.5	19.0
Schering Canada Inc.	9.1	7.3
Searle Canada Inc.	8.3	5.8
Servier Canada Inc. (Not a patentee in 1994)	8.5	
SmithKline Beecham Pharma Inc.	9.0	12.3
Solvay Kingswood Inc.	8.5	4.4
The Upjohn Company of Canada (includes Animal Health)	8.8	11.2
Warner-Lambert Canada Inc. (Parke-Davis)	20.0	16.8
Warner-Wellcome Consumer Health Products	3.6	2.8
Westwood-Squibb, Division of Bristol-Myers Squibb Canada Inc.	1.6	0.0
Wyeth-Ayerst Canada Inc.	16.4 <sup>9</sup>	21.3
Yamanouchi Pharmaceutical Co., Ltd.	0.0	0.0
Zeneca Pharma Inc.	9.6	10.5

Source: PMPRB

- 1 The revenues from royalties are included in calculating each company's ratio, but are deducted, when appropriate, for the industry-wide aggregation to avoid double-counting. Federal and provincial government grants have been netted from the expenditures used to calculate the individual R&D-to-sales ratios but are included in the aggregate statistics. Differences between the list of firms filing data on prices and those filing R&D data are due to differences in reporting practices between patentees and their affiliates or licencees.
- 2 These ratios have been verified with the firm and are due to the fact that funding for R&D expenditures was provided by associated companies.
- 3 Glaxo Canada Inc. purchased Burroughs Wellcome Inc. in July 1995 to form Glaxo Wellcome Inc. The R&D-to-sales ratios for Burroughs Wellcome Inc. and Glaxo Canada Inc. were, respectively, 16.9% and 12.5% in 1994.
- 4 Hoechst Roussel Canada Inc. and Marion Merrell Dow Canada merged in 1995 to form Hoechst Marion Roussel Canada Inc. The R&D-to-sales ratios for Hoechst Roussel Canada Inc. and Marion Merrell Dow Canada were, respectively, 17.1% and 14.1% in 1994.
- 5 Includes Syncare Pharmaceutical Inc. and Syntex Inc. in 1995. The R&D-to-sales ratios for Syncare Pharmaceutical Inc. and Syntex Inc. were 0.0% and 7.3% respectively in 1994.
- 6 Ortho-McNeil Inc. and Janssen Pharmaceutica Inc.
- 7 Included with Ortho-McNeil Inc. under Johnson & Johnson Pharmaceutical Companies in Canada in 1994.
- 8 SmithKline Beecham Animal Health business in Canada was purchased by Pfizer Canada Inc. in 1995. The R&D-to-sales ratio for SmithKline Beecham Animal Health was 1.2% in 1994.
- 9 Wyeth-Ayerst Canada Inc. bought Cyanamid Canada Inc. in 1995. The R&D-to-sales ratio for Cyanamid Canada Inc. was 6.2% in 1994.



**Table 12 Current R&D Expenditures by Province and by R&D Performer, 1995**

Province		R&D Performer					Total	Percentage of Expenditures
		Patentees	Other Companies	Universities	Hospitals	Others		
Newfoundland	\$(000) %	639.11 37.5	43.26 2.5	415.79 24.4	300.35 17.6	305.93 18.0	1,704.43 100	0.29
Prince Edward Island	\$(000) %	3.67 2.6	0.0 0.0	30.51 21.5	3.11 2.2	104.44 73.7	141.73 100	0.02
Nova Scotia	\$(000) %	667.69 11.2	278.06 4.7	1,180.02 19.8	2,513.46 42.1	1,325.39 22.2	5,964.62 100	1.00
New Brunswick	\$(000) %	50.30 8.8	20.92 3.6	70.59 12.3	177.10 30.9	254.76 44.4	573.67 100	0.10
Québec	\$(000) %	170,101.62 64.3	33,689.07 12.7	9,540.24 3.6	29,298.47 11.1	21,818.71 8.3	264,448.11 100	44.36
Ontario	\$(000) %	158,063.01 59.0	23,234.49 8.6	17,931.39 6.7	38,840.04 14.5	30,042.13 11.2	268,111.07 100	44.97
Manitoba	\$(000) %	3,075.85 36.7	432.15 5.2	1,093.37 13.0	2,041.30 24.3	1,743.94 20.8	8,386.61 100	1.41
Saskatchewan	\$(000) %	355.83 7.6	239.60 5.1	1,713.49 36.6	1,560.65 33.4	810.96 17.3	4,680.54 100	0.78
Alberta	\$(000) %	3,606.09 15.8	1,422.05 6.2	8,961.94 39.3	4,725.98 20.7	4,101.58 18.0	22,817.64 100	3.83
British Columbia	\$(000) %	3,235.79 16.7	1,995.82 10.3	4,210.96 21.8	6,880.30 35.6	3,014.43 15.6	19,337.30 100	3.24
Yukon & N.W.T.	\$(000) %	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0 100	0.00
Canada	\$(000) %	339,798.96 57.0	61,355.43 10.3	45,148.30 7.6	86,340.76 14.5	63,522.28 10.6	596,165.72 100	

Source: PMPRB

- The percentage under each R&D category gives the percentage of all money spent in that category in that province.
- Expenditures as a percentage of total means percentage of R&D expenditures in that province compared to total R&D in Canada.
- Rows and columns may not equal totals due to rounding.
- Current expenditures plus capital expenditures (equipment + depreciation) = total R&D expenditures.

# Glossary

---

**Note To Reader:** This glossary is included for the convenience of the reader. For more detailed information and definitions please refer to the Patent Act, the Patented Medicines Regulations and the Compendium of Guidelines, Policies and Procedures, or contact the PMPRB.

**Active Ingredient:** Chemical responsible for the claimed pharmacologic effect of a drug product.

**Advanced Ruling Certificate (ARC):** A non-binding certificate may be issued pursuant to subsection 98(4) of the Act at the request of a patentee when the Board is satisfied that the price or proposed price of the medicine would not exceed the maximum non-excessive price under the Board's Guidelines.

**ATC:** Anatomical Therapeutic Chemical classification system that divides drugs into different groups according to their site of action and therapeutic and chemical characteristics. This system is used as a guide for selecting comparable medicines for purposes of price review.

**Dedication of Patent:** A practice whereby a patentee notifies the Commissioner of Patents that it has surrendered its rights and entitlements flowing from the patent for the benefit of the public to use and enjoy (PMPRB Bulletin 15, January 1995, p.4).

**Drug Identification Number (DIN):** A registration number that the Health Protection Branch of Health Canada assigns to each prescription and non-prescription drug product marketed under the Food and Drug Regulations. The DIN is assigned using information in the following areas: manufacturer of the product; active ingredient(s); strength of active ingredient(s); pharmaceutical dosage form; brand/trade name; and route of administration.

**Drug Product:** A particular presentation of a medicine characterized by its pharmaceutical dosage form and the strength of the active ingredient(s).

**Drug Product, Existing:** An existing drug product is a DIN for which a benchmark price has been established in accordance with the Board's Guidelines. (See Chapter 1, subsection 3.3 of the Compendium of Guidelines, Policies and Procedures.)

**Drug Product, New:** A new drug product is one for which the introductory price is under review. Drug products are considered new in the year during which they are introduced in Canada. For price review purposes, new drug products for 1995 are those introduced between December 1, 1994 and November 30, 1995. Because of the filing requirements under the Patented Medicines Regulations and the manner of calculating benchmark prices, drug products introduced in December are considered to have been introduced in the following year. (See Chapter 1, subsection 3.2 of the Compendium of Guidelines, Policies and Procedures.)

**Emergency Drug Release (EDR) Program:** A program operated by Health Canada to give practitioners access to drugs that are not approved or otherwise available for sale in Canada. Health Canada may authorize the sale of a quantity of drug for use in the treatment of a patient under the care of that practitioner.

**Generic Product:** A drug product with the same active ingredient, strength and dosage form of a brand-name drug product.

**General Public (GP) Number:** A number that the Health Protection Branch of Health Canada assigns to proprietary medicines that are registered according to the requirements of Division 10 of the Food and Drug Regulations. These products may be sold in non-pharmacy outlets in certain provinces.

**Investigational New Drug (IND):** A drug that has been authorized for clinical evaluation (i.e., testing on humans) by Health Canada but that is not yet approved for sale for the indication under study.



**Licence, Compulsory:** A licence granted by the Commissioner of Patents in accordance with subsection 39(4) of the Patent Act that has been continued pursuant to subsection 11(1) of the Patent Act Amendment Act, 1992 which permits the licensee to import, make, use or sell a patented invention pertaining to a medicine. Royalties payable are determined by the Commissioner of Patents who sets the terms of licences pursuant to subsection 39(5) of the Patent Act. Except for those compulsory licences issued prior to December 20, 1991, which are continued pursuant to subsection 11(1) of the Patent Act, licences issued after December 20, 1991 have no effect.

**Licence, Voluntary:** A contractual agreement between a patent holder and a licensee under which the licensee is entitled to enjoy the benefit of the patent or to exercise any rights in relation to the patent for some consideration (i.e., royalties in the form of a share of the licensee's sales).

**Medicine:** Any substance or mixture of substances made by any means, whether produced biologically, chemically, or otherwise, that is applied or administered in vivo in humans or in animals to aid in the diagnosis, treatment, mitigation or prevention of disease, symptoms, disorders, abnormal physical states, or modifying organic functions in humans and or animals, however administered.

For greater certainty, this definition includes vaccines, topical preparations, anaesthetics and diagnostic products used in vivo, regardless of delivery mechanism (e.g., transdermal, capsule form, injectable, inhaler, etc.). This definition excludes medical devices, in vitro diagnostic products and disinfectants that are not used in vivo (Compendium of Guidelines, Policies and Procedures, Introduction, subsection 1.5).

**Notice of Compliance (NOC):** A notice in respect of a medicine issued by the Health Protection Branch of Health Canada under section C.08.004 of the Food and Drug Regulations. The issuance of a NOC indicates that a drug product meets the required Health Canada standards for use in humans or animals and that the product is approved for sale in Canada.

**Patent:** An instrument issued by the Commissioner of Patents in the form of letters patent for an invention that provides its holder with a monopoly, limited in time, for the claims made within the patent. A patent gives the patentee the exclusive right to make, sell or otherwise exploit the invention for the term of the patent.

**Patentee:** As defined by subsection 79(1) of the Patent Act, "the person for the time being entitled to the benefit of the patent for that invention (pertaining to a medicine) and includes, where any other person is entitled to exercise any rights in relation to that patent other than under a licence continued by subsection 11(1) of the Patent Act Amendment Act, 1992, that other person in respect of those rights;"

**Research and Development (R&D):** Basic or applied research for the purpose of creating new, or improving existing, materials, devices, products or processes (e.g., manufacturing processes).

#### **Research and Development — Applied**

**Research:** Work that advances scientific knowledge with a specific practical application in view such as creating new or improved products or processes through manufacturing processes or through preclinical or clinical studies.

#### **Research and Development — Basic**

**Research:** Work that advances scientific knowledge without a specific application in view.

**Research and Development — Clinical**

**Research:** The assessment of the effect of a new medicine on humans. It typically consists of three successive phases, beginning with limited testing for safety in healthy humans then proceeding to further safety and efficacy studies in patients suffering from the target disease.

**Research and Development — Preclinical**

**Research:** Tests on animals to evaluate the pharmacological and toxicological effects of medicines.

**Research and Development Expenditures:**

For the purposes of the Patented Medicines Regulations, 1994, in particular sections 5 and 6, research and development includes activities for which expenditures would have qualified for the investment tax credit for scientific research and experimental development under the Income Tax Act as it read on December 1, 1987.

**Voluntary Compliance Undertaking (VCU):**

A written undertaking by a patentee to adjust its price to conform with the PMPRB's Excessive Price Guidelines (see Chapter 1 of the Compendium of Guidelines, Policies and Procedures). Pursuant to the Board's Compliance and Enforcement Policy (see Chapter 2, section 7) the Chairperson or the Board may approve a VCU in lieu of issuing a Notice of Hearing if it is consistent with the Patent Act and the policies of the Board and in the public interest. The Board reports publicly on all VCUs approved by the Chairperson or the Board.



**Table 13**  
**Patented Drug Products Introduced in Canada in 1995**

**HUMAN**

**Category 1**

Brand Name	DIN	Company
ADENOSCAN - 3MG/ML	02139294	FUJISAWA CANADA INC.
AREDIA - 60MG/VIAL	02059770	CIBA-GEIGY CANADA LTD.
COLESTID - 1000MG/TAB	02132680	THE UPJOHN COMPANY OF CANADA
COLESTID - 5000MG/DOSE	02132699	THE UPJOHN COMPANY OF CANADA
DIDROCAL	02176017	PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.
DIFLUCAN - 150MG/CAP	02141442	PFIZER CANADA INC.
DOVONEX - 0.05MG/G	02150956	LEO LABORATORIES CANADA LTD.
FLOVENT - 0.025MG/DOSE	02174731	GLAXO WELLCOME INC.
FLOVENT - 0.05MG/DOSE	02174758	GLAXO WELLCOME INC.
FLOVENT - 0.125MG/DOSE	02174766	GLAXO WELLCOME INC.
FLOVENT - 0.25MG/DOSE	02174774	GLAXO WELLCOME INC.
GYNECURE VAGINAL - 300MG/OVULE	02095009	PFIZER CANADA INC.
*GYNECURE TANDEM	02171902	PFIZER CANADA INC.
*GYNECURE TANDEM	02171910	PFIZER CANADA INC.
HYDROMORPH CONTIN - 3MG/CAP	02125323	PURDUE FREDERICK
HYDROMORPH CONTIN - 6MG/CAP	02125331	PURDUE FREDERICK
IMITREX - 50MG/TAB	02163764	GLAXO WELLCOME INC.
INNOHEP - 10000UNIT/ML	02167840	LEO LABORATORIES CANADA LTD.
INNOHEP - 11700UNIT/ML	02167859	LEO LABORATORIES CANADA LTD.
IOPIDINE - 5MG/ML	02076306	ALCON CANADA INC.
LIPIDIL MICRO - 200MG/CAP	02146959	JOUVEINAL INC.
MANERIX - 300MG/TAB	02166747	HOFFMANN-LA ROCHE LIMITED
OCTOSTIM - 0.015MG/ML	02024179	FERRING INC.
OCTOSTIM - 0.15MG/DOSE		FERRING INC.
*PMS-FLUOXETINE - 10MG/CAP	02177579	PHARMASCIENCE INC.
*PMS-FLUOXETINE - 20MG/CAP	02177587	PHARMASCIENCE INC.
QUINTASA - 1000MG/DOSE	02153521	FERRING INC.
QUINTASA - 1000MG/SUP	02153564	FERRING INC.
QUINTASA - 2000MG/DOSE	02153548	FERRING INC.
QUINTASA - 4000MG/DOSE	02153556	FERRING INC.
RENOVA - 0.5MG/G	02052407	JANSSEN-ORTHO INC.
SANDIMMUNE NEORAL - 100MG/CAP	02150670	SANDOZ CANADA INC.
SANDIMMUNE NEORAL - 100MG/ML	02150697	SANDOZ CANADA INC.
SANDIMMUNE NEORAL - 25MG/CAP	02150689	SANDOZ CANADA INC.
SANDIMMUNE NEORAL - 50MG/CAP	02150662	SANDOZ CANADA INC.
SEREVENT - 0.025MG/DOSE	02136139	GLAXO WELLCOME INC.
TIMOPTIC XE - 2.5MG/ML	02171880	MERCK FROSST CANADA INC.
TIMOPTIC XE - 5MG/ML	02171899	MERCK FROSST CANADA INC.

**Category 2**

Brand Name	DIN	Company	New Chemical Entity
ZINECARD - 250MG/VIAL	02153432	PHARMACIA INC.	NCE
ZINECARD - 500MG/VIAL	02153440	PHARMACIA INC.	NCE

**Category 3**

Brand Name	DIN	Company	New Chemical Entity
AQUASITE 2/1	02029901	CIBA-GEIGY CANADA LTD.	
BIAXIN - 25MG/ML	02146908	ABBOTT LABORATORIES LIMITED	
CEFTIN - 250MG/POUCH	02145286	GLAXO WELLCOME INC.	
CEFTIN - 25MG/ML	01943049	GLAXO WELLCOME INC.	
CEFZIL - 250MG/TAB	02163659	BRISTOL-MYERS SQUIBB PHARMACEUTICAL GROUP	NCE
CEFZIL - 25MG/ML	02163675	BRISTOL-MYERS SQUIBB PHARMACEUTICAL GROUP	NCE
CEFZIL - 500MG/TAB	02163667	BRISTOL-MYERS SQUIBB PHARMACEUTICAL GROUP	NCE
CEFZIL - 50MG/ML	02163683	BRISTOL-MYERS SQUIBB PHARMACEUTICAL GROUP	NCE
*CELLCEPT - 250MG/CAP	02192748	HOFFMANN-LA ROCHE LIMITED	
COZAAR - 25MG/TAB	02182815	MERCK FROSST CANADA INC.	NCE

COZAAR - 50MG/TAB	02182874	MERCK FROSST CANADA INC.	NCE
CYTOVENE - 250MG/CAP	02186802	HOFFMANN-LA ROCHE LIMITED	
DDAVP - 0.1MG/TAB	00824305	FERRING INC.	
DDAVP - 0.2MG/TAB	00824143	FERRING INC.	
DEMADEX - 100MG/TAB	02129035	BOEHRINGER MANNHEIM CANADA LTD.	NCE
DEMADEX - 10MG/TAB	02129019	BOEHRINGER MANNHEIM CANADA LTD.	NCE
DEMADEX - 5MG/TAB	02129000	BOEHRINGER MANNHEIM CANADA LTD.	NCE
*DEMADEX - 10MG/ML	02129094	BOEHRINGER MANNHEIM CANADA LTD.	
DIFLUCAN - 10MG/ML	02024152	PFIZER CANADA INC.	
ENTOCORT - 0.02MG/ML	02052431	ASTRA PHARMA INC.	
ESTRING - 2MG/RING	02168898	PHARMACIA INC.	
FAMVIR - 500MG/TAB	02177102	SMITHKLINE BEECHAM PHARMA INC.	NCE
FRAGMIN - 10000UNIT/ML	02132664	PHARMACIA INC.	NCE
FRAGMIN - 12500UNIT/ML	02132621	PHARMACIA INC.	NCE
FRAGMIN - 25000UNIT/ML	02132648	PHARMACIA INC.	NCE
FRAGMIN - 2500UNIT/ML	02132656	PHARMACIA INC.	NCE
LAMICTAL - 100MG/TAB	02142104	GLAXO WELLCOME INC.	NCE
LAMICTAL - 150MG/TAB	02142112	GLAXO WELLCOME INC.	NCE
LAMICTAL - 25MG/TAB	02142082	GLAXO WELLCOME INC.	NCE
LOGIPARIN - 10000UNIT/ML	02056682	NOVO NORDISK CANADA INC.	NCE
*MAXIPIME - 1000MG/VIAL	02163632	BRISTOL-MYERS SQUIBB PHARMACEUTICAL GROUP	
*MAXIPIME - 2000MG/VIAL	02163640	BRISTOL-MYERS SQUIBB PHARMACEUTICAL GROUP	
MEPRON - 250MG/TAB	02009358	GLAXO WELLCOME INC.	
NEUROLITE - 20MCI/TEST		DU PONT MERCK PHARMA INC.	NCE
OCUFLOX - 3MG/ML	02143291	ALLERGAN INC.	
ORGARAN - 1250UNIT/ML	02129043	ORGANON CANADA LTD. (AKZO)	NCE
PHOTOFRIN - 15MG/VIAL	02020033	LIGAND PHARMACEUTICALS INC.	NCE
PHOTOFRIN - 75MG/VIAL	02019876	LIGAND PHARMACEUTICALS INC.	NCE
PREVACID - 15MG/CAP	02165503	ABBOTT LABORATORIES LIMITED	NCE
PREVACID - 30MG/CAP	02165511	ABBOTT LABORATORIES LIMITED	NCE
PRIMACOR - 1MG/ML	02006391	SANOFI WINTHROP	NCE
PROLEUKIN - 22000000UNIT/VIAL	02130181	LIGAND PHARMACEUTICALS INC.	NCE
SEVORANE - 1000MG/ML	02172763	ABBOTT LABORATORIES LIMITED	NCE
TAXOTERE - 20MG/VIAL	02177099	RHONE-POULENC RORER CANADA INC.	NCE
TAXOTERE - 80MG/VIAL	02177080	RHONE-POULENC RORER CANADA INC.	NCE
VISIPAQUE 270 - 550MG/ML	02145766	SANOFI WINTHROP	NCE
VISIPAQUE 320 - 652MG/ML	02145774	SANOFI WINTHROP	NCE
ZEMURON - 10MG/ML	02108208	ORGANON CANADA LTD. (AKZO)	NCE
ZONALON - 50MG/G	02142147	GENDERM CANADA INC.	

## VETERINARY

### Category 1

Brand Name	DIN	Company	
INTERCEPTOR FLAVOUR - 11.5MG/TAB	02141418	CIBA-GEIGY CANADA LTD.	
INTERCEPTOR FLAVOUR - 2.3MG/TAB	02141434	CIBA-GEIGY CANADA LTD.	
INTERCEPTOR FLAVOUR - 23MG/TAB	02141396	CIBA-GEIGY CANADA LTD.	
INTERCEPTOR FLAVOUR - 5.75MG/TAB	02141426	CIBA-GEIGY CANADA LTD.	
PROGRAM - 266MG/UNIT	02192632	CIBA-GEIGY CANADA LTD.	
SUPER-OV - 7.5UNIT/ML	02126214	BOEHRINGER INGELHEIM (CANADA) LTD.	

### Category 2

Brand Name	DIN	Company	New Chemical Entity
OPTIMMUNE - 2MG/G	02142155	SCHERING CANADA INC.	

### Category 3

Brand Name	DIN	Company	New Chemical Entity
DRONTAL	02083566	BAYER INC., AGRICULTURAL DIVISION	

\* Introduced in December 1995 and under the Board's Guidelines will be reviewed in 1996.



**Table 14**  
**Patented Drug Products and Canadian Patentees,**  
**January 1 - December 31, 1995**

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
<b>3M PHARMACEUTICALS, 3M CANADA INC.</b>					
<b>Human:</b>					
02162806	MINITRAN 0.2 - 18MG/PATCH	nitroglycerin	C01DA01	transdermal patch	not sold
02163527	MINITRAN 0.4 - 36MG/PATCH	nitroglycerin	C01DA01	transdermal patch	not sold
02163535	MINITRAN 0.6 - 54MG/PATCH	nitroglycerin	C01DA01	transdermal patch	not sold
02164337	MINITRAN 0.8 - 72MG/PATCH	nitroglycerin	C01DA01	transdermal patch	not sold
01966200	TAMBOCOR - 100MG/TAB	flecainide acetate	C01BC02	tablet	
00817155	TAMBOCOR - 150MG/TAB	flecainide acetate	C01BC02	tablet	not sold
00628239	TAMBOCOR - 200MG/TAB	flecainide acetate	C01BC02	tablet	not sold
01966197	TAMBOCOR - 50MG/TAB	flecainide acetate	C01BC02	tablet	
<b>ABBOTT LABORATORIES LIMITED</b>					
<b>Human:</b>					
00749702	ABBOKINASE - 250000UNIT/VIAL	urokinase	B01AD01	powder for injectable solution	expired
01984853	BIAXIN - 250MG/TAB	clarythromycin	J01FA03	tablet	
02146908	BIAXIN - 25MG/ML	clarythromycin	J01FA03	powder for oral suspension	introduced
02126710	BIAXIN - 500MG/TAB	clarythromycin	J01FA03	tablet	
00891738	CALCIJEX - 0.001MG/ML	calcitriol	A11CC04	injectable solution	
00891746	CALCIJEX - 0.002MG/ML	calcitriol	A11CC04	injectable solution	
00596418	EPIVAL - 125MG/TAB	divalproex sodium	N03AG02	enteric-coated tablet	
00596426	EPIVAL - 250MG/TAB	divalproex sodium	N03AG02	enteric-coated tablet	
00596434	EPIVAL - 500MG/TAB	divalproex sodium	N03AG02	enteric-coated tablet	
00893862	ERYBID - 500MG/TAB	erythromycin	J01FA01	tablet	
00682276	ERYTHROCIN ADD-VANTAGE - 1000MG/VIAL	erythromycin lactobionate	J01FA01	powder for injectable solution	
00682268	ERYTHROCIN ADD-VANTAGE - 500MG/VIAL	erythromycin lactobionate	J01FA01	powder for injectable solution	
00818674	HYTRIN - 10MG/TAB	terazosin hydrochloride	C02CA03	tablet	
00818658	HYTRIN - 1MG/TAB	terazosin hydrochloride	C02CA03	tablet	
00818682	HYTRIN - 2MG/TAB	terazosin hydrochloride	C02CA03	tablet	
00818666	HYTRIN - 5MG/TAB	terazosin hydrochloride	C02CA03	tablet	
00727695	LUPRON - 5MG/ML	leuprolide acetate	L02AE01	injectable solution	expired
00884502	LUPRON DEPOT - 3.75MG/VIAL	leuprolide acetate	L02AE01	injectable solution	
00836273	LUPRON DEPOT - 7.5MG/VIAL	leuprolide acetate	L02AE01	injectable solution	
00769991	PCE DISPERTAB - 333MG/TAB	erythromycin	J01FA01	tablet	
02165503	PREVACID - 15MG/CAP	lansoprazole	A02BC02	sustained-release capsule	introduced (nce)
02165511	PREVACID - 30MG/CAP	lansoprazole	A02BC02	sustained-release capsule	introduced (nce)
02172763	SEVORANE - 1000MG/ML	sevoflurane	N01AB04	inhalation anesthetic	introduced (nce)
02016109	SURVANTA - 25MG/ML	beractant	R07AA02	endo-tracheal suspension	
<b>ALCON CANADA INC.</b>					
<b>Human:</b>					
00893560	ALOMIDE - 1MG/ML	lodoxamide tromethamine	S01GX02	ophthalmic solution	expired
00695688	BETOPTIC - 5MG/ML	betaxolol hydrochloride	S01ED02	ophthalmic solution	
01908448	BETOPTIC S - 2.5MG/ML	betaxolol hydrochloride	S01ED02	ophthalmic suspension	
00568082	BSS PLUS	sodium bicarbonate/ dextrose/glutathione	S01XA51	ophthalmic solution	
01945270	CILOXAN - 3MG/ML	ciprofloxacin hydrochloride	S01AA09	ophthalmic solution	
00888354	IOPIDINE - 10MG/ML	apraclonidine hydrochloride	S01XA05	ophthalmic solution	
02076306	IOPIDINE - 5MG/ML	apraclonidine hydrochloride	S01XA05	ophthalmic solution	introduced
00575240	PILOPINE-HS - 40MG/G	pilocarpine hydrochloride	S01EB01	ophthalmic gel	
00390291	TEARS NATURELE 1/3	dextran/hydroxypropyl methylcellulose	S01XA04	ophthalmic solution	
00743445	TEARS NATURELE II 1/3	dextran/hydroxypropyl methylcellulose	S01XA04	ophthalmic drops	
<b>ALLERGAN INC.</b>					
<b>Human:</b>					
01968300	ACULAR - 5MG/ML	ketorolac tromethamine	S01BC03	ophthalmic solution	
	ILOTYCIN - 5MG/G	erythromycin	S01AA07	ointment	
02011255	NAFTIN - 10MG/G	naftifine hydrochloride	D01AE08	cream	
02011263	NAFTIN - 10MG/G	naftifine hydrochloride	D01AE08	gel	
02143291	OCUFLOX - 3MG/ML	ofloxacin	S01AA10	ophthalmic solution	introduced

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
<b>ALPHA THERAPEUTIC CORPORATION</b>					
<b>Human:</b>					
01924745	ALPHANINE - 1UNIT/DOSE	factor IX(human)	B02BD01	injectable solution	not sold
	ALPHANINE SD - 1UNIT/DOSE	factor IX(human)	B02BD01	injectable solution	
00740780	PROFILATE - 1UNIT/DOSE	antihemophilic factor	B02BD03	injectable solution	not sold
<b>ALZA CORPORATION</b>					
<b>Human:</b>					
00328200	OCUSERT - 11MG/IMP	pilocarpine	S01EB01	ophthalmic device	expired
00328197	OCUSERT - 5MG/IMP	pilocarpine	S01EB01	ophthalmic device	expired
00327379	PROGESTASERT - 38MG/WIR	progesterone	G02BA02	intra-uterine device	expired
<b>AMERSHAM CANADA LIMITED</b>					
<b>Human:</b>					
	CERETEC	technetium tc-99m exametazime	V04DA03	powder for injectable solution	
	HEPATATE II	technetium tc-99m tin colloid	V04DA13	powder for injectable solution	
	MEDRONATE II	technetium tc-99m medronate sodium	V04DA06	powder for injectable solution	
<b>AMGEN CANADA INC.</b>					
<b>Human:</b>					
01968017	NEUPOGEN - 0.3MG/ML	filgrastim	L03AA02	injectable solution	
<b>ASTRA PHARMA INC.</b>					
<b>Human:</b>					
02148641	BAMBEC - 10MG/TAB	bambuterol hydrochloride		tablet	not sold
02148668	BAMBEC - 20MG/TAB	bambuterol hydrochloride		tablet	not sold
00402540	BETALOC - 100MG/TAB	metoprolol tartrate	C07AB01	tablet	
00719846	BETALOC - 1MG/ML	metoprolol tartrate	C07AB01	injectable solution	
00402605	BETALOC - 50MG/TAB	metoprolol tartrate	C07AB01	tablet	
02028743	BETALOC CR - 190MG/TAB	metoprolol succinate	C07AB01	sustained-release tablet	not sold
02028727	BETALOC CR - 47.5MG/TAB	metoprolol succinate	C07AB01	sustained-release tablet	not sold
02028735	BETALOC CR - 95MG/TAB	metoprolol succinate	C07AB01	sustained-release tablet	not sold
00497827	BETALOC DURULES - 200MG/TAB	metoprolol tartrate	C07AB01	sustained-release tablet	
00444774	BRICANYL SPACER - 0.25MG/DOSE	terbutaline sulfate	R03AC02	aerosol for inhalation	not sold
00786616	BRICANYL TURBUHALER - 0.5MG/DOSE	terbutaline sulfate	R03AC02	powder for inhalation	
01958100	CARDURA-1 - 1MG/TAB	doxazosin mesylate	C02CA04	tablet	
01958097	CARDURA-2 - 2MG/TAB	doxazosin mesylate	C02CA04	tablet	
01958119	CARDURA-4 - 4MG/TAB	doxazosin mesylate	C02CA04	tablet	
00886858	EMLA 25/25	lidocaine/prilocaine	D04AB52	cream	
02057794	EMLA 25/25	lidocaine/prilocaine	D04AB52	transdermal patch	
02166062	EMLA 25/25	lidocaine/prilocaine	D04AB52	cream	not sold
02052431	ENTOCORT - 0.02MG/ML	budesonide	A07EA04	enema	introduced
02134810	FOSCAVIR - 24MG/ML	foscarnet sodium		injectable solution	not sold
02119579	LOSEC - 10MG/CAP	omeprazole	A02BC01	capsule	not sold
00846503	LOSEC - 20MG/CAP	omeprazole	A02BC01	capsule	
02016788	LOSEC - 40MG/CAP	omeprazole	A02BC01	capsule	not sold
00749362	NITROGARD-SR - 1MG/TAB	nitroglycerin	C01DA01	sustained-release tablet	
00749397	NITROGARD-SR - 2MG/TAB	nitroglycerin	C01DA01	sustained-release tablet	
00749389	NITROGARD-SR - 3MG/TAB	nitroglycerin	C01DA01	sustained-release tablet	
00749370	NITROGARD-SR - 5MG/TAB	nitroglycerin	C01DA01	sustained-release tablet	
00627127	PENGLOBE - 400MG/TAB	bacampicillin hydrochloride	J01CA07	tablet	
00627135	PENGLOBE - 800MG/TAB	bacampicillin hydrochloride	J01CA07	tablet	
00851787	PLENDIL - 10MG/TAB	felodipine	C08CA03	sustained-release tablet	
02057778	PLENDIL - 2.5MG/TAB	felodipine	C08CA03	sustained-release tablet	
00851779	PLENDIL - 5MG/TAB	felodipine	C08CA03	sustained-release tablet	
00817228	PULMICORT INHALER - 0.05MG/DOSE	budesonide	R03BA02	aerosol for inhalation	not sold
00634549	PULMICORT INHALER - 0.2MG/DOSE	budesonide	R03BA02	aerosol for inhalation	not sold
01978918	PULMICORT NEBUAMP - 0.25MG/ML	budesonide	R03BA02	suspension for inhalation	
01978926	PULMICORT NEBUAMP - 0.5MG/ML	budesonide	R03BA02	suspension for inhalation	
00634530	PULMICORT SPACER - 0.05MG/DOSE	budesonide	R03BA02	aerosol for inhalation	not sold



DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
00814091	PULMICORT SPACER - 0.2MG/DOSE	budesonide	R03BA02	aerosol for inhalation	not sold
00852074	PULMICORT TURBUHALER - 0.1MG/DOSE	budesonide	R03BA02	powder for inhalation	
00851752	PULMICORT TURBUHALER - 0.2MG/DOSE	budesonide	R03BA02	powder for inhalation	
00851760	PULMICORT TURBUHALER - 0.4MG/DOSE	budesonide	R03BA02	powder for inhalation	
02051788	RAMACE - 1.25MG/CAP	ramipril	C02EA09	capsule	not sold
02051796	RAMACE - 2.5MG/CAP	ramipril	C02EA09	capsule	not sold
02051818	RAMACE - 5MG/CAP	ramipril	C02EA09	capsule	not sold
01974424	RHINOCORT AQ NASAL AEROSOL - 0.05MG/DOSE	budesonide	R01AD03	nasal aerosol	not sold
01974432	RHINOCORT AQ NASAL AEROSOL - 0.1MG/DOSE	budesonide	R01AD03	nasal aerosol	
00636460	RHINOCORT NASAL AEROSOL - 0.05MG/DOSE	budesonide	R01AD03	nasal aerosol	
02035324	RHINOCORT TURBUHALER - 0.1MG/DOSE	budesonide	R01AD03	powder for nasal inhalation	
02035340	RHINOCORT TURBUHALER - 0.2MG/DOSE	budesonide	R01AD03	powder for nasal inhalation	not sold
02036401	ROXIAM - 100MG/ML	remoxipride hydrochloride		injectable solution	not sold
02036371	ROXIAM - 150MG/CAP	remoxipride hydrochloride		capsule	not sold
02036398	ROXIAM - 300MG/CAP	remoxipride hydrochloride		capsule	not sold
02036363	ROXIAM - 75MG/CAP	remoxipride hydrochloride		capsule	not sold

## AYERST VETERINARY LABORATORIES

00844292	AMIGLYDE - V - 250MG/ML	amikacin sulfate		injectable solution	
00844306	AMIGLYDE - V - 50MG/ML	amikacin sulfate		injectable solution	not sold
00844225	CEFA - 1000MG/TAB	cefadroxil		tablet	
00844241	CEFA - 100MG/TAB	cefadroxil		tablet	
00844233	CEFA - 200MG/TAB	cefadroxil		tablet	
00849413	CEFA - 50MG/ML	cefadroxil		powder for oral solution	
00844284	CEFA - 50MG/TAB	cefadroxil		tablet	
	ECOLAN	escherichia coli		injectable suspension	not sold
	ECOLAN-RC	escherichia coli rota corona		injectable suspension	
00573760	FACTREL - 0.05MG/ML	gonadorelin hydrochloride		injectable solution	expired
02148676	GUARDIAN - 0.03MG/TAB	moxidectin		tablet	not sold
02148684	GUARDIAN - 0.068MG/TAB	moxidectin		tablet	not sold
02148692	GUARDIAN - 0.136MG/TAB	moxidectin		tablet	not sold
	HEVLAN TC (VACCINE)	hemorrhagic enteritis		injectable suspension	not sold
	SYNCHROCEPT-B - 0.5MG/ML	fenprostalene		injectable solution	
00845000	TORBUGESIC - 10MG/ML	butorphanol tartrate		injectable solution	
00844993	TORBUTROL - 10MG/TAB	butorphanol tartrate		tablet	
00844977	TORBUTROL - 1MG/TAB	butorphanol tartrate		tablet	
00844985	TORBUTROL - 5MG/TAB	butorphanol tartrate		tablet	

## BAXTER CORPORATION

<b>Human:</b>					
	GAMMAGARD S/D - 50MG/ML	immune globulin intravenous (human)	J06BA02	powder for injectable solution	
00808709	HEMOFIL-M	factor VIII	B02BD02	powder for injectable solution	
00690279	INTRALIPID 10%	fat emulsion	B05BA02	injectable solution	dedicated <sup>1</sup>
00690287	INTRALIPID 20%	fat emulsion	B05BA02	injectable solution	dedicated <sup>1</sup>

## BAYER INC.

<b>Human:</b>					
00852082	ADALAT FT - 10MG/TAB	nifedipine	C08CA01	tablet	not sold
02155907	ADALAT XL - 30MG/TAB	nifedipine	C08CA01	sustained-release tablet	
02155990	ADALAT XL - 60MG/TAB	nifedipine	C08CA01	sustained-release tablet	
	BILTRICIDE - 600MG/TAB	praziquantel	P02BA01	tablet	
00629243	CANESTEN 1 - 500MG/TAB	clotrimazole	G01AF02	vaginal insert	not sold
02150948	CANESTEN 1 COMBI-PAK	clotrimazole	G01AF02	vaginal insert and cream	
02155931	CIPRO - 100MG/TAB	ciprofloxacin hydrochloride	J01MA02	tablet	
02155958	CIPRO - 250MG/TAB	ciprofloxacin hydrochloride	J01MA02	tablet	
02155966	CIPRO - 500MG/TAB	ciprofloxacin hydrochloride	J01MA02	tablet	
02155974	CIPRO - 750MG/TAB	ciprofloxacin hydrochloride	J01MA02	tablet	
02155982	CIPRO IV - 10MG/ML	ciprofloxacin lactate	J01MA02	injectable solution	

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
01902695	GAMIMUNE N - 100MG/ML	immune globulin intravenous (human)	J06BA02	injectable solution	not sold
00559261	GAMIMUNE N - 50MG/ML	immune globulin intravenous (human)	J06BA02	injectable solution	
02155923	NIMOTOP - 30MG/CAP	nimodipine	N07XC01	capsule	
02155915	NIMOTOP IV - 0.2MG/ML	nimodipine	N07XC01	injectable solution	
02190893	PRANDASE - 100MG/TAB	acarbose	A10BF01	tablet	not sold
02190885	PRANDASE - 50MG/TAB	acarbose	A10BF01	tablet	not sold
00803529	PROLASTIN - 25MG/ML	alpha1-proteinase	R07AX01	powder for injectable solution	
02020572	THROMBATE III - 1000UNIT/VIAL	antithrombin III	B01AB03	powder for injectable solution	not sold
02020580	THROMBATE III - 500UNIT/VIAL	antithrombin III	B01AB03	powder for injectable solution	

## BAYER INC., AGRICULTURAL DIVISION

### Veterinary:

	BAYTRIL - 100MG/ML	enrofloxacin		oral suspension	not sold
	BAYTRIL - 100MG/ML	enrofloxacin		injectable solution	not sold
00812285	BAYTRIL - 22.7MG/ML	enrofloxacin		injectable solution	not sold
00719773	BAYTRIL - 22.7MG/TAB	enrofloxacin		tablet	
00719757	BAYTRIL - 32.3MG/ML	enrofloxacin		egg dip concentrate	
00719765	BAYTRIL - 5.7MG/TAB	enrofloxacin		tablet	
01923781	BAYTRIL - 50MG/ML	enrofloxacin		injectable solution	
00719781	BAYTRIL - 68MG/TAB	enrofloxacin		tablet	
00469319	CUTTER PASTE - 455MG/G	febantel		oral paste	
00894885	DRONCIT - 11.5MG/TAB	praziquantel		tablet	expired
00469297	DRONCIT - 23MG/TAB	praziquantel		tablet	expired
00469289	DRONCIT - 34MG/TAB	praziquantel		tablet	expired
02094991	DRONCIT - 56.8MG/ML	praziquantel		injectable solution	expired
02083566	DRONTAL 18.2/72.6	praziquantel/pyrantel		tablet	introduced
02076241	DRONTAL PLUS 113.4/22.7/22.7	febantel/praziquantel/pyrantel		tablet	
02076268	DRONTAL PLUS 340.2/68/68	febantel/praziquantel/pyrantel		tablet	
00573795	NEGABOT PLUS 67.5/400	febantel/metrifonate		oral paste	not sold
00597856	VERCOM 34/3.4	febantel/praziquantel		oral paste	not sold

## BERLEX CANADA INC.

### Human:

02169649	BETASERON - 0.3MG/VIAL	interferon beta-1b	L03AA03	powder for injectable solution	
01989987	MAGNEVIST - 469MG/ML	gadopentetate dimeglumine	V08CA01	injectable solution	
02078597	ULTRAVIST 240 - 499MG/ML	iopromide	V08AB06	injectable solution	
02078600	ULTRAVIST 300 - 623MG/ML	iopromide	V08AB06	injectable solution	
02078619	ULTRAVIST 370 - 769MG/ML	iopromide	V08AB06	injectable solution	

## BLOCK DRUG COMPANY (CANADA) LTD.

### Human:

02178796	COLPERMIN - 187MG/CAP	peppermint oil	A02DA02	enteric-coated capsule	
----------	-----------------------	----------------	---------	------------------------	--

## BOEHRINGER INGELHEIM (CANADA) LTD.

### Human:

00790486	BRONALIDE - 0.25MG/DOSE	flunisolide	R03BA03	aerosol for inhalation	
02057735	PROSTEP 11 - 15MG/PATCH	nicotine	N07BA01	transdermal patch	
02057743	PROSTEP 22 - 30MG/PATCH	nicotine	N07BA01	transdermal patch	

### Veterinary:

02080001	SEDIVET - 10MG/ML	romifidine		injectable solution	
00698229	SPUTOLYSIN - 5MG/G	dembrexin		oral powder	
	SPUTOLYSIN - 5MG/ML	dembrexin		injectable solution	not sold
02126214	SUPER-OV - 7.5UNIT/ML	follicle stimulating hormone (porcine origin)		powder for injectable solution	introduced

## BOEHRINGER MANNHEIM CANADA LTD.

### Human:

02129035	DEMADEX - 100MG/TAB	torsemide	C03CA03	tablet	introduced (nce)
*02129094	DEMADEX - 10MG/ML	torsemide	C03CA03	injectable solution	
02129019	DEMADEX - 10MG/TAB	torsemide	C03CA03	tablet	introduced (nce)
02129027	DEMADEX - 20MG/TAB	torsemide	C03CA03	tablet	not sold
02129000	DEMADEX - 5MG/TAB	torsemide	C03CA03	tablet	introduced (nce)
01927051	OSTAC - 30MG/ML	clodronate disodium	M05BA02	injectable solution	
01927078	OSTAC - 400MG/CAP	clodronate disodium	M05BA02	capsule	



DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
<b>BRISTOL-MYERS SQUIBB PHARMACEUTICAL GROUP</b>					
<b>Human:</b>					
01911562	AZACTAM - 1000MG/VIAL	aztreonam	J01DF01	powder for injectable solution	not sold
01911554	AZACTAM - 2000MG/VIAL	aztreonam	J01DF01	powder for injectable solution	not sold
01911570	AZACTAM - 500MG/VIAL	aztreonam	J01DF01	powder for injectable solution	not sold
00546305	CAPOTEN - 100MG/TAB	captopril	C02EA01	tablet	
00695661	CAPOTEN - 12.5MG/TAB	captopril	C02EA01	tablet	
00546283	CAPOTEN - 25MG/TAB	captopril	C02EA01	tablet	
00546291	CAPOTEN - 50MG/TAB	captopril	C02EA01	tablet	
00891843	CAPOZIDE 25/12.5	captopril/hydrochlorothiazide		tablet	not sold
02015099	CAPOZIDE 25/15	captopril/hydrochlorothiazide		tablet	not sold
00620998	CAPOZIDE 25/25	captopril/hydrochlorothiazide		tablet	not sold
00621005	CAPOZIDE 50/15	captopril/hydrochlorothiazide		tablet	not sold
00621013	CAPOZIDE 50/25	captopril/hydrochlorothiazide		tablet	not sold
	CARDIOTEC	technetium tc-99m teboroxime		powder for injectable solution	not sold
02163659	CEFZIL - 250MG/TAB	cefprozil	J01DA19	tablet	introduced (nce)
02163675	CEFZIL - 25MG/ML	cefprozil	J01DA19	powder for oral suspension	introduced (nce)
02163667	CEFZIL - 500MG/TAB	cefprozil	J01DA19	tablet	introduced (nce)
02163683	CEFZIL - 50MG/ML	cefprozil	J01DA19	powder for oral suspension	introduced (nce)
	CHOLETEC - 45MG/VIAL	technetium tc-99m mebrofenin	V04DA11	powder for injectable solution	
00702277	DESYREL - 150MG/TAB	trazodone hydrochloride	N06AX02	tablet	
00824135	DESYREL - 300MG/TAB	trazodone hydrochloride	N06AX02	tablet	not sold
01958011	ISOVUE-128 - 261MG/ML	iopamidol	V08AB04	injectable solution	
01958003	ISOVUE-200 - 408MG/ML	iopamidol	V08AB04	injectable solution	
01958976	ISOVUE-300 - 612MG/ML	iopamidol	V08AB04	injectable solution	
01958038	ISOVUE-370 - 755MG/ML	iopamidol	V08AB04	injectable solution	
02168529	MAXIPIME - 1000MG/BOTTLE	cefepime hydrochloride	J01DA18	powder for injectable solution	not sold
*02163632	MAXIPIME - 1000MG/VIAL	cefepime hydrochloride	J01DA18	powder for injectable solution	
02168863	MAXIPIME - 2000MG/BOTTLE	cefepime hydrochloride	J01DA18	powder for injectable solution	not sold
*02163640	MAXIPIME - 2000MG/VIAL	cefepime hydrochloride	J01DA18	powder for injectable solution	
02163624	MAXIPIME - 500MG/VIAL	cefepime hydrochloride	J01DA18	powder for injectable solution	not sold
01907107	MONOPRIL - 10MG/TAB	fosinopril	C02EA05	tablet	
01907115	MONOPRIL - 20MG/TAB	fosinopril	C02EA05	tablet	
01907093	MONOPRIL - 5MG/TAB	fosinopril	C02EA05	tablet	not sold
00893749	PRAVACHOL - 10MG/TAB	pravastatin sodium	B04AB03	tablet	
00893757	PRAVACHOL - 20MG/TAB	pravastatin sodium	B04AB03	tablet	
02016087	PROHANCE - 279.3MG/ML	gadoteridol	V08CA02	injectable solution	
02087375	SERZONE - 100MG/TAB	nefazodone hydrochloride	N06AX03	tablet	
02087383	SERZONE - 150MG/TAB	nefazodone hydrochloride	N06AX03	tablet	
02087391	SERZONE - 200MG/TAB	nefazodone hydrochloride	N06AX03	tablet	
02087405	SERZONE - 300MG/TAB	nefazodone hydrochloride	N06AX03	tablet	not sold
02087294	SERZONE - 50MG/TAB	nefazodone hydrochloride	N06AX03	tablet	not sold
02113031	STADOL NS - 10MG/ML	butorphanol tartrate	N02AF01	injectable solution	
01940546	VIDEX - 100MG/TAB	didanosine	J05AB07	tablet	
01940589	VIDEX - 100MG/VIAL	didanosine	J05AB07	powder for oral solution	not sold
01940554	VIDEX - 150MG/TAB	didanosine	J05AB07	tablet	
01940597	VIDEX - 167MG/VIAL	didanosine	J05AB07	powder for oral solution	not sold
01940627	VIDEX - 2000MG/VIAL	didanosine	J05AB07	powder for oral solution	not sold
01940600	VIDEX - 250MG/VIAL	didanosine	J05AB07	powder for oral solution	not sold
01940511	VIDEX - 25MG/TAB	didanosine	J05AB07	tablet	
01940619	VIDEX - 375MG/VIAL	didanosine	J05AB07	powder for oral solution	not sold
01940635	VIDEX - 4000MG/VIAL	didanosine	J05AB07	powder for oral solution	not sold
01940538	VIDEX - 50MG/TAB	didanosine	J05AB07	tablet	
<b>Veterinary:</b>					
00673064	TORBUTROL - 2MG/ML	butorphanol tartrate		injectable solution	not sold
<b>CANDERM PHARMACAL LTD.</b>					
<b>Human:</b>					
01945149	CONDYLINE - 5MG/ML	podofilox	D11AF04	topical solution	
01958690	NEOSTRATA HQ - 20MG/G	hydroquinone	D11AX02	gel	
<b>CANGENE CORPORATION</b>					
<b>Human:</b>					
01930605	WINRHO - 0.12MG/VIAL	RHo(D) immune globulin (human)	J06BB01	powder for injectable solution	not sold
01919326	WINRHO - 0.3MG/VIAL	RHo(D) immune globulin (human)	J06BB01	powder for injectable solution	not sold

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
02022842	WINRHO SD - 0.12MG/VIAL	RHo(D) immune globulin (human)	J06BB01	powder for injectable solution	
02022834	WINRHO SD - 0.3MG/VIAL	RHo(D) immune globulin (human)	J06BB01	powder for injectable solution	
<b>CIBA-GEIGY CANADA LTD.</b>					
<b>Human:</b>					
02029901	AQUASITE 2/1	polyethylene glycol 400/dextran 70	S01XA51	ophthalmic drops	introduced
02059762	AREDIA - 30MG/VIAL	pamidronate disodium	M05BA03	powder for injectable solution	expired introduced
01974491	AREDIA - 3MG/ML	pamidronate disodium	M05BA03	injectable solution	
02059770	AREDIA - 60MG/VIAL	pamidronate disodium	M05BA03	powder for injectable solution	
02059789	AREDIA - 90MG/VIAL	pamidronate disodium	M05BA03	powder for injectable solution	
02018411	CORSYM 7.5/0.8	phenylpropanolamine/ chlorpheniramine polistirex	R01BA50	sustained-release oral suspension	
02018403	DELSYM - 6MG/ML	dextromethorphan polistirex	R05DA05	sustained-release oral suspension	not sold
02018381	DURAFEDRIN - 12MG/ML	pseudoephedrine polistirex	R01BA02	sustained-release oral suspension	
02108186	ESTRACOMB .05/.05-.25	estradiol 17b/estradiol 17b & norethindrone acetate	G03FA01	transdermal patch	
00756792	ESTRADERM 100 - 8MG/PATCH	estradiol 17b	G03CA02	transdermal patch	
00756849	ESTRADERM 25 - 2MG/PATCH	estradiol 17b	G03CA02	transdermal patch	
00756857	ESTRADERM 50 - 4MG/PATCH	estradiol 17b	G03CA02	transdermal patch	
01943065	HABITROL 14 - 35MG/PATCH	nicotine	N07BA01	transdermal patch	
01943073	HABITROL 21 - 52.5MG/PATCH	nicotine	N07BA01	transdermal patch	
01943057	HABITROL 7 - 17.5MG/PATCH	nicotine	N07BA01	transdermal patch	
02128209	LENTARON - 250MG/VIAL	formestane	L02BG02	powder for injectable solution	
00667285	LIPACTIN - 5MG/G	heparin sodium/zinc sulfate	D11AX06	gel	
02131625	LIVOSTIN - 0.5MG/ML	levocabastine hydrochloride	S01GX03	ophthalmic suspension	
00885843	LOTENSIN - 10MG/TAB	benazepril hydrochloride	C02EA08	tablet	
00885851	LOTENSIN - 20MG/TAB	benazepril hydrochloride	C02EA08	tablet	
00885835	LOTENSIN - 5MG/TAB	benazepril hydrochloride	C02EA08	tablet	
02162873	LOTENSIN-HCT 10/12.5	benazepril hydrochloride/ hydrochlorothiazide		tablet	not sold
02162881	LOTENSIN-HCT 20/25	benazepril hydrochloride/ hydrochlorothiazide		tablet	not sold
02162865	LOTENSIN-HCT 5/6.25	benazepril hydrochloride/ hydrochlorothiazide		tablet	not sold
02162318	MAALOX HRF	antacid-alginate compound	A02EA50	oral suspension	
02162326	MAALOX HRF	antacid-alginate compound	A02EA50	tablet	
00651184	PROBAX - 20MG/G	propolis	D02AX02	ointment	not sold
02162245	PRODIEM PLAIN - 672MG/G	psyllium	A06AC01	oral granules	
02162253	PRODIEM PLUS 542/124	psyllium/senna	A06AC50	oral granules	
00584223	TRANSDERM-NITRO 0.2 - 25MG/PATCH	nitroglycerin	C01DA01	transdermal patch	
00852384	TRANSDERM-NITRO 0.4 - 50MG/PATCH	nitroglycerin	C01DA01	transdermal patch	
02046156	TRANSDERM-NITRO 0.6 - 75MG/PATCH	nitroglycerin	C01DA01	transdermal patch	
02046164	TRANSDERM-NITRO 0.8 - 100MG/PATCH	nitroglycerin	C01DA01	transdermal patch	
00550094	TRANSDERM-V - 1.5MG/PATCH	scopolamine	A04AD01	transdermal patch	
01940414	VOLTAREN OPHTHA - 1MG/ML	diclofenac sodium	S01BC04	ophthalmic drops	
<b>Veterinary:</b>					
00846449	INTERCEPTOR - 11.5MG/TAB	milbemycin oxime		tablet	
00846422	INTERCEPTOR - 2.3MG/TAB	milbemycin oxime		tablet	
00846457	INTERCEPTOR - 23MG/TAB	milbemycin oxime		tablet	
00846430	INTERCEPTOR - 5.75MG/TAB	milbemycin oxime		tablet	
02016702	INTERCEPTOR CHEW - 11.5MG/TAB	milbemycin oxime		tablet	
02016710	INTERCEPTOR CHEW - 2.3MG/TAB	milbemycin oxime		tablet	
02016729	INTERCEPTOR CHEW - 23MG/TAB	milbemycin oxime		tablet	
02016699	INTERCEPTOR CHEW - 5.75MG/TAB	milbemycin oxime		tablet	
02141418	INTERCEPTOR FLAVOUR - 11.5MG/TAB	milbemycin oxime		tablet	introduced
02141434	INTERCEPTOR FLAVOUR - 2.3MG/TAB	milbemycin oxime		tablet	introduced



DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
02141396	INTERCEPTOR FLAVOUR - 23MG/TAB	milbemycin oxime		tablet	introduced
02141426	INTERCEPTOR FLAVOUR - 5.75MG/TAB	milbemycin oxime		tablet	introduced
02057832	PROGRAM - 133MG/UNIT	lufenuron		oral suspension	introduced
02192632	PROGRAM - 266MG/UNIT	lufenuron		oral suspension	
02087359	PROGRAM - 204.9MG/TAB	lufenuron		tablet	
02087367	PROGRAM - 409.8MG/TAB	lufenuron		tablet	
02087332	PROGRAM - 45MG/TAB	lufenuron		tablet	
02087340	PROGRAM - 90MG/TAB	lufenuron		tablet	

### CONNAUGHT LABORATORIES LTD.

<b>Human:</b>					
01905023	MULTITEST CMI	skin test antigens	V04CX02	injectable suspension	
00764221	PROHIBIT	vaccine - hemophilus influenzae b	J07AG01	injectable suspension	not sold

### DISTA PRODUCTS LIMITED

<b>Human:</b>					
01968041	TALIDAN - 10MG/CAP	fluoxetine hydrochloride	N06AB01	capsule	not sold
01968033	TALIDAN - 20MG/CAP	fluoxetine hydrochloride	N06AB01	capsule	not sold

### DRAXIS HEALTH INC.

<b>Human:</b>					
02123312	ELDEPRYL - 5MG/TAB	selegiline hydrochloride	N04BD01	tablet	not sold
02123320	PERMAX - 0.05MG/TAB	pergolide mesylate	N04BC02	tablet	
02123339	PERMAX - 0.25MG/TAB	pergolide mesylate	N04BC02	tablet	
02123347	PERMAX - 1MG/TAB	pergolide mesylate	N04BC02	tablet	
01927272	SD DEPRENYL - 5MG/TAB	selegiline hydrochloride	N04BD01	tablet	

### DU PONT MERCK PHARMA INC.

<b>Human:</b>					
	CARDIOLITE	technetium tc-99m sestamibi	V04DA10	powder for injectable solution	
	NEUROLITE - 20MCI/TEST	technetium tc-99m bismate	V04DA14	powder for injectable solution	introduced (nce)

### ELI LILLY CANADA INC.

<b>Human:</b>					
00778338	AXID - 150MG/CAP	nizatidine	A02BA04	capsule	not sold
00778346	AXID - 300MG/CAP	nizatidine	A02BA04	capsule	
00465186	CECLOR - 250MG/CAP	cefaclor	J01DA06	capsule	
00465208	CECLOR - 25MG/ML	cefaclor	J01DA06	powder for oral suspension	
00832790	CECLOR - 37.4MG/ML	cefaclor	J01DA06	powder for oral suspension	
00465194	CECLOR - 500MG/CAP	cefaclor	J01DA06	capsule	not sold
00465216	CECLOR - 50MG/ML	cefaclor	J01DA06	powder for oral suspension	
00832804	CECLOR BID - 75MG/ML	cefaclor	J01DA06	powder for oral suspension	
02161761	CECLOR CD - 375MG/TAB	cefaclor	J01DA06	sustained-release tablet	
02161788	CECLOR CD - 500MG/TAB	cefaclor	J01DA06	sustained-release tablet	
00548375	CESAMET - 1MG/CAP	nabilone	A04AD04	capsule	not sold
00555665	ELDISINE - 5MG/VIAL	vindesine sulfate	L01CA03	powder for injectable solution	
	GEMZAR - 1000MG/VIAL	gemcitabine hydrochloride		powder for injectable solution	
00015377	GLUCAGON - 1MG/ML	glucagon hydrochloride	H04AA01	powder for injectable solution	
00745626	HUMATROPE - 1MG/ML	somatropin	H01AC02	powder for injectable solution	
00889113	HUMULIN-10/90 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	not sold
01962639	HUMULIN-10/90 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
00889105	HUMULIN-20/80 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
01962655	HUMULIN-20/80 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
00795879	HUMULIN-30/70 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
01959212	HUMULIN-30/70 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	not sold
00889091	HUMULIN-40/60 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
01962647	HUMULIN-40/60 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
00889121	HUMULIN-50/50 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
01962663	HUMULIN-50/50 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
00646148	HUMULIN-L - 100UNIT/ML	insulin (lente) human biosynthetic	A10AA02	injectable suspension	
00587737	HUMULIN-N - 100UNIT/ML	insulin (isophane) human biosynthetic	A10AA02	injectable suspension	
01959239	HUMULIN-N - 100UNIT/ML	insulin (isophane) human biosynthetic	A10AA02	injectable suspension	
00586714	HUMULIN-R - 100UNIT/ML	insulin (regular) human biosynthetic	A10AA01	injectable solution	
01959220	HUMULIN-R - 100UNIT/ML	insulin (regular) human biosynthetic	A10AA01	injectable solution	
00733075	HUMULIN-U - 100UNIT/ML	insulin (ultralente) human biosynthetic	A10AA03	injectable suspension	
00514535	ILETIN-II LENTE PORK - 100UNIT/ML	pork insulin/zinc	A10AA02	injectable suspension	
00514551	ILETIN-II NPH PORK - 100UNIT/ML	pork insulin/zinc/protamine	A10AA02	injectable suspension	
00513644	ILETIN-II REGULAR PORK - 100UNIT/ML	pork insulin/zinc	A10AA01	injectable solution	
00446580	ILETIN-LENTE - 100UNIT/ML	pork/bovine insulin/zinc	A10AA02	injectable suspension	
00446572	ILETIN-NPH - 100UNIT/ML	pork/bovine insulin/zinc/ protamine	A10AA02	injectable suspension	
00446610	ILETIN-PROTAMINE ZINC - 100UNIT/ML	pork/bovine insulin/zinc/ protamine	A10AA03	injectable suspension	not sold
00446564	ILETIN-REGULAR - 100UNIT/ML	pork/bovine insulin/zinc	A10AA01	injectable solution	
00446602	ILETIN-SEMILENTE - 100UNIT/ML	pork/bovine insulin/zinc	A10AA02	injectable suspension	not sold
00446599	ILETIN-ULTRALENTE - 100UNIT/ML	pork/bovine insulin/zinc	A10AA03	injectable suspension	not sold
00015202	ILOSONE - 250MG/CAP	erythromycin estolate	J01FA01	capsule	
00015474	ILOSONE - 25MG/ML	erythromycin estolate	J01FA01	oral suspension	
00244384	ILOSONE - 500MG/TAB	erythromycin estolate	J01FA01	tablet	not sold
00210641	ILOSONE - 50MG/ML	erythromycin estolate	J01FA01	oral suspension	
00015369	KEFLIN - 1000MG/VIAL	cephalothin sodium	J01DA02	powder for injectable solution	
00659150	KEFLIN - 2000MG/VIAL	cephalothin sodium	J01DA02	powder for injectable solution	not sold
00244406	KEFLIN - 2000MG/VIAL	cephalothin sodium	J01DA02	powder for injectable solution	
00298484	KEFLIN - 4000MG/VIAL	cephalothin sodium	J01DA02	powder for injectable solution	not sold
00752525	KEFLIN ADD-VANTAGE - 1000MG/VIAL	cephalothin sodium	J01DA02	powder for injectable solution	not sold
00752533	KEFLIN ADD-VANTAGE - 2000MG/VIAL	cephalothin sodium	J01DA02	powder for injectable solution	not sold
01927264	KEFUROX - 1500MG/VIAL	cefuroxime sodium	J01DA14	powder for injectable solution	
01986082	KEFUROX - 7500MG/VIAL	cefuroxime sodium	J01DA14	powder for injectable solution	
01927256	KEFUROX - 750MG/VIAL	cefuroxime sodium	J01DA14	powder for injectable solution	
01935801	KEFUROX ADD-VANTAGE - 1500MG/VIAL	cefuroxime sodium	J01DA14	powder for injectable solution	
01935828	KEFUROX ADD-VANTAGE - 750MG/VIAL	cefuroxime sodium	J01DA14	powder for injectable solution	
00411450	KEFZOL - 10000MG/VIAL	cefazolin sodium	J01DA03	powder for injectable solution	
00322296	KEFZOL - 1000MG/VIAL	cefazolin sodium	J01DA03	powder for injectable solution	
00322288	KEFZOL - 500MG/VIAL	cefazolin sodium	J01DA03	powder for injectable solution	
00411442	KEFZOL ADD-VANTAGE - 1000MG/VIAL	cefazolin sodium	J01DA03	powder for injectable solution	
00411434	KEFZOL ADD-VANTAGE - 500MG/VIAL	cefazolin sodium	J01DA03	powder for injectable solution	
02044757	LORABID - 200MG/CAP	loracarbef		capsule	not sold
02161206	LORABID - 20MG/ML	loracarbef		powder for oral suspension	not sold
02044749	LORABID - 400MG/CAP	loracarbef		capsule	not sold
02161214	LORABID - 40MG/ML	loracarbef		powder for oral suspension	not sold
00439320	MANDOL - 1000MG/VIAL	cefamandole nafate	J01DA04	powder for injectable solution	
00439312	MANDOL - 2000MG/VIAL	cefamandole nafate	J01DA04	powder for injectable solution	
00439304	MANDOL - 500MG/VIAL	cefamandole nafate	J01DA04	powder for injectable solution	not sold
00648930	MANDOL ADD-VANTAGE - 1000MG/VIAL	cefamandole nafate	J01DA04	powder for injectable solution	
00842621	MANDOL ADD-VANTAGE - 2000MG/VIAL	cefamandole nafate	J01DA04	powder for injectable solution	not sold
00569755	MOXAM - 1000MG/VIAL	moxalactam disodium		powder for injectable solution	not sold
00569763	MOXAM - 2000MG/VIAL	moxalactam disodium		powder for injectable solution	not sold
00851825	NEBCIN ADD-VANTAGE - 10MG/ML	tobramycin sulfate	J01GB03	injectable solution	not sold



DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
00611182	ONCOVIN - 1MG/ML	vincristine sulfate	L01CA02	injectable solution	
02018985	PROZAC - 10MG/CAP	fluoxetine hydrochloride	N06AB01	capsule	
00636622	PROZAC - 20MG/CAP	fluoxetine hydrochloride	N06AB01	capsule	
01917021	PROZAC - 4MG/ML	fluoxetine hydrochloride	N06AB01	oral solution	
00886971	TAZIDIME - 1000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
00886955	TAZIDIME - 2000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
00888338	TAZIDIME - 500MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
00886963	TAZIDIME - 6000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
00887129	TAZIDIME ADD-VANTAGE - 1000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
01980645	TAZIDIME ADD-VANTAGE - 2000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
02015110	VANCOCIN - 1000MG/VIAL	vancomycin hydrochloride	J01XA01	powder for injectable solution	
00800430	VANCOCIN - 125MG/CAP	vancomycin hydrochloride	J01XA01	capsule	
00788716	VANCOCIN - 250MG/CAP	vancomycin hydrochloride	J01XA01	capsule	
00722146	VANCOCIN C.P. - 1000MG/VIAL	vancomycin hydrochloride	J01XA01	powder for injectable solution	
00015423	VANCOCIN C.P. - 500MG/VIAL	vancomycin hydrochloride	J01XA01	powder for injectable solution	
00803537	VANCOCIN C.P. ADD-VANTAGE - 1000MG/VIAL	vancomycin hydrochloride	J01XA01	powder for injectable solution	
00803510	VANCOCIN C.P. ADD-VANTAGE - 500MG/VIAL	vancomycin hydrochloride	J01XA01	powder for injectable solution	
00015431	VELBE - 1MG/ML	vinblastine sulfate	L01CA01	powder for injectable solution	expired

## FABRIGEN INC.

<b>Human:</b>					
02078481	AVIRAX - 1000MG/VIAL	acyclovir sodium	J05AB03	powder for injectable solution	not sold
02078465	AVIRAX - 200MG/CAP	acyclovir	J05AB03	capsule	not sold
02078627	AVIRAX - 200MG/TAB	acyclovir	J05AB03	tablet	
02078635	AVIRAX - 400MG/TAB	acyclovir	J05AB03	tablet	
02078643	AVIRAX - 40MG/ML	acyclovir	J05AB03	oral suspension	not sold
02078473	AVIRAX - 50MG/G	acyclovir	D06BB02	ointment	not sold
02078503	AVIRAX - 50MG/G	acyclovir	D06BB02	cream	not sold
02078651	AVIRAX - 800MG/TAB	acyclovir	J05AB03	tablet	

## FERRING INC.

<b>Human:</b>					
00873993	ACTHREL - 0.1MG/VIAL	corticotropin ovine trifluoracetate	H01BA02	powder for injectable solution	
00836362	DDAVP - 0.004MG/ML	desmopressin acetate	H01BA02	injectable solution	
00402516	DDAVP - 0.01MG/DOSE	desmopressin acetate	H01BA02	nasal aerosol	
00824305	DDAVP - 0.1MG/ML	desmopressin acetate	H01BA02	nasal solution	
00824305	DDAVP - 0.1MG/TAB	desmopressin acetate	H01BA02	tablet	introduced
00824143	DDAVP - 0.2MG/TAB	desmopressin acetate	H01BA02	tablet	introduced
02125226	DECAPEPTYL-CR - 3.75MG/VIAL	triptorelin acetate	L02AE04	powder for injectable solution	
02125226	NIDAGEL - 7.5MG/G	metronidazole	G01AF01	vaginal gel	
02024179	OCTOSTIM - 0.015MG/ML	desmopressin acetate	H01BA02	injectable solution	introduced
02024179	OCTOSTIM - 0.15MG/DOSE	desmopressin acetate	H01BA02	nasal aerosol	introduced
00780197	OCTOSTIM - 1.5MG/ML	desmopressin acetate	H01BA02	nasal solution	not sold
02153521	QUINTASA - 1000MG/DOSE	5-aminosalicylic acid	A07EC02	rectal suspension	introduced
02153564	QUINTASA - 1000MG/SUP	5-aminosalicylic acid	A07EC02	suppository	introduced
02153548	QUINTASA - 2000MG/DOSE	5-aminosalicylic acid	A07EC02	rectal suspension	introduced
02153556	QUINTASA - 4000MG/DOSE	5-aminosalicylic acid	A07EC02	rectal suspension	introduced

## FISONS CORPORATION LTD.

<b>Human:</b>					
00555649	INTAL INHALER - 1MG/DOSE	sodium cromoglycate	R03BC01	aerosol for inhalation	
00261238	INTAL SPINCAPS - 20MG/CART	sodium cromoglycate	R03BC01	powder for inhalation	
00638641	INTAL SYNCRONER - 1MG/DOSE	sodium cromoglycate	R03BC01	aerosol for inhalation	
00888397	MYKROX - 0.5MG/TAB	metolazone	C03BA02	tablet	not sold
00842702	PENNTUSS 2/0.8	codeine/chlorpheniramine polistirex	R05DA50	sustained-release oral suspension	
00766038	TILADE - 2MG/DOSE	nedocromil sodium	R03BC02	aerosol for inhalation	

## FRANK W. HORNER INC.

<b>Human:</b>					
00511641	DEPEN - 250MG/TAB	penicillamine	M01CC01	tablet	
00710105	VIADENT - 0.3MG/ML	sanguinarine	A01AD03	oral rinse	
00713473	VIADENT - 1.2MG/ML	sanguinarine	A01AD03	toothpaste	not sold
01946331	VIADENT FLUORIDE - 14MG/ML	sanguinarine	A01AD03	toothpaste	

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
<b>FUJISAWA CANADA INC.</b>					
<b>Human:</b>					
02139294	ADENOSCAN - 3MG/ML	adenosine	C01EB03	injectable solution	introduced
	AMBISOME - 50MG/VIAL	amphotericin b	J02AA01	powder for injectable solution	
02175991	PROGRAF - 1MG/CAP	tacrolimus	L04AA06	capsule	
02175983	PROGRAF - 5MG/CAP	tacrolimus	L04AA06	capsule	
02176009	PROGRAF - 5MG/ML	tacrolimus	L04AA06	injectable solution	
<b>GALDERMA CANADA INC.</b>					
<b>Human:</b>					
02148749	DIFFERIN - 1MG/G	adapalene		topical gel	not sold
02148757	DIFFERIN - 1MG/ML	adapalene		topical solution	not sold
02013223	METROGEL - 7.5MG/G	metronidazole	D06BX01	topical gel	
<b>GENDERM CANADA INC.</b>					
<b>Human:</b>					
02142147	ZONALON - 50MG/G	doxepin hydrochloride	D04AA04	cream	introduced
00740306	ZOSTRIX - 0.25MG/G	capsaicin	M02AB01	cream	
02004240	ZOSTRIX-HP - 0.75MG/G	capsaicin	M02AB01	cream	
<b>GENENTECH CANADA INC.</b>					
<b>Human:</b>					
01916742	PROTROPIN	somatrem	H01AC01	powder for injectable solution	
01959263	PROTROPIN	somatrem	H01AC01	powder for injectable solution	
<b>GLAXO WELLCOME INC.</b>					
<b>Human:</b>					
00828521	BECLODISK - 0.1MG/DOSE	beclomethasone dipropionate	R03BA01	powder for inhalation	
00828548	BECLODISK - 0.2MG/DOSE	beclomethasone dipropionate	R03BA01	powder for inhalation	
01949993	BECLOVENT - 0.1MG/CAP	beclomethasone dipropionate	R03BA01	powder for inhalation	
01950002	BECLOVENT - 0.2MG/CAP	beclomethasone dipropionate	R03BA01	powder for inhalation	
00886882	CEFTIN - 125MG/TAB	cefuroxime axetil	J01DA14	tablet	
02145286	CEFTIN - 250MG/POUCH	cefuroxime axetil	J01DA14	powder for oral suspension	introduced
00886890	CEFTIN - 250MG/TAB	cefuroxime axetil	J01DA14	tablet	
01943049	CEFTIN - 25MG/ML	cefuroxime axetil	J01DA14	powder for oral suspension	introduced
00886904	CEFTIN - 500MG/TAB	cefuroxime axetil	J01DA14	tablet	
00253154	CEPOREX - 250MG/CAP	cephalexin	J01DA01	capsule	expired
00253146	CEPOREX - 500MG/CAP	cephalexin	J01DA01	capsule	expired
01968092	CEPTAZ - 1000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
01974408	CEPTAZ - 1000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
01974416	CEPTAZ - 2000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
01974394	CEPTAZ - 500MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	not sold
01927175	EXOSURF - 108MG/KIT	colfosceril palmitate	R07AA01	endo-tracheal suspension kit	
01927183	EXOSURF - 108MG/VIAL	colfosceril palmitate	R07AA01	endo-tracheal suspension vial	not sold
02038269	EXOSURF - 67.5MG/VIAL	colfosceril palmitate	R07AA01	endo-tracheal suspension vial	not sold
02048043	FLONASE - 0.05MG/DOSE	fluticasone propionate	R01AD05	nasal aerosol	
02174731	FLOVENT - 0.025MG/DOSE	fluticasone propionate	R03BA05	aerosol for inhalation	introduced
02174693	FLOVENT - 0.05MG/DOSE	fluticasone propionate	R03BA05	powder for inhalation	not sold
02174758	FLOVENT - 0.05MG/DOSE	fluticasone propionate	R03BA05	aerosol for inhalation	introduced
02174766	FLOVENT - 0.125MG/DOSE	fluticasone propionate	R03BA05	aerosol for inhalation	introduced
02174707	FLOVENT - 0.1MG/DOSE	fluticasone propionate	R03BA05	powder for inhalation	not sold
02174715	FLOVENT - 0.25MG/DOSE	fluticasone propionate	R03BA05	powder for inhalation	not sold
02174774	FLOVENT - 0.25MG/DOSE	fluticasone propionate	R03BA05	aerosol for inhalation	introduced
02174723	FLOVENT - 0.5MG/DOSE	fluticasone propionate	R03BA05	powder for inhalation	not sold
00640034	FORTAZ - 1000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
00640042	FORTAZ - 2000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
00640026	FORTAZ - 500MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
00791679	FORTAZ - 6000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	
01950614	IMITREX - 100MG/TAB	sumatriptan succinate	N02CX03	tablet	
01950606	IMITREX - 12MG/ML	sumatriptan succinate	N02CX03	injectable solution	
02163764	IMITREX - 50MG/TAB	sumatriptan succinate	N02CX03	tablet	introduced
02142104	LAMICTAL - 100MG/TAB	lamotrigine	N03AX03	tablet	introduced (nce)
02142112	LAMICTAL - 150MG/TAB	lamotrigine	N03AX03	tablet	introduced (nce)
02142120	LAMICTAL - 200MG/TAB	lamotrigine	N03AX03	tablet	not sold
02142139	LAMICTAL - 250MG/TAB	lamotrigine	N03AX03	tablet	not sold
02142082	LAMICTAL - 25MG/TAB	lamotrigine	N03AX03	tablet	introduced (nce)
02142090	LAMICTAL - 50MG/TAB	lamotrigine	N03AX03	tablet	not sold



DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
02009358	MEPRON - 250MG/TAB	atovaquone	P01XA02	tablet	introduced
02087308	MIVACRON - 2MG/ML	mivacurium chloride	M03AC06	injectable solution	
02091283	NAVELBINE - 10MG/ML	vinorelbine tartrate	L01CA04	injectable solution	
01924656	NUROMAX - 1MG/ML	doxacurium chloride	M03AC05	injectable solution	
01902660	RETROVIR - 100MG/CAP	zidovudine	J05AB05	capsule	
01902644	RETROVIR - 10MG/ML	zidovudine	J05AB05	injectable solution	
01902652	RETROVIR - 10MG/ML	zidovudine	J05AB05	syrup	
02136139	SEREVENT - 0.025MG/DOSE	salmeterol xinafoate	R03AC05	aerosol for inhalation	introduced
02136147	SEREVENT - 0.05MG/DOSE	salmeterol xinafoate	R03AC05	powder for inhalation	
00675210	TRACRIUM - 10MG/ML	atracurium besylate	M03AC04	injectable solution	
00832766	VENTODISK - 0.2MG/DOSE	salbutamol sulfate	R03AC01	powder for inhalation	
00832758	VENTODISK - 0.4MG/DOSE	salbutamol sulfate	R03AC01	powder for inhalation	
01938878	VENTOLIN - 0.2MG/CAP	salbutamol sulfate	R03AC01	powder for inhalation	
01938851	VENTOLIN - 0.4MG/CAP	salbutamol sulfate	R03AC01	powder for inhalation	
02035421	VENTOLIN - 0.4MG/ML	salbutamol sulfate	R03CC01	oral solution	
00782351	VOLMAX - 4MG/TAB	salbutamol sulfate	R03CC01	sustained-release tablet	not sold
00782378	VOLMAX - 8MG/TAB	salbutamol sulfate	R03CC01	sustained-release tablet	not sold
01959069	WELLFERON - 10000000UNIT/ML	interferon alpha-n1	L03AA01	injectable solution	
01959077	WELLFERON - 3000000UNIT/ML	interferon alpha-n1	L03AA01	injectable solution	
02161176	WELLFERON - 5000000UNIT/ML	interferon alpha-n1	L03AA01	injectable solution	not sold
00553379	ZANTAC - 150MG/TAB	ranitidine hydrochloride	A02BA02	tablet	
00782386	ZANTAC - 15MG/ML	ranitidine hydrochloride	A02BA02	oral solution	
00603791	ZANTAC - 25MG/ML	ranitidine hydrochloride	A02BA02	injectable solution	
00641790	ZANTAC - 300MG/TAB	ranitidine hydrochloride	A02BA02	tablet	
00849421	ZANTAC C - 150MG/CAP	ranitidine hydrochloride	A02BA02	capsule	
00849448	ZANTAC C - 300MG/CAP	ranitidine hydrochloride	A02BA02	capsule	
01951831	ZANTAC EFFERVESCENT - 150MG/POUCH	ranitidine hydrochloride	A02BA02	effervescent granules	not sold
02076284	ZANTAC EFFERVESCENT - 150MG/TAB	ranitidine hydrochloride	A02BA02	effervescent tablet	not sold
01951823	ZANTAC EFFERVESCENT - 300MG/POUCH	ranitidine hydrochloride	A02BA02	effervescent granules	not sold
02076292	ZANTAC EFFERVESCENT - 300MG/TAB	ranitidine hydrochloride	A02BA02	effervescent tablet	not sold
00481890	ZINACEF - 1500MG/VIAL	cefuroxime sodium	J01DA14	powder for injectable solution	not sold
00577227	ZINACEF - 250MG/VIAL	cefuroxime sodium	J01DA14	powder for injectable solution	
00890936	ZINACEF - 750MG/VIAL	cefuroxime sodium	J01DA14	powder for injectable solution	
00497843	ZINACEF - 750MG/VIAL	cefuroxime sodium	J01DA14	powder for injectable solution	
01911821	ZOFRAN - 2MG/ML	ondansetron hydrochloride	A04AA01	injectable solution	
01925970	ZOFRAN - 4MG/TAB	ondansetron hydrochloride	A04AA01	tablet	
01925989	ZOFRAN - 8MG/TAB	ondansetron hydrochloride	A04AA01	tablet	
00899321	ZOVIRAX - 1000MG/VIAL	acyclovir sodium	J05AB03	powder for injectable solution	
00590924	ZOVIRAX - 200MG/CAP	acyclovir	J05AB03	capsule	
00634506	ZOVIRAX - 200MG/TAB	acyclovir	J05AB03	tablet	
01911627	ZOVIRAX - 400MG/TAB	acyclovir	J05AB03	tablet	
00886157	ZOVIRAX - 40MG/ML	acyclovir	J05AB03	oral suspension	
00605336	ZOVIRAX - 500MG/VIAL	acyclovir sodium	J05AB03	powder for injectable solution	
00569771	ZOVIRAX - 50MG/G	acyclovir	D06BB02	ointment	
02039524	ZOVIRAX - 50MG/G	acyclovir	D06BB02	cream	
01911635	ZOVIRAX - 800MG/TAB	acyclovir	J05AB03	tablet	

## HOECHST MARION ROUSSEL CANADA INC.

<b>Human:</b>					
02050943	ALTACE - 1.25MG/CAP	ramipril	C02EA09	capsule	
02050986	ALTACE - 10MG/CAP	ramipril	C02EA09	capsule	
02050951	ALTACE - 2.5MG/CAP	ramipril	C02EA09	capsule	
02050978	ALTACE - 5MG/CAP	ramipril	C02EA09	capsule	
00863904	ANANDRON - 100MG/TAB	nilutamide	L02BB03	tablet	
00863890	ANANDRON - 50MG/TAB	nilutamide	L02BB03	tablet	
00760439	CITRUCEL - 166.66666MG/G	methylcellulose	A06AC03	powder	not sold
00546216	CLAFORAN - 1000MG/VIAL	cefotaxime sodium	J01DA08	powder for injectable solution	
00546224	CLAFORAN - 2000MG/VIAL	cefotaxime sodium	J01DA08	powder for injectable solution	
00546208	CLAFORAN - 500MG/VIAL	cefotaxime sodium	J01DA08	powder for injectable solution	
00839248	CLAFORAN ADD-VANTAGE - 1000MG/VIAL	cefotaxime sodium	J01DA08	powder for injectable solution	
00839256	CLAFORAN ADD-VANTAGE - 2000MG/VIAL	cefotaxime sodium	J01DA08	powder for injectable solution	not sold
02059754	DERMATOP - 1MG/G	prednicarbate		ointment	not sold
00894869	PENTASA - 250MG/CAP	5-aminosalicylic acid	A07EC02	capsule	not sold

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
00894877	PENTASA - 250MG/TAB	5-aminosalicylic acid	A07EC02	tablet	
01940384	PENTASA - 500MG/TAB	5-aminosalicylic acid	A07EC02	tablet	
01989596	RENEDIL - 10MG/TAB	felodipine	C08CA03	sustained-release tablet	
02069539	RENEDIL - 2.5MG/TAB	felodipine	C08CA03	sustained-release tablet	
01989618	RENEDIL - 5MG/TAB	felodipine	C08CA03	sustained-release tablet	
00619760	RYTHMODAN LA - 250MG/TAB	disopyramide	C01BA03	sustained-release tablet	
02068028	SABRIL - 1000MG/POUCH	vigabatrin	N03AG03	powder for oral solution	not sold
02068001	SABRIL - 2000MG/POUCH	vigabatrin	N03AG03	powder for oral solution	not sold
02067994	SABRIL - 3000MG/POUCH	vigabatrin	N03AG03	powder for oral solution	not sold
02068036	SABRIL - 500MG/POUCH	vigabatrin	N03AG03	powder for oral solution	not sold
02065819	SABRIL - 500MG/TAB	vigabatrin	N03AG03	tablet	
00786624	SELDANE - 120MG/TAB	terfenadine	R06AX05	tablet	
00590908	SELDANE - 60MG/TAB	terfenadine	R06AX05	tablet	
00680028	SUPREFACT - 1MG/ML	buserelin acetate	L02AE02	injectable solution	
00680036	SUPREFACT - 1MG/ML	buserelin acetate	L02AE02	nasal solution	
	TERFENADINE BIG V - 120MG/TAB	terfenadine	R06AX05	tablet	
00893498	TERFENADINE BIG V - 60MG/TAB	terfenadine	R06AX05	tablet	
	TERFENADINE CERTIFIED - 120MG/TAB	terfenadine	R06AX05	tablet	
	TERFENADINE CONTAC - 120MG/TAB	terfenadine	R06AX05	tablet	not sold
	TERFENADINE CONTAC - 60MG/TAB	terfenadine	R06AX05	tablet	not sold
00893501	TERFENADINE GUARDIAN - 60MG/TAB	terfenadine	R06AX05	tablet	not sold
00893528	TERFENADINE IDA - 60MG/TAB	terfenadine	R06AX05	tablet	
	TERFENADINE JEAN COUTU - 120MG/TAB	terfenadine	R06AX05	tablet	not sold
00881708	TERFENADINE JEAN COUTU - 60MG/TAB	terfenadine	R06AX05	tablet	not sold
	TERFENADINE LIFE BRAND - 120MG/TAB	terfenadine	R06AX05	tablet	
00870927	TERFENADINE LIFE BRAND - 60MG/TAB	terfenadine	R06AX05	tablet	
00881694	TERFENADINE LONDON DRUGS - 60MG/TAB	terfenadine	R06AX05	tablet	not sold
	TERFENADINE PHARMAPLUS - 120MG/TAB	terfenadine	R06AX05	tablet	
00893552	TERFENADINE PHARMAPLUS - 60MG/TAB	terfenadine	R06AX05	tablet	
	TERFENADINE SAFEWAY - 120MG/TAB	terfenadine	R06AX05	tablet	
00586625	TRENTAL - 400MG/TAB	pentoxifylline	C04AD01	sustained-release tablet	
<b>HOFFMANN-LA ROCHE LIMITED</b>					
<b>Human:</b>					
00491772	ANAPROX - 275MG/TAB	naproxen sodium	M01AE02	tablet	
00869031	ANAPROX DS - 550MG/TAB	naproxen sodium	M01AE02	tablet	
00874019	ANEXATE - 0.1MG/ML	flumazenil	V03AB13	injectable solution	
00550078	BACTRIM 16/80	trimethoprim/sulfa methoxazole	J01EE01	injectable solution	
00272477	BACTRIM 20/100	trimethoprim/sulfa methoxazole	J01EE01	tablet	not sold
00272485	BACTRIM 8/40	trimethoprim/sulfa methoxazole	J01EE01	oral suspension	
00272469	BACTRIM 80/400	trimethoprim/sulfa methoxazole	J01EE01	tablet	
00371823	BACTRIM DS 160/800	trimethoprim/sulfa methoxazole	J01EE01	tablet	
02143348	CARDENE - 2.5MG/ML	nicardipine hydrochloride	C08CA02	injectable solution	not sold
00791695	CARDENE - 20MG/CAP	nicardipine hydrochloride	C08CA02	capsule	
00791709	CARDENE - 30MG/CAP	nicardipine hydrochloride	C08CA02	capsule	
02034514	CARDENE SR - 30MG/CAP	nicardipine hydrochloride	C08CA02	sustained-release capsule	not sold
01950657	CARDENE SR - 45MG/CAP	nicardipine hydrochloride	C08CA02	sustained-release capsule	not sold
01950649	CARDENE SR - 60MG/CAP	nicardipine hydrochloride	C08CA02	sustained-release capsule	not sold
*02192748	CELLCEPT - 250MG/CAP	mycophenolate mofetil	L04AA05	capsule	
02186802	CYTOVENE - 250MG/CAP	ganciclovir	J05AB06	capsule	introduced
00865516	CYTOVENE - 500MG/VIAL	ganciclovir sodium	J05AB06	powder for injectable solution	
01946366	EXZOLE - 10MG/G	sulconazole nitrate		cream	not sold



DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
01946358	EXZOLE - 10MG/ML	sulconazole nitrate		topical solution	not sold
00692719	FANSIDAR 500/25	sulfadoxine/pyrimethamine	P01BD50	tablet	
00890979	FEMSTAT - 100MG/SUP	butoconazole nitrate		suppository	not sold
00776173	FEMSTAT - 20MG/G	butoconazole nitrate		cream	not sold
00890987	FEMSTAT - 20MG/G	butoconazole nitrate		cream	not sold
	GARDRIN - 0.035MG/CAP	enprostil	A02BB02	capsule	not sold
01990918	HIVID - 0.375MG/TAB	zalcitabine	J05AB08	tablet	
01990896	HIVID - 0.75MG/TAB	zalcitabine	J05AB08	tablet	
01951874	IN-EX DUAL PACK	sulconazole and butoconazole nitrate		topical and vaginal cream	not sold
01955535	IN-EX DUAL PACK	sulconazole and butoconazole nitrate		topical cream and vaginal ovule	not sold
01909959	INHIBACE - 0.5MG/TAB	cilazapril	C02EA07	tablet	not sold
01911465	INHIBACE - 1MG/TAB	cilazapril	C02EA07	tablet	
01911473	INHIBACE - 2.5MG/TAB	cilazapril	C02EA07	tablet	
01911481	INHIBACE - 5MG/TAB	cilazapril	C02EA07	tablet	
00899348	MANERIX - 100MG/TAB	moclobemide	N06AG01	tablet	
00899356	MANERIX - 150MG/TAB	moclobemide	N06AG01	tablet	
02166747	MANERIX - 300MG/TAB	moclobemide	N06AG01	tablet	introduced
00884367	MOBIFLEX - 20MG/TAB	tenoxicam	M01AC02	tablet	
00299413	NAPROSYN - 125MG/TAB	naproxen	M01AE02	tablet	not sold
00335193	NAPROSYN - 250MG/TAB	naproxen	M01AE02	tablet	
00587923	NAPROSYN - 25MG/ML	naproxen	M01AE02	oral suspension	
00583367	NAPROSYN - 375MG/TAB	naproxen	M01AE02	tablet	
00531022	NAPROSYN - 500MG/SUP	naproxen	M01AE02	suppository	
00525537	NAPROSYN - 500MG/TAB	naproxen	M01AE02	tablet	
01937340	NAPROSYN E - 250MG/TAB	naproxen	M01AE02	tablet	
01937359	NAPROSYN E - 375MG/TAB	naproxen	M01AE02	tablet	
01937332	NAPROSYN E - 500MG/TAB	naproxen	M01AE02	tablet	
00788775	NAPROSYN SR - 1000MG/TAB	naproxen	M01AE02	sustained-release tablet	not sold
00788767	NAPROSYN SR - 750MG/TAB	naproxen	M01AE02	sustained-release tablet	
00615307	NAXEN - 125MG/TAB	naproxen	M01AE02	tablet	
00615315	NAXEN - 250MG/TAB	naproxen	M01AE02	tablet	
00615323	NAXEN - 375MG/TAB	naproxen	M01AE02	tablet	
00756814	NAXEN - 500MG/SUP	naproxen	M01AE02	suppository	
00615331	NAXEN - 500MG/TAB	naproxen	M01AE02	tablet	
02039567	NAXEN SR - 1000MG/TAB	naproxen	M01AE02	sustained-release tablet	not sold
02039478	NAXEN SR - 750MG/TAB	naproxen	M01AE02	sustained-release tablet	not sold
00421456	RHINALAR - 0.25MG/ML	flunisolide	R01AD02	nasal aerosol	
00481823	ROCALTROL - 0.00025MG/CAP	calcitriol	A11CC04	capsule	
00481815	ROCALTROL - 0.0005MG/CAP	calcitriol	A11CC04	capsule	
00824291	ROCALTROL - 0.001MG/ML	calcitriol	A11CC04	oral solution	
00851957	ROCEPHIN - 1000MG/VIAL	ceftriaxone disodium	J01DA13	powder for injectable solution	
00657417	ROCEPHIN - 1000MG/VIAL	ceftriaxone disodium	J01DA13	powder for injectable solution	
00657409	ROCEPHIN - 2000MG/VIAL	ceftriaxone disodium	J01DA13	powder for injectable solution	
00657387	ROCEPHIN - 250MG/VIAL	ceftriaxone disodium	J01DA13	powder for injectable solution	
00657425	ROCEPHIN - 500MG/VIAL	ceftriaxone disodium	J01DA13	powder for injectable solution	not sold
00894699	ROCEPHIN ADD-VANTAGE - 1000MG/VIAL	ceftriaxone disodium	J01DA13	powder for injectable solution	
00894702	ROCEPHIN ADD-VANTAGE - 2000MG/VIAL	ceftriaxone disodium	J01DA13	powder for injectable solution	not sold
00812471	ROFERON-A - 18000000UNIT/VIAL	interferon alfa-2a	L03AA01	powder for injectable solution	not sold
00812498	ROFERON-A - 18000000UNIT/VIAL	interferon alfa-2a	L03AA01	injectable solution	
01912003	ROFERON-A - 18000000UNIT/VIAL	interferon alfa-2a	L03AA01	powder for injectable solution	not sold
00812501	ROFERON-A - 3000000UNIT/VIAL	interferon alfa-2a	L03AA01	injectable solution	
01911988	ROFERON-A - 3000000UNIT/VIAL	interferon alfa-2a	L03AA01	powder for injectable solution	
00891002	ROFERON-A - 36000000UNIT/VIAL	interferon alfa-2a	L03AA01	injectable solution	
00893641	ROFERON-A - 4500000UNIT/VIAL	interferon alfa-2a	L03AA01	powder for injectable solution	not sold
02179717	ROFERON-A - 6000000UNIT/VIAL	interferon alfa-2a	L03AA01	powder for injectable solution	not sold
01911996	ROFERON-A - 9000000UNIT/VIAL	interferon alfa-2a	L03AA01	powder for injectable solution	not sold
02019914	ROFERON-A - 9000000UNIT/VIAL	interferon alfa-2a	L03AA01	injectable solution	
02070847	SORIATANE - 10MG/CAP	acitretin	D05BB02	capsule	expired
02070863	SORIATANE - 25MG/CAP	acitretin	D05BB02	capsule	expired
00615269	SULCOSYN - 10MG/G	sulconazole nitrate		cream	not sold
00615277	SULCOSYN - 10MG/ML	sulconazole nitrate		topical solution	not sold
00851655	SYN-CAPTOPRIL - 100MG/TAB	captopril	C02EA01	tablet	
00851639	SYN-CAPTOPRIL - 12.5MG/TAB	captopril	C02EA01	tablet	
00851883	SYN-CAPTOPRIL - 25MG/TAB	captopril	C02EA01	tablet	
00851647	SYN-CAPTOPRIL - 50MG/TAB	captopril	C02EA01	tablet	

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
00878790	SYN-FLUNISOLIDE - 0.25MG/ML	flunisolide	R01AD02	nasal aerosol	
00675369	SYNFLEX - 275MG/TAB	naproxen sodium	M01AE02	tablet	
01900897	SYNFLEX DS - 550MG/TAB	naproxen sodium	M01AE02	tablet	
00616400	TEGISON - 10MG/CAP	etretinate	D05BB01	capsule	expired
00616419	TEGISON - 25MG/CAP	etretinate	D05BB01	capsule	expired
01911767	TICLID - 125MG/TAB	ticlopidine hydrochloride	B01AC04	tablet	not sold
01911759	TICLID - 250MG/TAB	ticlopidine hydrochloride	B01AC04	tablet	
00882909	TORADOL - 10MG/ML	ketorolac tromethamine	M01AB05	injectable solution	
00864048	TORADOL - 10MG/TAB	ketorolac tromethamine	M01AB05	tablet	
01908499	TORADOL - 15MG/ML	ketorolac tromethamine	M01AB05	injectable solution	not sold
00882917	TORADOL - 30MG/ML	ketorolac tromethamine	M01AB05	injectable solution	
00884499	TORADOL - 5MG/ML	ketorolac tromethamine	S01BC03	ophthalmic solution	not sold
00784516	VERSED - 1MG/ML	midazolam hydrochloride	N05CD05	injectable solution	
00766011	VERSED - 5MG/ML	midazolam hydrochloride	N05CD05	injectable solution	

#### Veterinary:

	AUREO S-700 - 154000MG/KG	chlortetracycline hydrochloride/sulfamethazine		oral powder	not sold
	AUREO S-700G - 154000MG/KG	chlortetracycline hydrochloride/sulfamethazine		feed premix	
	AUREO SP250 G	chlortetracycline hydrochl./sulfamethazine/penicillin g proc.		feed premix	
	AUREOMIX 500G	chlortetracycline hydrochl./sulfamethazine/penicillin g proc.		feed premix	not sold
	AUREOMIX 625G	chlortetracycline hydrochl./sulfamethazine/penicillin g proc.		feed premix	
	AUREOMYCIN 100G - 220000MG/KG	chlortetracycline hydrochloride		feed premix	
	AUREOMYCIN 50G - 110000MG/KG	chlortetracycline hydrochloride		feed premix	
00592307	BENZELMIN - 375MG/G	oxfendazole		oral paste	expired
00598895	BENZELMIN - 90.6MG/ML	oxfendazole		oral suspension	expired
00630489	BENZELMIN-B 28.5/454.5	oxfendazole/trichlorfon		oral paste	expired
	CYGRO - 10000MG/KG	maduramicin ammonium		oral powder	
01913379	SYNANTHIC - 225MG/ML	oxfendazole		susp. for intra-ruminal injection	expired
00764132	SYNANTHIC - 90.6MG/ML	oxfendazole		susp. for intra-ruminal injection	expired

#### ICN CANADA LTD.

##### Human:

00704008	VIRAZOLE - 6000MG/VIAL	ribavirin	J05AB04	powder for inhalation	
----------	------------------------	-----------	---------	-----------------------	--

#### IMMUNO (CANADA) LTD.

##### Human:

	ANTITHROMBIN III IMMUNO	antithrombin III	B01AB03	powder for injectable solution	not sold
00781339	BEBULIN VH	factor IX complex (human)	B02BD01	powder for injectable solution	not sold
00781347	BEBULIN VH	factor IX complex (human)	B02BD01	powder for injectable solution	
	CMV IVEEGAM IMMUNO - 1000MG/VIAL	cmv immune globulin intravenous (human)	J06BB07	powder for injectable solution	not sold
	FACTOR VII IMMUNO VH	factor VII concentrate		powder for injectable solution	
00609137	FEIBA VH IMMUNO	factor VIII anti inhibitor	B02BD04	powder for injectable solution	
	IMMUMINE VH	factor IX (human)	B02BD01	powder for injectable solution	
01959344	IVEEGAM IMMUNO - 10000MG/VIAL	immune globulin intravenous (human)	J06BA02	powder for injectable solution	not sold
01959336	IVEEGAM IMMUNO - 1000MG/VIAL	immune globulin intravenous (human)	J06BA02	powder for injectable solution	not sold
01959328	IVEEGAM IMMUNO - 2500MG/VIAL	immune globulin intravenous (human)	J06BA02	powder for injectable solution	not sold
01959301	IVEEGAM IMMUNO - 5000MG/VIAL	immune globulin intravenous (human)	J06BA02	powder for injectable solution	
01959379	IVEEGAM IMMUNO - 500MG/VIAL	immune globulin intravenous (human)	J06BA02	powder for injectable solution	not sold
01959298	IVEEGAM IMMUNO - 7500MG/VIAL	immune globulin intravenous (human)	J06BA02	powder for injectable solution	not sold
00719603	KRYOBULIN VH	factor VIII complex (human)	B02BD02	powder for injectable solution	not sold
00719811	KRYOBULIN VH	factor VIII complex (human)	B02BD02	powder for injectable solution	not sold



DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
00719838	KRYOBULIN VH	factor VIII complex (human)	B02BD02	powder for injectable solution	not sold
01958968	TISSEEL KIT VH 0.5	fibrin sealant	B02BC04	powder for topical solution	
01949020	TISSEEL KIT VH 1.0	fibrin sealant	B02BC04	powder for topical solution	
01949012	TISSEEL KIT VH 2.0	fibrin sealant	B02BC04	powder for topical solution	
01974327	TISSEEL KIT VH 5.0	fibrin sealant	B02BC04	powder for topical solution	

## JANSSEN-ORTHO INC.

<b>Human:</b>					
00755818	ALFENTA - 0.5MG/ML	alfentanil hydrochloride	N01AH03	injectable solution	not sold
01968440	CYCLEN 0.25/0.035	norgestimate/ethinyl estradiol	G03AA05	tablet	
01992872	CYCLEN 0.25/0.035	norgestimate/ethinyl estradiol	G03AA05	tablet	
01937413	DURAGESIC - 10MG/PATCH	fentanyl	N02AB02	transdermal patch	
01937383	DURAGESIC - 2.5MG/PATCH	fentanyl	N02AB02	transdermal patch	
01937391	DURAGESIC - 5MG/PATCH	fentanyl	N02AB02	transdermal patch	not sold
01937405	DURAGESIC - 7.5MG/PATCH	fentanyl	N02AB02	transdermal patch	
00590665	DURALITH - 300MG/TAB	lithium carbonate	N05AN01	sustained-release tablet	
01968424	FLOXIN - 200MG/TAB	ofloxacin	J01MA03	tablet	
02049414	FLOXIN - 20MG/ML	ofloxacin	J01MA03	injectable solution	
01968416	FLOXIN - 300MG/TAB	ofloxacin	J01MA03	tablet	not sold
01968408	FLOXIN - 400MG/TAB	ofloxacin	J01MA03	tablet	
02049422	FLOXIN - 40MG/ML	ofloxacin	J01MA03	injectable solution	
02049430	FLOXIN - 4MG/ML	ofloxacin	J01MA03	injectable solution	
00610089	HISMANAL - 10MG/TAB	astemizole	R06AX04	tablet	
00756806	HISMANAL - 1MG/ML	astemizole	R06AX04	oral suspension	not sold
00610070	HISMANAL - 2MG/ML	astemizole	R06AX04	oral suspension	
02022117	LEUSTATIN - 1MG/ML	cladribine	L01BB05	injectable solution	
02020017	LIVOSTIN - 0.5MG/ML	levocabastine hydrochloride	R01AC02	nasal suspension	
00642851	MOTILIUM - 10MG/TAB	domperidone	A03FA02	tablet	
00855820	MOTILIUM - 10MG/TAB	domperidone maleate	A03FA02	tablet	not sold
00633836	NIZORAL - 200MG/TAB	ketoconazole	J02AB01	tablet	
00703974	NIZORAL - 20MG/G	ketoconazole	D01AC05	cream	
00788813	NIZORAL - 20MG/ML	ketoconazole	J02AB01	oral suspension	
00803588	NIZORAL - 20MG/ML	ketoconazole	D11AC06	shampoo	
00602957	ORTHO 7/7/7 .5-.75-1/0.035	norethindrone/ethinyl estradiol	G03AB02	tablet	not sold
00602965	ORTHO 7/7/7 .5-.75-1/0.035	norethindrone/ethinyl estradiol	G03AB02	tablet	
02042533	ORTHO-CEPT 0.15/0.03	desogestrel/ethinyl estradiol	G03AA06	tablet	
02042541	ORTHO-CEPT 0.15/0.03	desogestrel/ethinyl estradiol	G03AA06	tablet	
02015978	ORTHOCLONE-OKT3 - 1MG/ML	muromonab-cd3	L04AA04	injectable solution	
00836338	PREPULSID - 10MG/TAB	cisapride monohydrate	A03FA03	tablet	introduced
00836354	PREPULSID - 1MG/ML	cisapride monohydrate	A03FA03	oral suspension	
02054817	PREPULSID - 20MG/TAB	cisapride monohydrate	A03FA03	tablet	
00836311	PREPULSID - 5MG/TAB	cisapride monohydrate	A03FA03	tablet	
02052407	RENOVA - 0.5MG/G	tretinoin	D10AD01	cream	
02025280	RISPERDAL - 1MG/TAB	risperidone	N05AX02	tablet	introduced
02025299	RISPERDAL - 2MG/TAB	risperidone	N05AX02	tablet	
02025302	RISPERDAL - 3MG/TAB	risperidone	N05AX02	tablet	
02025310	RISPERDAL - 4MG/TAB	risperidone	N05AX02	tablet	
02047454	SPORANOX - 100MG/CAP	itraconazole	J02AC02	capsule	
01951319	SUFENTA - 0.05MG/ML	sufentanil citrate	N01AH04	injectable solution	introduced
00894710	TERAZOL 3 - 80MG/SUP	terconazole	G01AG01	vaginal suppository	
01934155	TERAZOL 3 - 8MG/G	terconazole	G01AG01	vaginal cream	
02130874	TERAZOL 3 DUALPAK	terconazole	G01AG01	vaginal cream and suppository	
00894729	TERAZOL 7 - 4MG/G	terconazole	G01AG01	vaginal cream	
00364126	TOLECTIN - 200MG/TAB	tolmetin sodium	M01AB03	tablet	introduced
00484938	TOLECTIN - 400MG/CAP	tolmetin sodium	M01AB03	capsule	
00632740	TOLECTIN - 600MG/TAB	tolmetin sodium	M01AB03	tablet	
02028700	TRI-CYCLEN .18-.215-.25/0.035	norgestimate/ethinyl estradiol	G03AB03	tablet	
02029421	TRI-CYCLEN .18-.215-.25/0.035	norgestimate/ethinyl estradiol	G03AB03	tablet	

<b>Veterinary:</b>					
00788724	APPERTEX - 2.5MG/TAB	clazuril		tablet	not sold
00729957	SPARTRIX - 10MG/TAB	carnidazole		tablet	expired
00731374	WILDNIL - 3MG/ML	carfentanil citrate		injectable solution	not sold

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
<b>JOUEVINAL INC.</b>					
<b>Human:</b>					
	CERICLAMINE - 100MG/CAP	cericlamine		capsule	not sold
	CERICLAMINE - 150MG/CAP	cericlamine		capsule	not sold
02146959	LIPIDIL MICRO - 200MG/CAP	fenofibrate	B04AC03	capsule	introduced
02053136	MAXAIR - 0.25MG/DOSE	pirbuterol acetate	R03AC06	aerosol for inhalation	not sold
00609110	RECTOVALONE - 2.5MG/ML	tixocortol pivalate	A07EA03	rectal suspension	not sold
<b>KENRAL INC.</b>					
<b>Human:</b>					
01912070	DOMPERIDONE MALEATE - 10MG/TAB	domperidone maleate	A03FA02	tablet	
02128918	KENRAL-CEFACLO - 250MG/CAP	cefactor	J01DA06	capsule	not sold
02128977	KENRAL-CEFACLO - 25MG/ML	cefactor	J01DA06	powder for oral suspension	not sold
02128926	KENRAL-CEFACLO - 500MG/CAP	cefactor	J01DA06	capsule	not sold
02128985	KENRAL-CEFACLO - 50MG/ML	cefactor	J01DA06	powder for oral suspension	not sold
02128993	KENRAL-CEFACLO - 75MG/ML	cefactor	J01DA06	powder for oral suspension	not sold
02128845	KENRAL-FLUOXETINE - 10MG/CAP	fluoxetine hydrochloride	N06AB01	capsule	not sold
02128853	KENRAL-FLUOXETINE - 20MG/CAP	fluoxetine hydrochloride	N06AB01	capsule	not sold
02128861	KENRAL-FLUOXETINE - 4MG/ML	fluoxetine hydrochloride	N06AB01	oral solution	not sold
02128888	KENRAL-NIZATIDINE - 150MG/CAP	nizatidine	A02BA04	capsule	not sold
02128896	KENRAL-NIZATIDINE - 300MG/CAP	nizatidine	A02BA04	capsule	not sold
00828823	RANITIDINE HYDROCHLORIDE - 150MG/TAB	ranitidine hydrochloride	A02BA02	tablet	
00828688	RANITIDINE HYDROCHLORIDE - 300MG/TAB	ranitidine hydrochloride	A02BA02	tablet	
00878715	SALBUTAMOL SULFATE - 0.4MG/ML	salbutamol sulfate	R03CC01	oral solution	not sold
<b>LEO LABORATORIES CANADA LTD.</b>					
<b>Human:</b>					
01976133	DOVONEX - 0.05MG/G	calcipotriol	D05AX01	ointment	
02150956	DOVONEX - 0.05MG/G	calcipotriol	D05AX01	cream	introduced
02194341	DOVONEX - 0.05MG/ML	calcipotriol	D05AX01	scalp lotion	not sold
02167840	INNOHEP - 10000UNIT/ML	tinzaparin sodium	B01AB05	injectable suspension	introduced
02167859	INNOHEP - 11700UNIT/ML	tinzaparin sodium	B01AB05	injectable suspension	introduced
00474517	ONE-ALPHA - 0.00025MG/CAP	alfacalcidol	A11CC03	capsule	
00759546	ONE-ALPHA - 0.0002MG/ML	alfacalcidol	A11CC03	oral solution	
00474525	ONE-ALPHA - 0.001MG/CAP	alfacalcidol	A11CC03	capsule	
<b>LIGAND PHARMACEUTICALS INC.</b>					
<b>Human:</b>					
02020033	PHOTOFRIN - 15MG/VIAL	porfimer sodium	L01XX11	powder for injectable solution	introduced (nce)
02019876	PHOTOFRIN - 75MG/VIAL	porfimer sodium	L01XX11	powder for injectable solution	introduced (nce)
02130181	PROLEUKIN - 22000000UNIT/VIAL	aldesleukin	L03AA04	powder for injectable solution	introduced (nce)
<b>MALLINCKRODT MEDICAL INC.</b>					
<b>Human:</b>					
	99MTC TECHNESCAN MAG3 UD PED.	technetium tc-99m mertiatide	V04DA12	powder for injectable solution	
	99MTC TECHNESCAN MAG3 UD REG.	technetium tc-99m mertiatide	V04DA12	powder for injectable solution	
00727725	HEXABRIX 160 - 294.5MG/ML	meglumine and sodium ioxaglate	V04AF03	injectable solution	not sold
00788805	HEXABRIX 200 - 369MG/ML	meglumine and sodium ioxaglate	V04AF03	injectable solution	
00603740	HEXABRIX 320 - 589MG/ML	meglumine and sodium ioxaglate	V04AF03	injectable solution	
01900838	OPTIRAY 160 - 339MG/ML	ioversol	V08AB05	injectable solution	not sold
01900846	OPTIRAY 240 - 509MG/ML	ioversol	V08AB05	injectable solution	
02034492	OPTIRAY 300 - 636MG/ML	ioversol	V08AB05	injectable solution	not sold
01900854	OPTIRAY 320 - 678MG/ML	ioversol	V08AB05	injectable solution	
02034484	OPTIRAY 350 - 742MG/ML	ioversol	V08AB05	injectable solution	
	TECHNESCAN MAG3	technetium tc-99m mertiatide	V04DA12	powder for injectable solution	



DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
<b>MALLINCKRODT VETERINARY INC.</b>					
01950576	CLINACOX - 5000MG/KG	diclazuril		feed premix	
00670898	ESTRUMATE - 0.25MG/ML	cloprostenol sodium		injectable solution	
00673056	PLANATE - 0.0875MG/ML	cloprostenol sodium		injectable solution	
<b>MERCK FROSST CANADA INC.</b>					
<b>Human:</b>					
00456888	CLINORIL - 150MG/TAB	sulindac	M01AB02	tablet	
00432369	CLINORIL - 200MG/TAB	sulindac	M01AB02	tablet	
02182882	COZAAR - 100MG/TAB	losartan potassium	C02EX01	tablet	not sold
02182815	COZAAR - 25MG/TAB	losartan potassium	C02EX01	tablet	introduced (nce)
02182874	COZAAR - 50MG/TAB	losartan potassium	C02EX01	tablet	introduced (nce)
00587699	DOLOBID - 250MG/TAB	diflunisal	N02BA04	tablet	
00576131	DOLOBID - 500MG/TAB	diflunisal	N02BA04	tablet	
02201011	FOSAMAX - 10MG/TAB	alendronate sodium	M05BA04	tablet	not sold
02201038	FOSAMAX - 40MG/TAB	alendronate sodium	M05BA04	tablet	not sold
00568368	HEPTAVAX-B	vaccine - hepatitis B	J07BC01	injectable suspension	not sold
00463248	INDOCID-SR - 75MG/CAP	indomethacin	M01AB01	sustained-release capsule	
00466085	M-M-R II	vaccine - measles/ mumps/rubella	J07BD51	injectable suspension	
01980653	MEFOXIN - 1000MG/VIAL	cefoxitin sodium	J01DA05	powder for injectable solution	expired
00663697	MEFOXIN - 1000MG/VIAL	cefoxitin sodium	J01DA05	powder for injectable solution	expired
00663700	MEFOXIN - 2000MG/VIAL	cefoxitin sodium	J01DA05	powder for injectable solution	expired
00893668	MEFOXIN ADD-VANTAGE - 1000MG/VIAL	cefoxitin sodium	J01DA05	powder for injectable solution	expired
00893676	MEFOXIN ADD-VANTAGE - 2000MG/VIAL	cefoxitin sodium	J01DA05	powder for injectable solution	expired
00795844	MEVACOR - 10MG/TAB	lovastatin	B04AB01	tablet	not sold
00795860	MEVACOR - 20MG/TAB	lovastatin	B04AB01	tablet	
00795852	MEVACOR - 40MG/TAB	lovastatin	B04AB01	tablet	
01908294	NOROXIN - 3MG/ML	norfloxacin	S01AA08	ophthalmic solution	
00643025	NOROXIN - 400MG/TAB	norfloxacin	J01MA01	tablet	
01942948	PEDVAXHIB	vaccine - hemophilus influenzae b	J07AG03	injectable suspension	
00728128	PEPCID - 10MG/ML	famotidine	A02BA03	injectable solution	
00710121	PEPCID - 20MG/TAB	famotidine	A02BA03	tablet	
00710113	PEPCID - 40MG/TAB	famotidine	A02BA03	tablet	
00728101	PEPCID - 8MG/ML	famotidine	A02BA03	oral suspension	not sold
00431648	PNEUMOVAX 23	vaccine - polyvalent pneumococcal	J07AL01	injectable suspension	
00717274	PRIMAXIN 250/250	imipenem/cilastatin sodium	J01DH50	powder for injectable solution	
01911430	PRIMAXIN 250/250 ADD-VANTAGE	imipenem/cilastatin sodium	J01DH50	powder for injectable solution	
00717282	PRIMAXIN 500/500	imipenem/cilastatin sodium	J01DH50	powder for injectable solution	
01911449	PRIMAXIN 500/500 ADD-VANTAGE	imipenem/cilastatin sodium	J01DH50	powder for injectable solution	
00890952	PRIMAXIN IM 500/500	imipenem/cilastatin sodium	J01DH50	powder for injectable solution	not sold
00893684	PRIMAXIN IM 750/750	imipenem/cilastatin sodium	J01DH50	powder for injectable solution	not sold
00839396	PRINIVIL - 10MG/TAB	lisinopril	C02EA03	tablet	
00839418	PRINIVIL - 20MG/TAB	lisinopril	C02EA03	tablet	
00839426	PRINIVIL - 40MG/TAB	lisinopril	C02EA03	tablet	not sold
00839388	PRINIVIL - 5MG/TAB	lisinopril	C02EA03	tablet	
00839434	PRINIVIL - 80MG/TAB	lisinopril	C02EA03	tablet	not sold
02108194	PRINZIDE 10/12.5	lisinopril/hydrochlorothiazide	C02LM02	tablet	
00884413	PRINZIDE 20/12.5	lisinopril/hydrochlorothiazide	C02LM02	tablet	
00884421	PRINZIDE 20/25	lisinopril/hydrochlorothiazide	C02LM02	tablet	
02010909	PROSCAR - 5MG/TAB	finasteride	G04BX04	tablet	
00749486	RECOMBIVAX HB - 0.01MG/ML	vaccine - hepatitis B(rDNA)	J07BC02	injectable suspension	
01934023	RECOMBIVAX HB - 0.04MG/ML	vaccine - hepatitis B(rDNA)	J07BC02	injectable suspension	
02028786	SINEMET CR 25/100	carbidopa/levodopa	N04BA50	sustained-release tablet	
00870935	SINEMET CR 50/200	carbidopa/levodopa	N04BA50	sustained-release tablet	
00509353	TIMOLIDE 10/25	timolol maleate/ hydrochlorothiazide	C07BA03	tablet	expired
02171880	TIMOPTIC XE - 2.5MG/ML	timolol maleate	S01ED01	ophthalmic gel	introduced
02171899	TIMOPTIC XE - 5MG/ML	timolol maleate	S01ED01	ophthalmic gel	introduced
00657298	VASERETIC 10/25	enalapril maleate/ hydrochlorothiazide	C02LM01	tablet	
00670901	VASOTEC - 10MG/TAB	enalapril maleate	C02EA02	tablet	
00851795	VASOTEC - 2.5MG/TAB	enalapril maleate	C02EA02	tablet	
00670928	VASOTEC - 20MG/TAB	enalapril maleate	C02EA02	tablet	

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
00708887	VASOTEC - 40MG/TAB	enalapril maleate	C02EA02	tablet	not sold
00708879	VASOTEC - 5MG/TAB	enalapril maleate	C02EA02	tablet	
01923846	VASOTEC I.V. - 1.25MG/ML	enalaprilat	C02EA04	injectable solution	
00884332	ZOCOR - 10MG/TAB	simvastatin	B04AB02	tablet	
00884340	ZOCOR - 20MG/TAB	simvastatin	B04AB02	tablet	
00884359	ZOCOR - 40MG/TAB	simvastatin	B04AB02	tablet	not sold
00884324	ZOCOR - 5MG/TAB	simvastatin	B04AB02	tablet	
02186810	ZYMAXIN - 200MG/TAB	ibuprofen lysine	M01AE01	tablet	not sold

## MERCK FROSST-MSD AGVET

02060574	ENACARD - 10MG/TAB	enalapril maleate		tablet	
02060531	ENACARD - 1MG/TAB	enalapril maleate		tablet	
02060558	ENACARD - 2.5MG/TAB	enalapril maleate		tablet	
02060582	ENACARD - 20MG/TAB	enalapril maleate		tablet	
02060566	ENACARD - 5MG/TAB	enalapril maleate		tablet	
00717150	EQVALAN LIQUID FOR HORSES - 10MG/ML	ivermectin		oral liquid	
00594431	EQVALAN PASTE FOR HORSES - 18.6916MG/G	ivermectin		oral paste	
00651966	HEARTGARD 30 - 0.068MG/TAB	ivermectin		tablet	
00651982	HEARTGARD 30 - 0.136MG/TAB	ivermectin		tablet	
00651990	HEARTGARD 30 - 0.272MG/TAB	ivermectin		tablet	
00812315	HEARTGARD 30 CHEW - 0.068MG/TAB	ivermectin		tablet	
00812323	HEARTGARD 30 CHEW - 0.136MG/TAB	ivermectin		tablet	
00870064	HEARTGARD 30 CHEW - 0.272MG/TAB	ivermectin		tablet	
01909975	HEARTGARD 30 PLUS 0.068/57	ivermectin/pyrantel pamoate		tablet	
01909983	HEARTGARD 30 PLUS 0.136/114	ivermectin/pyrantel pamoate		tablet	
01909991	HEARTGARD 30 PLUS 0.272/227	ivermectin/pyrantel pamoate		tablet	
00622125	IVOMEC DRENCH FOR SHEEP - 0.83MG/ML	ivermectin		injectable suspension	
00630470	IVOMEC INJ. FOR CATTLE - 10MG/ML	ivermectin		injectable suspension	
00583340	IVOMEC INJ. FOR SWINE - 10MG/ML	ivermectin		injectable suspension	not sold
00761842	IVOMEC POUR-ON - 5MG/ML	ivermectin		topical solution	
01926950	IVOMEC SR BOLUS FOR CATTLE - 1720MG/BOLUS	ivermectin		sustained-release bolus	
01913085	IVOMEC SWINE PREMIX - 6000MG/KG	ivermectin		oral powder	

## NOVO NORDISK CANADA INC.

<b>Human:</b>					
01986813	INSULATARD NPH - 100UNIT/ML	insulin (isophane) human semi-synthetic	A10AA02	injectable suspension	not sold
02056682	LOGIPARIN - 10000UNIT/ML	tinzaparin sodium	B01AB05	injectable suspension	introduced (nce)
02056690	LOGIPARIN - 11700UNIT/ML	tinzaparin sodium	B01AB05	injectable suspension	not sold
01985973	MIXTARD 15/85 - 100UNIT/ML	insulin (regular/isophane) human semi-synthetic	A10AA04	injectable suspension	not sold
01986821	MIXTARD 30/70 - 100UNIT/ML	insulin (regular/isophane) human semi-synthetic	A10AA04	injectable suspension	not sold
01985965	MIXTARD 50/50 - 100UNIT/ML	insulin (regular/isophane) human semi-synthetic	A10AA04	injectable suspension	not sold
02024292	NOVOLIN GE 10/90 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
02024306	NOVOLIN GE 20/80 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
02024217	NOVOLIN GE 30/70 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
02025248	NOVOLIN GE 30/70 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
02024314	NOVOLIN GE 40/60 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
02024322	NOVOLIN GE 50/50 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	
02024241	NOVOLIN GE LENTE - 100UNIT/ML	insulin (lente) human biosynthetic	A10AA02	injectable suspension	



DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
02024225	NOVOLIN GE NPH - 100UNIT/ML	insulin (isophane) human biosynthetic	A10AA02	injectable suspension	
02024268	NOVOLIN GE NPH - 100UNIT/ML	insulin (isophane) human biosynthetic	A10AA02	injectable suspension	
02024233	NOVOLIN GE TORONTO - 100UNIT/ML	insulin (regular) human biosynthetic	A10AA01	injectable suspension	
02024284	NOVOLIN GE TORONTO - 100UNIT/ML	insulin (regular) human biosynthetic	A10AA01	injectable suspension	
02024276	NOVOLIN GE ULTRALENTE - 100UNIT/ML	insulin (ultralente) human biosynthetic	A10AA03	injectable suspension	
01988700	NOVOLINSET 30/70 - 100UNIT/ML	insulin (regular/isophane) human semi-synthetic	A10AA04	injectable suspension	not sold
02024411	NOVOLINSET GE 10/90 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	not sold
02024438	NOVOLINSET GE 20/80 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	not sold
02024446	NOVOLINSET GE 30/70 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	not sold
02024454	NOVOLINSET GE 40/60 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	not sold
02025264	NOVOLINSET GE 50/50 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AA04	injectable suspension	not sold
02024403	NOVOLINSET GE NPH - 100UNIT/ML	insulin (isophane) human biosynthetic	A10AA02	injectable suspension	not sold
02025256	NOVOLINSET GE TORONTO - 100UNIT/ML	insulin (regular) human biosynthetic	A10AA01	injectable suspension	not sold
01986090	NOVOLINSET NPH - 100UNIT/ML	insulin (isophane) human semi-synthetic	A10AA02	injectable suspension	not sold
01927477	NOVOLINSET TORONTO - 100UNIT/ML	insulin (regular) human semi-synthetic	A10AA01	injectable suspension	not sold
01986805	VELOSULIN HUMAN - 100UNIT/ML	insulin (regular) human semi-synthetic	A10AA01	injectable suspension	

## NOVOPHARM LTD.

### Human:

02022176	NOVO-FAMOTIDINE - 10MG/ML	famotidine	A02BA03	injectable solution	not sold
02022133	NOVO-FAMOTIDINE - 20MG/TAB	famotidine	A02BA03	tablet	
02022141	NOVO-FAMOTIDINE - 40MG/TAB	famotidine	A02BA03	tablet	
02022168	NOVO-FAMOTIDINE - 8MG/ML	famotidine	A02BA03	oral suspension	not sold

## OHMEDA, DIVISION OF CANADIAN OXYGEN LIMITED

### Human:

00418994	STADOL - 2MG/ML	butorphanol tartrate	N02AF01	injectable solution	not sold
----------	-----------------	----------------------	---------	---------------------	----------

## ORGANON CANADA LTD. (AKZO)

### Human:

02042479	MARVELON 0.15/0.03	desogestrel/ethinyl estradiol	G03AA06	tablet	
02042487	MARVELON 0.15/0.03	desogestrel/ethinyl estradiol	G03AA06	tablet	
00687405	NORCURON - 10MG/VIAL	vecuronium bromide	M03AC03	powder for injectable solution	
02129043	ORGARAN - 1250UNIT/ML	danaparoid sodium	B01AB07	injectable solution	introduced (nce)
02108208	ZEMURON - 10MG/ML	rocuronium bromide	M03AC07	injectable solution	introduced (nce)

## PFIZER CANADA INC.

### Human:

00871044	CARDURA - 1MG/TAB	doxazosin mesylate	C02CA04	tablet	not sold
00871052	CARDURA - 2MG/TAB	doxazosin mesylate	C02CA04	tablet	not sold
00871060	CARDURA - 4MG/TAB	doxazosin mesylate	C02CA04	tablet	not sold
00871079	CARDURA - 8MG/TAB	doxazosin mesylate	C02CA04	tablet	not sold
00622109	CEFOBID - 1000MG/VIAL	cefoperazone sodium	J01DA12	powder for injectable solution	not sold
00622117	CEFOBID - 2000MG/VIAL	cefoperazone sodium	J01DA12	powder for injectable solution	not sold
00891819	DIFLUCAN - 100MG/TAB	fluconazole	J02AC01	tablet	
02024152	DIFLUCAN - 10MG/ML	fluconazole	J02AC01	oral suspension	introduced
02141442	DIFLUCAN - 150MG/CAP	fluconazole	J02AC01	capsule	introduced
00891827	DIFLUCAN - 200MG/TAB	fluconazole	J02AC01	tablet	not sold
00891835	DIFLUCAN - 2MG/ML	fluconazole	J02AC01	injectable solution	
02024160	DIFLUCAN - 40MG/ML	fluconazole	J02AC01	oral suspension	not sold
00891800	DIFLUCAN - 50MG/TAB	fluconazole	J02AC01	tablet	
02171902*	GYNECURE TANDEM	tioconazole	G01AF05	vaginal ointment and cream	

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
*02171910 02095009	GYNECURE TANDEM GYNECURE VAGINAL - 300MG/OVULE	tioconazole tioconazole	G01AF05 G01AF05	vaginal ovule and cream vaginal ovule	introduced
02095017 02093170 02093189 00878936 00878901 00878928 01942441	GYNECURE VAGINAL - 65MG/G MINIPRESS XL - 2.5MG/TAB MINIPRESS XL - 5MG/TAB NORVASC - 10MG/TAB NORVASC - 2.5MG/TAB NORVASC - 5MG/TAB PLAX PEPPERMINT 20/2/2.5	tioconazole prazosin hydrochloride prazosin hydrochloride amlodipine besylate amlodipine besylate amlodipine besylate sodium benzoate/sodium salicylate/sodium lauryl sulfate	G01AF05 C02CA02 C02CA02 C08CA04 C08CA04 C08CA04 A01AD10	vaginal ointment sustained-release tablet sustained-release tablet tablet tablet tablet oral rinse	not sold not sold not sold
01942506	PLAX REGULAR 20/2/2.5	sodium benzoate/sodium salicylate/sodium lauryl sulfate	A01AD10	oral rinse	
01942409	PLAX SOFT MINT 20/2/2.5	sodium benzoate/sodium salicylate/sodium lauryl sulfate	A01AD10	oral rinse	
01900986 01900978 01900951 02095025 00874116	REACTINE - 10MG/TAB REACTINE - 20MG/TAB REACTINE - 5MG/TAB TROSYD AF - 10MG/G UNASYN 1000/2000	cetirizine hydrochloride cetirizine hydrochloride cetirizine hydrochloride tioconazole sulbactam sodium/ampicillin sodium	R06AE03 R06AE03 R06AE03 D01AC04	tablet tablet tablet cream powder for injectable solution	not sold not sold
01955527	UNASYN 1000/2000	sulbactam sodium/ampicillin sodium		powder for injectable solution	not sold
00874108	UNASYN 500/1000	sulbactam sodium/ampicillin sodium		powder for injectable solution	not sold
01955519	UNASYN 500/1000	sulbactam sodium/ampicillin sodium		powder for injectable solution	not sold
02091291 01962779 01962787 01962795 02132702 01962817	ZITHROMAX - 250MG/CAP ZOLOFT - 100MG/CAP ZOLOFT - 150MG/CAP ZOLOFT - 200MG/CAP ZOLOFT - 25MG/CAP ZOLOFT - 50MG/CAP	azithromycin sertraline hydrochloride sertraline hydrochloride sertraline hydrochloride sertraline hydrochloride sertraline hydrochloride	J01FA04 N06AB02 N06AB02 N06AB02 N06AB02 N06AB02	capsule capsule capsule capsule capsule capsule	not sold not sold not sold
<b>Pfizer Canada Inc., VET. Division</b>					
01912992 01913034 01913026 01913018 02038331	CESTEX - 100MG/TAB CESTEX - 12.5MG/TAB CESTEX - 25MG/TAB CESTEX - 50MG/TAB CLAVAMOX 100/25	epsiprantel epsiprantel epsiprantel epsiprantel amoxicillin trihydrate/ clavulanate potassium		tablet tablet tablet tablet tablet	
02038315	CLAVAMOX 200/50	amoxicillin trihydrate/ clavulanate potassium		tablet	
02038358	CLAVAMOX 300/75	amoxicillin trihydrate/ clavulanate potassium		tablet	
02027879	CLAVAMOX 50/12.5	amoxicillin trihydrate/ clavulanate potassium		oral suspension	
02038323	CLAVAMOX 50/12.5	amoxicillin trihydrate/ clavulanate potassium		tablet	
00884545 01950673 00755559	COXISTAC - 60000MG/KG DOMITOR - 1MG/ML DORMOSEDAN - 10MG/ML ENDURALL - K	salinomycin medetomidine hydrochloride detomidine hydrochloride inactivated rabies vaccine, porcine cell line origin		oral powder injectable solution injectable solution injectable solution	not sold not sold
	FELOCELL CVR	modified live feline rhino- tracheitis-panleukopenia virus		injectable solution	
	FELOCELL CVR-C	modified live feline rhinotracheitis		injectable solution	
	FELOMUNE CVR	modified live feline rhino- tracheitis-calicivirus vaccine		injectable solution	
	FIRSTDOSE CPV	modified live canine parvovirus vaccine		injectable solution	
	LEUKOCELL	inactivated feline leukaemia vaccine		injectable solution	not sold
00725064 00606081	LEUKOCELL 2 LIFE-GUARD-H.E. PARATECT BOLUS - 22700MG/TAB	feline leukemia vaccine nutrients/electrolytes morantel tartrate		injectable solution oral powder sustained-release oral device	not sold



DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
00778923	PARATECT FLEX - 19800MG/TAB	morantel tartrate		sustained-release oral device	
00606103	POSISTAC - 12500MG/KG	salinomycin		oral powder	not sold
00633828	POSISTAC - 50000MG/KG	salinomycin		oral powder	not sold
00603724	POSISTAC - 60000MG/KG	salinomycin		oral powder	
02006936	RABGUARD-TC	inactivated rabies vaccine		injectable solution	
00698083	RESORB	electrolyte product		powder for oral suspension	
	SYNERGISTIN 60/120	sulbactam/ampicillin		injectable suspension	
	VANGUARD 5	modified live canine distemper-adenovirus type 2		injectable solution	
	VANGUARD 5 CV	canine combination vaccine		injectable solution	
	VANGUARD 5B	modified live canine distemper adenovirus type 2		injectable solution	
	VANGUARD 5L	modified live canine distemper-adenovirus type 2		injectable solution	
	VANGUARD CPV (KILLED)	inactivated canine parvovirus vaccine		injectable solution	
	VANGUARD CPV (MLV)	modified live canine parvovirus vaccine		injectable solution	not sold

## PHARMACIA INC.

### Human:

02071002	ADRIAMYCIN PFS - 2MG/ML	doxorubicin hydrochloride	L01DB01	injectable solution	
02065657	ADRIAMYCIN RDF - 10MG/VIAL	doxorubicin hydrochloride	L01DB01	powder for injectable solution	
02069563	ADRIAMYCIN RDF - 150MG/VIAL	doxorubicin hydrochloride	L01DB01	powder for injectable solution	
00698040	ADRIAMYCIN RDF - 20MG/VIAL	doxorubicin hydrochloride	L01DB01	powder for injectable solution	not sold
02069555	ADRIAMYCIN RDF - 50MG/VIAL	doxorubicin hydrochloride	L01DB01	powder for injectable solution	
	AMPEROZIDE - 0.5MG/TAB	amperozide		tablet	not sold
	AMPEROZIDE - 2.5MG/TAB	amperozide		tablet	not sold
	AMPEROZIDE - 5MG/TAB	amperozide		tablet	not sold
02063808	DIPENTUM - 250MG/CAP	olsalazine sodium	A07EC03	capsule	
00875856	DIPENTUM - 500MG/TAB	olsalazine sodium	A07EC03	tablet	not sold
02063794	EMCYT - 140MG/CAP	estramustine phosphate disodium	L01XX10	capsule	
02168898	ESTRING - 2MG/RING	estradiol	G03CA02	vaginal ring	introduced
02132664	FRAGMIN - 10000UNIT/ML	dalteparin sodium	B01AB06	injectable solution	introduced (nce)
02132621	FRAGMIN - 12500UNIT/ML	dalteparin sodium	B01AB06	injectable solution	introduced (nce)
02132648	FRAGMIN - 25000UNIT/ML	dalteparin sodium	B01AB06	injectable solution	introduced (nce)
02132656	FRAGMIN - 2500UNIT/ML	dalteparin sodium	B01AB06	injectable solution	introduced (nce)
02068095	IDAMYCIN - 10MG/VIAL	darubicin hydrochloride	L01DB04	powder for injectable solution	
02065630	IDAMYCIN - 5MG/VIAL	idarubicin hydrochloride	L01DB04	powder for injectable solution	
	LINOMIDE - 10MG/TAB	roquinimex		tablet	not sold
	LINOMIDE - 2.5MG/TAB	roquinimex		tablet	not sold
	LINOMIDE - 5MG/TAB	roquinimex		tablet	not sold
02063786	MYCOBUTIN - 150MG/CAP	rifabutin	J04AK03	capsule	
	PHARMORUBICIN - 10MG/VIAL	epirubicin hydrochloride	L01DB03	powder for injectable solution	not sold
	PHARMORUBICIN - 20MG/VIAL	epirubicin hydrochloride	L01DB03	powder for injectable solution	not sold
	PHARMORUBICIN - 50MG/VIAL	epirubicin hydrochloride	L01DB03	powder for injectable solution	not sold
02065703	PHARMORUBICIN PFS - 2MG/ML	epirubicin hydrochloride	L01DB03	injectable solution	
02065746	PHARMORUBICIN RDF - 10MG/VIAL	epirubicin hydrochloride	L01DB03	powder for injectable solution	
01951882	PHARMORUBICIN RDF - 150MG/VIAL	epirubicin hydrochloride	L01DB03	powder for injectable solution	not sold
00698202	PHARMORUBICIN RDF - 20MG/VIAL	epirubicin hydrochloride	L01DB03	powder for injectable solution	not sold
02069512	PHARMORUBICIN RDF - 50MG/VIAL	epirubicin hydrochloride	L01DB03	powder for injectable solution	
02028689	PROMIT - 150MG/ML	dextran 1	B05AA03	injectable solution	not sold
	STERECYT - 100MG/TAB	prednimustine	L01AA07	tablet	not sold
	STERECYT - 20MG/TAB	prednimustine	L01AA07	tablet	not sold
02153432	ZINECARD - 250MG/VIAL	dexrazoxane	V03AF03	powder for injectable solution	introduced (nce)
02153440	ZINECARD - 500MG/VIAL	dexrazoxane	V03AF03	powder for injectable solution	introduced (nce)

## PHARMASCIENCE INC.

### Human:

02177617	DOM-FLUOXETINE - 10MG/CAP	fluoxetine hydrochloride	N06AB01	capsule	not sold
02177625	DOM-FLUOXETINE - 20MG/CAP	fluoxetine hydrochloride	N06AB01	capsule	not sold
02177609	DOM-FLUOXETINE - 4MG/ML	fluoxetine hydrochloride	N06AB01	oral solution	not sold
*02177579	PMS-FLUOXETINE - 10MG/CAP	fluoxetine hydrochloride	N06AB01	capsule	
*02177587	PMS-FLUOXETINE - 20MG/CAP	fluoxetine hydrochloride	N06AB01	capsule	
02177595	PMS-FLUOXETINE - 4MG/ML	fluoxetine hydrochloride	N06AB01	oral solution	not sold

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.					
Human:					
01997580	ASACOL - 400MG/TAB	5-aminosalicylic acid	A07EC02	tablet	introduced
02176017	DIDROCAL	etidronate disodium and calcium carbonate	M05BB01	tablet	
02063662	MACROBID - 100MG/CAP	nitrofurantoin	G04AC01	capsule	
PROVEL, DIVISION OF ELI LILLY CANADA INC.					
Veterinary:					
00616338	CARBIGRAN - 250000MG/KG	nicarbazin		feed premix	not sold
00590932	COMPUDOSE - 24MG/IMP	estradiol		injectable implant	
02123355	ENDECTO - 10MG/ML	abamectin		injectable solution	
01902687	MAXIBAN PREMIX - 160000MG/KG	narasin/nicarbazin		feed premix	introduced
00857602	MICOTIL - 300MG/ML	tilmicosin sulfate		injectable solution	
00707538	MONTEBAN 70 PREMIX - 70000MG/KG	narasin		feed premix	
00637645	TYLAN 50 SULFA G - 220000MG/KG	tylosin phosphate/ sulfamethazine		feed premix	
PURDUE FREDERICK					
Human:					
02163756	GASTROBID - 20MG/TAB	metoclopramide hydrochloride	A03FA01	sustained-release tablet	not sold
02125358	HYDROMORPH CONTIN - 10MG/CAP	hydromorphone hydrochloride	N02AA03	sustained-release capsule	not sold
02125366	HYDROMORPH CONTIN - 12MG/CAP	hydromorphone hydrochloride	N02AA03	sustained-release capsule	not sold
02125374	HYDROMORPH CONTIN - 20MG/CAP	hydromorphone hydrochloride	N02AA03	sustained-release capsule	not sold
02125382	HYDROMORPH CONTIN - 24MG/CAP	hydromorphone hydrochloride	N02AA03	sustained-release capsule	not sold
02125390	HYDROMORPH CONTIN - 30MG/CAP	hydromorphone hydrochloride	N02AA03	sustained-release capsule	not sold
02125323	HYDROMORPH CONTIN - 3MG/CAP	hydromorphone hydrochloride	N02AA03	sustained-release capsule	introduced
02125331	HYDROMORPH CONTIN - 6MG/CAP	hydromorphone hydrochloride	N02AA03	sustained-release capsule	introduced
00449636	TRILISATE 293/362	choline salicylate/ magnesium salicylate	N02BA02	tablet	
RHÔNE-POULENC RORER CANADA INC.					
Human:					
01926314	AZMACORT - 0.2MG/DOSE	triamcinolone acetonide	R03BA04	aerosol for inhalation	expired
02195976	SUPRAX - 200MG/TAB	cefixime	J01DA16	tablet	
02195992	SUPRAX - 20MG/ML	cefixime	J01DA16	oral suspension	introduced (nce)
02195984	SUPRAX - 400MG/TAB	cefixime	J01DA16	tablet	
02177099	TAXOTERE - 20MG/VIAL	docetaxel	L01CD02	injectable solution	
02177080	TAXOTERE - 80MG/VIAL	docetaxel	L01CD02	injectable solution	
SANDOZ CANADA INC.					
Human:					
01968130	DHE - 4MG/ML	dihydroergotamine mesylate	N02CA01	nasal aerosol	not sold
00872385	DYNACIRC - 1.25MG/CAP	isradipine		capsule	
00872393	DYNACIRC - 2.5MG/CAP	isradipine		capsule	
02031094	LAMISIL - 10MG/G	isradipine		capsule	not sold
02031108	LAMISIL - 125MG/TAB	terbinafine hydrochloride	D01AE09	cream	not sold
02031116	LAMISIL - 250MG/TAB	terbinafine hydrochloride	D01BA02	tablet	
02061562	LESCOL - 20MG/CAP	terbinafine hydrochloride	D01BA02	tablet	
02061570	LESCOL - 40MG/CAP	fluvastatin sodium	B04AB04	capsule	not sold
01992880	MIACALCIN - 100UNIT/ML	fluvastatin sodium	B04AB04	capsule	
01990926	MIACALCIN - 50UNIT/ML	calcitonin salmom	V03AG04	injectable solution	
00755605	SANDIMMUNE - 100MG/CAP	calcitonin salmom	V03AG04	injectable solution	not sold
00593249	SANDIMMUNE - 100MG/ML	cyclosporine	L04AA01	capsule	
00755591	SANDIMMUNE - 25MG/CAP	cyclosporine	L04AA01	oral solution	
01907182	SANDIMMUNE - 50MG/CAP	cyclosporine	L04AA01	capsule	introduced
00593257	SANDIMMUNE - 50MG/ML	cyclosporine	L04AA01	capsule	
02150670	SANDIMMUNE NEORAL - 100MG/CAP	cyclosporine	L04AA01	injectable solution	



DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
02150697	SANDIMMUNE NEORAL - 100MG/ML	cyclosporine	L04AA01	oral solution	introduced
02150689	SANDIMMUNE NEORAL - 25MG/CAP	cyclosporine	L04AA01	capsule	introduced
02150662	SANDIMMUNE NEORAL - 50MG/CAP	cyclosporine	L04AA01	capsule	introduced
00839191	SANDOSTATIN - 0.05MG/ML	octreotide	H01CB01	injectable solution	not sold
00839205	SANDOSTATIN - 0.1MG/ML	octreotide	H01CB01	injectable solution	
02049392	SANDOSTATIN - 0.2MG/ML	octreotide	H01CB01	injectable solution	
00839213	SANDOSTATIN - 0.5MG/ML	octreotide	H01CB01	injectable solution	
00568627	VISKAZIDE 10/25	pindolol/hydrochlorothiazide	C07BA02	tablet	
00568635	VISKAZIDE 10/50	pindolol/hydrochlorothiazide	C07BA02	tablet	

## SANOI WINTHROP

### Human:

	COROTROPE - 10MG/CAP	milrinone	C01CE02	caplet	not sold
	COROTROPE - 5MG/CAP	milrinone	C01CE02	caplet	not sold
	COROTROPE - 7.5MG/CAP	milrinone	C01CE02	caplet	not sold
02017644	INOCOR - 5MG/ML	amrinone lactate	C01CE01	injectable solution	
01962973	OMNIPAQUE 140 - 302MG/ML	iohexol	V08AB02	injectable solution	not sold
02172720	OMNIPAQUE 180 - 389MG/ML	iohexol	V08AB02	injectable solution	
02172739	OMNIPAQUE 240 - 518MG/ML	iohexol	V08AB02	injectable solution	
02172747	OMNIPAQUE 300 - 647MG/ML	iohexol	V08AB02	injectable solution	
02172755	OMNIPAQUE 350 - 755MG/ML	iohexol	V08AB02	injectable solution	
02172771	OMNISCAN - 287MG/ML	gadodiamide	V08CA03	injectable solution	
02006391	PRIMACOR - 1MG/ML	milrinone lactate	C01CE02	injectable solution	introduced (nce)
02145766	VISIPAQUE 270 - 550MG/ML	iodixanol	V08AB07	injectable solution	introduced (nce)
02145774	VISIPAQUE 320 - 652MG/ML	iodixanol	V08AB07	injectable solution	introduced (nce)

## SCHERING CANADA INC.

### Human:

02070855	ALDERM - 0.5MG/G	alclometasone dipropionate		ointment	not sold
02070871	ALDERM - 0.5MG/G	alclometasone dipropionate		cream	not sold
02165449	CEDAX - 18MG/ML	ceftibuten		powder for oral suspension	not sold
02165465	CEDAX - 200MG/CAP	ceftibuten		capsule	not sold
02165457	CEDAX - 36MG/ML	ceftibuten		powder for oral suspension	not sold
02165473	CEDAX - 400MG/CAP	ceftibuten		capsule	not sold
01970399	CHLOR-TRIPOLON N.D. 5/120	loratadine/pseudoephedrine sulfate	R06AX52	tablet	
00782696	CLARITIN - 10MG/TAB	loratadine	R06AX06	tablet	
02019973	CLARITIN - 1MG/ML	loratadine	R06AX06	syrup	
01945157	CLARITIN EXTRA 5/120	loratadine/pseudoephedrine sulfate	R06AX52	tablet	
00851736	ELOCOM - 1MG/G	mometasone furoate	D07AC08	ointment	
00851744	ELOCOM - 1MG/G	mometasone furoate	D07AC08	cream	
00871095	ELOCOM - 1MG/ML	mometasone furoate	D07AC08	lotion	
00705926	INTRON-A - 1000000UNIT/VIAL	interferon alfa-2b	L03AA01	powder for injectable suspension	
00705896	INTRON-A - 3000000UNIT/VIAL	interferon alfa-2b	L03AA01	powder for injectable suspension	
00889067	INTRON-A - 5000000UNIT/ML	interferon alfa-2b	L03AA01	injectable solution	
00705918	INTRON-A - 5000000UNIT/VIAL	interferon alfa-2b	L03AA01	powder for injectable suspension	
00713376	K-DUR - 1500MG/TAB	potassium chloride	A12BA01	sustained-release tablet	
00611174	LOTRIDERM 0.5/10	betamethasone dipropionate/ clotrimazole	D01AC50	cream	
00503398	NETROMYCIN - 100MG/ML	netilmicin sulfate	J01GB05	injectable solution	
00503363	NETROMYCIN - 25MG/ML	netilmicin sulfate	J01GB05	injectable solution	
00503371	NETROMYCIN - 50MG/ML	netilmicin sulfate	J01GB05	injectable solution	
01911910	NITRO-DUR 0.2 - 40MG/PATCH	nitroglycerin	C01DA01	transdermal patch	
01911902	NITRO-DUR 0.4 - 80MG/PATCH	nitroglycerin	C01DA01	transdermal patch	
01911929	NITRO-DUR 0.6 - 120MG/PATCH	nitroglycerin	C01DA01	transdermal patch	
02011271	NITRO-DUR 0.8 - 160MG/PATCH	nitroglycerin	C01DA01	transdermal patch	

### Veterinary:

00882887	AQUAFLO - 500000MG/KG	florfenicol		powder	
02142155	DURA SE-120 - 360MG/BOLUS	selenite sodium		bolus	not sold
	OPTIMMUNE - 2MG/G	cyclosporine		ophthalmic ointment	introduced

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
<b>SEARLE CANADA INC.</b>					
<b>Human:</b>					
01917056	ARTHROTEC <sup>2</sup> 0.2/50	misoprostol/diclofenac sodium	M01BX02	tablet	expired
00813966	CYTOTEC - 0.1MG/TAB	misoprostol	A02BB01	tablet	expired
00632600	CYTOTEC - 0.2MG/TAB	misoprostol	A02BB01	tablet	expired
00728144	CYTOTEC - 0.2MG/VIAL	misoprostol	A02BB01	powder for nasogastric suspension	expired
00659592	CYTOTEC - 0.4MG/TAB	misoprostol	A02BB01	tablet	expired
01946188	KERLONE - 10MG/TAB	betaxolol hydrochloride		tablet	not sold
01946161	KERLONE - 20MG/TAB	betaxolol hydrochloride		tablet	not sold
02010925	MAXAQUIN - 400MG/TAB	lomefloxacin		tablet	not sold
00874213	NITRODISC 0.2 - 16MG/PATCH	nitroglycerin	C01DA01	transdermal patch	not sold
00874221	NITRODISC 0.3 - 24MG/PATCH	nitroglycerin	C01DA01	transdermal patch	not sold
00874248	NITRODISC 0.4 - 32MG/PATCH	nitroglycerin	C01DA01	transdermal patch	not sold
02188783	SYNAREL - 2MG/ML	nafarelin acetate	H01CA02	nasal solution	
02187108	SYNPHASIC 1.0-0.5/0.035	norethindrone/ethinyl estradiol	G03AB02	tablet	
02187116	SYNPHASIC 1.0-0.5/0.035	norethindrone/ethinyl estradiol	G03AB02	tablet	
<b>SMITHKLINE BEECHAM PHARMA INC.</b>					
<b>Human:</b>					
01919628	ANCEF - 10000MG/VIAL	cefazolin sodium	J01DA03	powder for injectable solution	expired
01919601	ANCEF - 1000MG/VIAL	cefazolin sodium	J01DA03	powder for injectable solution	expired
01919636	ANCEF - 500MG/VIAL	cefazolin sodium	J01DA03	powder for injectable solution	expired
01911937	AUGMENTIN 25/6.25	amoxycillin trihydrate/ clavulanate potassium	J01CR01	oral suspension	not sold
01911953	AUGMENTIN 250/125	amoxycillin trihydrate/ clavulanate potassium	J01CR01	tablet	not sold
01911945	AUGMENTIN 50/12.5	amoxycillin trihydrate/ clavulanate potassium	J01CR01	oral suspension	not sold
01911961	AUGMENTIN 500/125	amoxycillin trihydrate/ clavulanate potassium	J01CR01	tablet	not sold
01916947	BACTROBAN - 20MG/G	mupirocin	D06AX07	ointment	
01919490	CEFIZOX - 1000MG/VIAL	ceftizoxime sodium	J01DA15	powder for injectable solution	
01919504	CEFIZOX - 2000MG/VIAL	ceftizoxime sodium	J01DA15	powder for injectable solution	
01916882	CLAVULIN 25/6.25	amoxycillin trihydrate/ clavulanate potassium	J01CR01	oral suspension	
01916866	CLAVULIN 250/125	amoxycillin trihydrate/ clavulanate potassium	J01CR01	tablet	
01916874	CLAVULIN 50/12.5	amoxycillin trihydrate/ clavulanate potassium	J01CR01	oral suspension	
01916858	CLAVULIN 500/125	amoxycillin trihydrate/ clavulanate potassium	J01CR01	tablet	
00632767	EMEX - 5MG/ML	metoclopramide hydrochloride	A03FA01	injectable solution	not sold
01915304	EMINASE - 30UNIT/VIAL	anistreplase	B01AD04	powder for injectable solution	not sold
01919431	ENGERIX-B	hepatitis B vaccine	J07BC02	injectable suspension	
02177102	FAMVIR - 500MG/TAB	famciclovir	J05AB09	tablet	introduced (nce)
02187078	HAVRIX - 1440EUNIT/ML	hepatitis A vaccine (inactivated)	J07BC03	injectable suspension	not sold
02108216	HAVRIX - 720EUNIT/ML	hepatitis A vaccine (inactivated)	J07BC03	injectable suspension	
02154471	KREDEX - 25MG/TAB	carvedilol		tablet	not sold
02154498	KREDEX - 50MG/TAB	carvedilol		tablet	not sold
02088371	KYTRIL - 1MG/ML	granisetron hydrochloride	A04AA02	injectable solution	not sold
02185881	KYTRIL - 1MG/TAB	granisetron hydrochloride	A04AA02	tablet	not sold
01970429	MONOCID - 1000MG/VIAL	cefonicid sodium		powder for injectable solution	not sold
01970410	MONOCID - 500MG/VIAL	cefonicid sodium		powder for injectable solution	not sold
02027887	PAXIL - 10MG/TAB	paroxetine hydrochloride	N06AB03	tablet	not sold
01940481	PAXIL - 20MG/TAB	paroxetine hydrochloride	N06AB03	tablet	
01940473	PAXIL - 30MG/TAB	paroxetine hydrochloride	N06AB03	tablet	
02027895	PAXIL - 50MG/TAB	paroxetine hydrochloride	N06AB03	tablet	not sold
02083531	RELAFEN - 500MG/TAB	nabumetone	M01AX02	tablet	
02083558	RELAFEN - 750MG/TAB	nabumetone	M01AX02	tablet	not sold
01916807	TAGAMET - 150MG/ML	cimetidine hydrochloride	A02BA01	injectable solution	
01916793	TAGAMET - 200MG/TAB	cimetidine	A02BA01	tablet	not sold
01916815	TAGAMET - 300MG/TAB	cimetidine	A02BA01	tablet	
01916785	TAGAMET - 400MG/TAB	cimetidine	A02BA01	tablet	



DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
01916777	TAGAMET - 600MG/TAB	cimetidine	A02BA01	tablet	
01916750	TAGAMET - 60MG/ML	cimetidine hydrochloride	A02BA01	oral solution	
01927280	TAGAMET - 6MG/ML	cimetidine hydrochloride	A02BA01	injectable solution	
01916769	TAGAMET - 800MG/TAB	cimetidine	A02BA01	tablet	
01916920	TICAR - 1000MG/VIAL	ticarcillin disodium	J01CA08	powder for injectable solution	not sold
01916890	TICAR - 20000MG/VIAL	ticarcillin disodium	J01CA08	powder for injectable solution	
00803480	TICAR - 30000MG/VIAL	ticarcillin disodium	J01CA08	powder for injectable solution	not sold
01916912	TICAR - 3000MG/VIAL	ticarcillin disodium	J01CA08	powder for injectable solution	
01916904	TICAR - 6000MG/VIAL	ticarcillin disodium	J01CA08	powder for injectable solution	not sold
01916939	TIMENTIN 3000/100	ticarcillin disodium/ clavulanate potassium	J01CR02	powder for injectable solution	

## SOLVAY KINGSWOOD INC.

### Human:

01919369	LUVOX - 100MG/TAB	fluvoxamine maleate	N06AB04	tablet	
01919334	LUVOX - 25MG/TAB	fluvoxamine maleate	N06AB04	tablet	not sold
01919342	LUVOX - 50MG/TAB	fluvoxamine maleate	N06AB04	tablet	
01919350	LUVOX - 75MG/TAB	fluvoxamine maleate	N06AB04	tablet	not sold

## THE UPJOHN COMPANY OF CANADA

### Human:

02132680	COLESTID - 1000MG/TAB	colestipol hydrochloride	B04AD02	tablet	introduced
02132699	COLESTID ORANGE - 5000MG/DOSE	colestipol hydrochloride	B04AD02	oral granules	introduced
00030910	CORTEF - 10MG/TAB	hydrocortisone	H02AB07	tablet	
00030929	CORTEF - 20MG/TAB	hydrocortisone	H02AB07	tablet	
00194913	NEO-CORTEF 10/5	hydrocortisone acetate/ neomycin sulfate	D07CA01	ointment	
00194921	NEO-CORTEF 15/5	hydrocortisone acetate/ neomycin sulfate	S01CA02	ophthalmic ointment	
00194948	NEO-CORTEF 15/5	hydrocortisone acetate/ neomycin sulfate	S01CA02	ophthalmic suspension	
00194883	NEO-CORTEF 5/5	hydrocortisone acetate/ neomycin sulfate	S01CA02	ophthalmic ointment	not sold
00194891	NEO-CORTEF 5/5	hydrocortisone acetate/ neomycin sulfate	D07CA01	ointment	
00860786	PREPIDIL - 0.5MG/SYRINGE	dinoprostone	G02AD01	intra-uterine gel	
01919679	PROSTIN E2 - 1MG/SYRINGE	dinoprostone	G02AD01	intra-uterine gel	
01919687	PROSTIN E2 - 2MG/SYRINGE	dinoprostone	G02AD01	intra-uterine gel	
00030635	SOLU-CORTEF - 1000MG/VIAL	hydrocortisone sodium succinate	H02AB07	powder for injectable solution	not sold
00030600	SOLU-CORTEF - 100MG/VIAL	hydrocortisone sodium succinate	H02AB07	powder for injectable solution	
00030619	SOLU-CORTEF - 250MG/VIAL	hydrocortisone sodium succinate	H02AB07	powder for injectable solution	
00030627	SOLU-CORTEF - 500MG/VIAL	hydrocortisone sodium succinate	H02AB07	powder for injectable solution	

### Veterinary:

00813567	EXCENEL - 50MG/ML	ceftiofur sodium		powder for injectable solution	
----------	-------------------	------------------	--	--------------------------------	--

## WARNER-LAMBERT CANADA INC. (PARKE-DAVIS)

### Human:

01947672	ACCUPRIL - 10MG/TAB	quinapril hydrochloride	C02EA06	tablet	
01947680	ACCUPRIL - 20MG/TAB	quinapril hydrochloride	C02EA06	tablet	
01947699	ACCUPRIL - 40MG/TAB	quinapril hydrochloride	C02EA06	tablet	
01947664	ACCUPRIL - 5MG/TAB	quinapril hydrochloride	C02EA06	tablet	
00846414	PRO-AIR - 0.01MG/DOSE	procaterol hydrochloride hemihydrate	R03AC04	aerosol for inhalation	expired
00670952	PRO-AIR - 0.025MG/TAB	procaterol hydrochloride hemihydrate		tablet	expired
00670960	PRO-AIR - 0.05MG/TAB	procaterol hydrochloride hemihydrate		tablet	expired
00670979	PRO-AIR - 0.075MG/TAB	procaterol hydrochloride hemihydrate		tablet	expired
00670987	PRO-AIR - 0.1MG/TAB	procaterol hydrochloride hemihydrate		tablet	expired

DIN/GP	Brand Name	Generic Name	ATC	Dosage Form	Comments
<b>WESTWOOD-SQUIBB PHARMACEUTICALS INC.</b>					
<b>Human:</b>					
02010283	HALOG - 1MG/G	halcinonide	D07AD02	ointment	expired
02010291	HALOG - 1MG/ML	halcinonide	D07AD02	topical solution	
01909150	LACHYDRIN - 120MG/ML	lactic acid	D02AX01	lotion	
01962701	ULTRAVATE - 0.5MG/G	halobetasol propionate	D07AD03	cream	
01962728	ULTRAVATE - 0.5MG/G	halobetasol propionate	D07AD03	ointment	
<b>WYETH-AYERST CANADA INC.</b>					
<b>Human:</b>					
02036274	ALREDASE - 200MG/TAB	tolrestat		tablet	
02036428	CEFOTAN - 1000MG/VIAL	cefotetan disodium	J01DA17	powder for injectable solution	
02103710	EFFEXOR - 100MG/TAB	cefotetan disodium	J01DA17	powder for injectable solution	
02103664	EFFEXOR - 12.5MG/TAB	venlafaxine hydrochloride	N06AA11	tablet	not sold
02103672	EFFEXOR - 25MG/TAB	venlafaxine hydrochloride	N06AA11	tablet	not sold
02103680	EFFEXOR - 37.5MG/TAB	venlafaxine hydrochloride	N06AA11	tablet	not sold
02103699	EFFEXOR - 50MG/TAB	venlafaxine hydrochloride	N06AA11	tablet	
02103702	EFFEXOR - 75MG/TAB	venlafaxine hydrochloride	N06AA11	tablet	not sold
02042096	FACTREL - 0.1MG/VIAL	gonadorelin hydrochloride	H01CA01	injectable solution	expired
00368377	FACTREL - 0.2MG/VIAL	gonadorelin hydrochloride	H01CA01	injectable solution	expired
00368385	FACTREL - 0.5MG/VIAL	gonadorelin hydrochloride	H01CA01	injectable solution	expired
02126206	HIBTITER	vaccine - hemophilus influenzae b	J07AG02	injectable suspension	not sold
02042266	INDERAL-L.A. - 120MG/CAP	propranolol hydrochloride	C07AA01	sustained-release capsule	
02042274	INDERAL-L.A. - 160MG/CAP	propranolol hydrochloride	C07AA01	sustained-release capsule	
02042231	INDERAL-L.A. - 60MG/CAP	propranolol hydrochloride	C07AA01	sustained-release capsule	
02042258	INDERAL-L.A. - 80MG/CAP	propranolol hydrochloride	C07AA01	sustained-release capsule	
00673021	MAGNACEF - 1000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	not sold
00673048	MAGNACEF - 2000MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	not sold
00673013	MAGNACEF - 500MG/VIAL	ceftazidime pentahydrate	J01DA09	powder for injectable solution	not sold
02042304	MICRO-K EXTENCAPS - 600MG/CAP	potassium chloride	A12BA01	sustained-release capsule	
02042312	MICRO-K EXTENCAPS - 750MG/CAP	potassium chloride	A12BA01	sustained-release capsule	
01919644	MICRO-K LS - 1875MG/PCK	potassium chloride	A12BA01	oral suspension	not sold
00665126	MINOCIN - 100MG/TAB	minocycline hydrochloride	J01AA04	tablet	not sold
00665117	MINOCIN - 50MG/TAB	minocycline hydrochloride	J01AA04	tablet	not sold
02170701	MONOCOR - 10MG/TAB	bisoprolol fumarate		tablet	not sold
02170728	MONOCOR - 5MG/TAB	bisoprolol fumarate		tablet	not sold
00614289	NOVANTRONE - 2MG/ML	mitoxantrone hydrochloride	L01DB05	injectable solution	
00564974	PIPRACIL - 2000MG/VIAL	piperacillin sodium	J01CA05	powder for injectable solution	
00564982	PIPRACIL - 3000MG/VIAL	piperacillin sodium	J01CA05	powder for injectable solution	
00857548	PIPRACIL - 4000MG/VIAL	piperacillin sodium	J01CA05	powder for injectable solution	
00564990	PIPRACIL - 4000MG/VIAL	piperacillin sodium	J01CA05	powder for injectable solution	
01970348	REV-EYES - 25MG/VIAL	dapiprazole hydrochloride	S01EX01	ophthalmic solution	not sold
02170817	TAZOCIN 2000/250	piperacillin sodium/tazobactam sodium	J01CR03	powder for injectable solution	
02170795	TAZOCIN 3000/375	piperacillin sodium/tazobactam sodium	J01CR03	powder for injectable solution	
02170809	TAZOCIN 4000/500	piperacillin sodium/tazobactam sodium	J01CR03	powder for injectable solution	
02093405	TETRAMUNE	DPT-hemophilus b conjugate vaccine	J07CA04	injectable suspension	not sold
<b>ZENECA PHARMA INC.</b>					
<b>Human:</b>					
02188872	BREVIBLOC - 100MG/ML	esmolol hydrochloride	C07AB05	injectable solution	not sold
02188880	BREVIBLOC - 10MG/ML	esmolol hydrochloride	C07AB05	injectable solution	
02188864	BREVIBLOC - 250MG/ML	esmolol hydrochloride	C07AB05	injectable solution	
02184478	CASODEX - 50MG/TAB	bicalutamide	L02BB04	tablet	not sold
02018950	DIPRIVAN - 10MG/ML	propofol	N01AX03	injectable solution	expired
02103729	ZESTORETIC 10/12.5	lisinopril/hydrochlorothiazide	C02LM02	tablet	
02045737	ZESTORETIC 20/12.5	lisinopril/hydrochlorothiazide	C02LM02	tablet	
02045729	ZESTORETIC 20/25	lisinopril/hydrochlorothiazide	C02LM02	tablet	
02049376	ZESTRIL - 10MG/TAB	lisinopril	C02EA03	tablet	
02049384	ZESTRIL - 20MG/TAB	lisinopril	C02EA03	tablet	
00839345	ZESTRIL - 40MG/TAB	lisinopril	C02EA03	tablet	
02049333	ZESTRIL - 5MG/TAB	lisinopril	C02EA03	tablet	not sold
00857599	ZOLADEX - 3.6MG/VIAL	goserelin acetate	L02AE03	injectable implant	

\* Introduced in December 1995 and under the Board's Guidelines will be reviewed in 1996.

1 Patent dedicated prior to January 30, 1995.

2 Further patent pending.



















